Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

ABSTRACT

The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the priority benefit of U.S. ProvisionalApplication Ser. No. 62/320,316, filed Apr. 8, 2016, which isincorporated herein by reference in its entirety.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

The content of the following submission on ASCII text file isincorporated herein by reference in its entirety: a computer readableform (CRF) of the Sequence Listing (file name: 761342000100SEQLIST.txt,date recorded: Dec. 28, 2016, size: 394 KB).

FIELD OF THE INVENTION

The present disclosure relates, in part, to pharmaceutical compositionsand methods of use for providing prophylactic, palliative, ortherapeutic relief of a wound, disorder, or disease of the skin in asubject, including a subject having, or at risk of developing, one ormore symptoms of epidermolysis bullosa.

BACKGROUND

A number of serious disease-related skin conditions are associated withone or more genetic disorders in patients suffering from these diseases.One such disease, epidermolysis bullosa (EB), is a group of geneticdisorders that cause the skin and mucous membranes of an affectedindividual to blister and erode in response to minor injury or friction,such as scraping, rubbing, or scratching. Dystrophic epidermolysisbullosa (DEB) is one of the major forms of EB. The signs and symptoms ofthis condition vary widely among affected individuals, ranging from mild(blistering may only affect the hands, feet, knees, and elbows) tosevere (widespread blistering and scarring, possibly leading to visionloss, disfigurement, and other serious, and sometimes fatal, medicalconditions).

Dystrophic epidermolysis bullosa is classified into three major types.Autosomal dominant dystrophic epidermolysis bullosa (referred to asdominant dystrophic epidermolysis bullosa or DDEB) is typically themildest form, with blistering often restricted to the hands, feet kneesand elbows. The other two types of dystrophic epidermolysis bullosa,Hallopeau-Siemens type recessive dystrophic epidermolysis bullosa, andnon-Hallopeau-Siemens type recessive epidermolysis bullosa (collectivelyreferred to as recessive dystrophic epidermolysis bullosa or RDEB) aremore severe. RDEB is most often characterized by extensive blisteringand scarring of the skin and mucosal membranes. Blisters are routinelypresent over the whole body, including on mucous membranes (such as thelining of the mouth and digestive tract), and healing of these blistersresults in extensive scarring. Damage to the mouth and esophagus canmake it difficult to chew and swallow food, leading to chronicmalnutrition and slow growth. Complications from extensive scarring caninclude fusion of the fingers and toes, joint deformities, and eyeinflammation leading to vision loss. Additionally, patients sufferingfrom RDEB have a high risk of developing squamous cell carcinoma, whichcan be unusually aggressive in this patient population, often becominglife-threatening. Although the three types of dystrophic epidermolysisbullosa differ in severity, they have many shared features, and arecaused by the same genetic mutations.

Dystrophic epidermolysis bullosa is caused by mutations to the Col7a1gene, which encodes the Collagen alpha-1 (VII) chain protein (Collagen7). More than 240 distinct mutations to this gene have been identifiedin DEB patients. Additionally, a significant decrease in expression ofthe PLODS gene, which encodes the collagen modifying Lysyl hydroxylase 3enzyme (LH3), has also been observed in dystrophic epidermolysispatients. Collagen alpha-1 (VII) chain protein functions to strengthenand stabilize the skin, while Lysyl hydroxylase 3 plays a critical rolein the synthesis and secretion of functional Collagen alpha-1 (VII)chain protein. Briefly, Col7a1 transcripts are translated, and theresulting peptides are post-translationally modified by hydroxylatingtheir proline residues (by prolyl hydroxylases) and their lysineresidues (by lysyl hydroxylases, such as LH3). Hydroxylysine residuescan then be glycosylated, and subsequently, three glycosylated peptidesform a triple helix known as pro-collagen, and are secreted from thecell. The secreted pro-collagen can then associate in to higher-orderstructures, forming anchoring fibrils. The anchoring fibrils are thenavailable to help organize, stabilize, and aid in adherence of theepithelial basement membrane. The epithelial basement membrane isresponsible for anchoring the epithelium to the underlying looseconnective tissue, and is essential for dermal-epidermal stability(dermoepidermal junction integrity). Mutations in the Col7a1 gene, anddiminished levels of PLODS expression, impair the ability of Collagenalpha-1 (VII) chain protein to properly connect the epidermis to thedermis in dystrophic epidermolysis bullosa patients, leading to fragileskin.

Treatment options for epidermolysis bullosa patients are limited, andcurrent care focuses on managing the symptoms of the disease, includingproviding medication to control pain and itching, administering oralantibiotics to stave off infections resulting from open wounds on theskin and mucosa, and surgical strategies to address scarring anddeformities. Investigational methods for treating the underlying causesof epidermolysis bullosa include administering purified Collagen 7,fibroblasts containing Collagen 7, or viral vectors encoding Collagen 7,by intradermal injection. Because many DEB patients have multiple woundsspanning large areas of trauma-prone sites (such as the sacrum, hips,feet, lower back, and hands), any treatment involving intradermalinjection would be extremely invasive, as these large wound areas wouldall need to be injected, likely repeatedly, although injection timeintervals are unclear.

Thus there exists a clear need for less invasive/minimallyinvasive/non-invasive treatment options for epidermolysis bullosapatients that can address the deficiencies in the Collagen alpha-1 (VII)chain protein, as well as deficiencies in the Lysyl hydroxylase 3protein, observed in this patient population.

All references cited herein, including patent applications, patentpublications, non-patent literature, and UniProtKB/Swiss-Prot Accessionnumbers are herein incorporated by reference in their entirety, as ifeach individual reference were specifically and individually indicatedto be incorporated by reference.

BRIEF SUMMARY

In order to meet these needs, the present disclosure relates, in part,to pharmaceutical compositions and methods of use for providingprophylactic, palliative, or therapeutic relief of a wound, disorder, ordisease of the skin in a subject, especially in a subject having, or atrisk of developing, one or more symptoms of epidermolysis bullosa. Inparticular, the present disclosure relates, in part, to a method oftreating an individual by administering (e.g., topically ortransdermally administering) a pharmaceutical composition comprising oneor more polynucleotides encoding a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type Icytoskeletal 17 polypeptide and/or a chimeric polypeptide thereof.

Accordingly, certain aspects of the present disclosure relate to apharmaceutical composition comprising a virus comprising a vector,wherein the vector comprises one or more transgenes encoding a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, or achimeric polypeptide thereof, and a pharmaceutically acceptable carrier.In some embodiments, the virus is an adenovirus, adeno-associated virus,retrovirus, lentivirus, sendai virus, herpes simplex virus, vacciniavirus, or any hybrid virus thereof. In some embodiments, the virus isreplication-defective. In some embodiments, the virus is a herpessimplex virus (HSV). In some embodiments, the herpes simplex virus is aherpes simplex type 1 virus, a herpes simplex type 2 virus, or anyderivatives thereof. In some embodiments, the herpes simplex viruscomprises a modified envelope. In some embodiments, the modifiedenvelope alters the herpes simplex virus tissue tropism relative to awild-type herpes simplex virus. In some embodiments, the modifiedenvelope comprises a mutant herpes simplex virus glycoprotein. In someembodiments, the vector is an HSV-1 amplicon or an HSV-1 hybridamplicon. In some embodiments, the HSV-1 hybrid amplicon is an HSV/AAVhybrid amplicon, an HSV/EBV hybrid amplicon, and HSV/EBV/RV hybridamplicon, or an HSV/Sleeping Beauty hybrid amplicon. In someembodiments, the vector is a recombinant herpes simplex virus genome. Insome embodiments, the recombinant herpes simplex virus genome is arecombinant HSV-1 genome, a recombinant HSV-2 genome, or any derivativesthereof. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in an immediate early herpessimplex virus gene. In some embodiments, the herpes simplex virus geneis ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, or UL55. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP4, ICP27, and UL55 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP4, ICP22, ICP27, ICP47, and UL55 genes.In some embodiments, the inactivating mutation in the ICP4, ICP27, andUL55 genes is a deletion of the coding sequence of the ICP4, ICP27, andUL55 genes. In some embodiments, the inactivating mutation in the ICP22and ICP47 genes is a deletion in the promoter region of the ICP22 andICP47 genes. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP4 and ICP22 genes.In some embodiment, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP0 and ICP4 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, and ICP22 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, and ICP27 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes.In some embodiments, the inactivating mutation is a deletion of thecoding sequence of the genes. In some embodiments, the recombinantherpes simplex virus genome further comprises an inactivating mutationin the ICP47 gene, an inactivating mutation in the UL41 gene, or aninactivation mutation in the ICP47 and UL41 genes. In some embodiments,the recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more viral gene loci. In some embodiments, therecombinant herpes simplex virus genome comprises the one or moretransgenes within one or more of the ICP4 viral gene loci. In someembodiments, the recombinant herpes simplex virus genome comprises theone or more transgenes within the UL41 viral gene locus. In someembodiments, the vector is capable of replicating within a target cellwhen delivered into said target cell. In some embodiments, thepharmaceutically acceptable carrier is suitable for topical ortransdermal administration. In some embodiments, the one or moretransgenes comprises an miRNA binding site. In some embodiments, the oneor more transgenes are operably linked to one or more heterologouspromoters. In some embodiments, the one or more heterologous promotersare one or more of the human cytomegalovirus (HCMV) immediate earlypromoter, the elongation factor-1 (EF1) promoter, and/or anycombinations thereof. In some embodiment, the vector comprises atransgene encoding a Collagen alpha-1 (VII) chain polypeptide. In someembodiments, the vector comprises two transgenes, wherein each transgeneencodes a Collagen alpha-1 (VII) chain polypeptide. In some embodiments,the Collagen alpha-1 (VII) chain polypeptide has at least 80% sequenceidentity to the sequence of SEQ ID NO: 2. In some embodiments, thecollagen alpha-1 (VII) chain polypeptide is a fragment, wherein thefragment has at least 100 consecutive amino acids of SEQ ID NO: 2. Insome embodiments, the Collagen alpha-1 (VII) chain polypeptide enhances,increases, augments, and/or supplements anchoring fibril formation of asubject when the polypeptide is expressed in one or more target cells ofthe subject. In some embodiments, the Collagen alpha-1 (VII) chainpolypeptide enhances, increases, augments, and/or supplements epithelialbasement membrane organization and/or epithelial basement adherence of asubject when the polypeptide is expressed in one or more target cells ofthe subject. In some embodiments, the Lysyl hydroxylase 3 polypeptidehas at least 80% sequence identity to the sequence of SEQ ID NO: 4. Insome embodiments, the Lysyl hydroxylase 3 polypeptide is a fragment,wherein the fragment has at least 100 consecutive amino acids of SEQ IDNO: 4. In some embodiments, the Lysyl hydroxylase 3 polypeptideenhances, increases, augments, and/or supplements the formation ofhydroxylysine residues on one or more collagen polypeptides of a subjectwhen the Lysyl hydroxylase 3 polypeptide is expressed in one or moretarget cells of the subject. In some embodiments, the Lysyl hydroxylase3 polypeptide enhances, increases, augments, and/or supplementsanchoring fibril formation, epithelial basement membrane organization,and/or epithelial basement adherence of a subject when the polypeptideis expressed in one or more target cells of the subject. In someembodiments, the vector comprises at least a first transgene and asecond transgene. In some embodiments, the first transgene encodes aCollagen alpha-1 (VII) chain polypeptide and the second transgeneencodes a Lysyl hydroxylase 3 polypeptide. In some embodiments, thevector comprises a transgene that is polycistronic. In some embodiments,the polycistronic transgene encodes a Collagen alpha-1 (VII) chainpolypeptide on a first open reading frame (ORF) and a Lysyl hydroxylase3 polypeptide on a second open reading frame (ORF). In some embodiments,the first and second ORFs are separated by an internal ribosomal entrysite (IRES). In some embodiments, the Collagen alpha-1 (VII) chainpolypeptide and the Lysyl hydroxylase 3 polypeptide are at about anequimolar ratio when the polypeptides are expressed in one or moretarget cells of a subject. In some embodiments, the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide enhance,increase, augment, and/or supplement anchoring fibril formation,epithelial basement membrane organization, and/or epithelial basementadherence of a subject when the polypeptides are expressed in one ormore target cells of the subject. In some embodiments, the chimericpolypeptide comprises a linker polypeptide between the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide. In someembodiments, the linker polypeptide is a T2A, P2A, E2A, or F2A linkerpolypeptide. In some embodiments, the linker polypeptide has at least80% sequence identity to the sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQID NO: 10 or SEQ ID NO: 12. In some embodiments, the chimericpolypeptide has at least 80% sequence identity to the sequence of SEQ IDNO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQID NO: 24, SEQ ID NO: 26 or SEQ ID NO: 28. In some embodiments, thechimeric polypeptide enhances, increases, augments, and/or supplementsanchoring fibril formation, epithelial basement membrane organization,and/or epithelial basement adherence of a subject when the polypeptideis expressed in one or more target cells of the subject.

Other aspects of the present disclosure relate to a method of providingprophylactic, palliative, or therapeutic relief of a wound, disorder, ordisease of the skin in a subject, the method comprising topically ortransdermally administering a pharmaceutical composition capable ofenhancing, increasing, augmenting, and/or supplementing the levels of aCollagen alpha-1 (VII) chain polypeptide and/or a Lysyl hydroxylase 3polypeptide in one or more cells of the subject. In some embodiments,the pharmaceutical composition comprises a virus comprising a vector,wherein the vector comprises one or more transgenes encoding a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, or achimeric polypeptide thereof, and a pharmaceutically acceptable carrier.In some embodiments, the virus is an adenovirus, adeno-associated virus,retrovirus, lentivirus, sendai virus, herpes simplex virus, vacciniavirus, or any hybrid virus thereof. In some embodiments, the virus isreplication-defective. In some embodiments, the virus is a herpessimplex virus (HSV). In some embodiments, the herpes simplex virus is aherpes simplex type 1 virus, a herpes simplex type 2 virus, or anyderivatives thereof. In some embodiments, the herpes simplex viruscomprises a modified envelope. In some embodiments, the modifiedenvelope alters the herpes simplex virus tissue tropism relative to awild-type herpes simplex virus. In some embodiments, the modifiedenvelope comprises a mutant herpes simplex virus glycoprotein. In someembodiments, the vector is an HSV-1 amplicon or an HSV-1 hybridamplicon. In some embodiments, the HSV-1 hybrid amplicon is an HSV/AAVhybrid amplicon, an HSV/EBV hybrid amplicon, and HSV/EBV/RV hybridamplicon, or an HSV/Sleeping Beauty hybrid amplicon. In someembodiments, the vector is a recombinant herpes simplex virus genome. Insome embodiments, the recombinant herpes simplex virus genome is arecombinant HSV-1 genome, a recombinant HSV-2 genome, or any derivativesthereof. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in an immediate early herpessimplex virus gene. In some embodiments, the herpes simplex virus geneis ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, or UL55. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP4, ICP27, and UL55 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP4, ICP22, ICP27, ICP47, and UL55 genes.In some embodiments, the inactivating mutation in the ICP4, ICP27, andUL55 genes is a deletion of the coding sequence of the ICP4, ICP27, andUL55 genes. In some embodiments, the inactivating mutation in the ICP22and ICP47 genes is a deletion in the promoter region of the ICP22 andICP47 genes. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP4 and ICP22 genes.In some embodiment, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP0 and ICP4 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, and ICP22 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, and ICP27 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes.In some embodiments, the inactivating mutation is a deletion of thecoding sequence of the genes. In some embodiments, the recombinantherpes simplex virus genome further comprises an inactivating mutationin the ICP47 gene, an inactivating mutation in the UL41 gene, or aninactivation mutation in the ICP47 and UL41 genes. In some embodiments,the recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more viral gene loci. In some embodiments, therecombinant herpes simplex virus genome comprises the one or moretransgenes within one or more of the ICP4 viral gene loci. In someembodiments, the recombinant herpes simplex virus genome comprises theone or more transgenes within the UL41 viral gene locus. In someembodiments, the vector is capable of replicating within a target cellwhen delivered into said target cell. In some embodiments, thepharmaceutically acceptable carrier is suitable for topical ortransdermal administration. In some embodiments, the one or moretransgenes comprises an miRNA binding site. In some embodiments, the oneor more transgenes are operably linked to one or more heterologouspromoters. In some embodiments, the one or more heterologous promotersare one or more of the human cytomegalovirus (HCMV) immediate earlypromoter, the elongation factor-1 (EF1) promoter, and/or anycombinations thereof. In some embodiments, the vector comprises atransgene encoding a Collagen alpha-1 (VII) chain polypeptide. In someembodiments, the vector comprises two transgenes, wherein each transgeneencodes a Collagen alpha-1 (VII) chain polypeptide. In some embodiments,the Collagen alpha-1 (VII) chain polypeptide has at least 80% sequenceidentity to the sequence of SEQ ID NO: 2. In some embodiments, thecollagen alpha-1 (VII) chain polypeptide is a fragment, wherein thefragment has at least 100 consecutive amino acids of SEQ ID NO: 2. Insome embodiments, the Collagen alpha-1 (VII) chain polypeptide enhances,increases, augments, and/or supplements anchoring fibril formation of asubject when the polypeptide is expressed in one or more target cells ofthe subject. In some embodiments, the Collagen alpha-1 (VII) chainpolypeptide enhances, increases, augments, and/or supplements epithelialbasement membrane organization and/or epithelial basement adherence of asubject when the polypeptide is expressed in one or more target cells ofthe subject. In some embodiments, the Lysyl hydroxylase 3 polypeptidehas at least 80% sequence identity to the sequence of SEQ ID NO: 4. Insome embodiments, the Lysyl hydroxylase 3 polypeptide is a fragment,wherein the fragment has at least 100 consecutive amino acids of SEQ IDNO: 4. In some embodiments, the Lysyl hydroxylase 3 polypeptideenhances, increases, augments, and/or supplements the formation ofhydroxylysine residues on one or more collagen polypeptides of a subjectwhen the Lysyl hydroxylase 3 polypeptide is expressed in one or moretarget cells of the subject. In some embodiments, the Lysyl hydroxylase3 polypeptide enhances, increases, augments, and/or supplementsanchoring fibril formation, epithelial basement membrane organization,and/or epithelial basement adherence of a subject when the polypeptideis expressed in one or more target cells of the subject. In someembodiments, the vector comprises at least a first transgene and asecond transgene. In some embodiments, the first transgene encodes aCollagen alpha-1 (VII) chain polypeptide and the second transgeneencodes a Lysyl hydroxylase 3 polypeptide. In some embodiments, thevector comprises a transgene that is polycistronic. In some embodiments,the polycistronic transgene encodes a Collagen alpha-1 (VII) chainpolypeptide on a first open reading frame (ORF) and a Lysyl hydroxylase3 polypeptide on a second open reading frame (ORF). In some embodiments,the first and second ORFs are separated by an internal ribosomal entrysite (IRES). In some embodiments, the Collagen alpha-1 (VII) chainpolypeptide and the Lysyl hydroxylase 3 polypeptide are at about anequimolar ratio when the polypeptides are expressed in one or moretarget cells of a subject. In some embodiments, the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide enhance,increase, augment, and/or supplement anchoring fibril formation,epithelial basement membrane organization, and/or epithelial basementadherence of a subject when the polypeptides are expressed in one ormore target cells of the subject. In some embodiments, the chimericpolypeptide comprises a linker polypeptide between the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide. In someembodiments, the linker polypeptide is a T2A, P2A, E2A, or F2A linkerpolypeptide. In some embodiments, the linker polypeptide has at least80% sequence identity to the sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQID NO: 10 or SEQ ID NO: 12. In some embodiments, the chimericpolypeptide has at least 80% sequence identity to the sequence of SEQ IDNO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQID NO: 24, SEQ ID NO: 26 or SEQ ID NO: 28. In some embodiments, thechimeric polypeptide enhances, increases, augments, and/or supplementsanchoring fibril formation, epithelial basement membrane organization,and/or epithelial basement adherence of a subject when the polypeptideis expressed in one or more target cells of the subject. In someembodiments, the pharmaceutical composition is administered one, twothree, four, five or more times per day. In some embodiments, thepharmaceutical composition is administered to one or more affectedand/or unaffected areas of the subject. In some embodiments, the diseaseor disorder of the skin is one or more of epidermolysis bullosa, skincancer, psoriasis, lichen planus, lupus, rosacea, eczema, cutaneouscandidiasis, cellulitis, impetigo, decubitus ulcers, erysipelas,ichthyosis vulgaris, dermatomyositis, acrodermatitis, stasis dermatitis,nethertons syndrome, epidermolysis bullosa simplex (LAMBS gene),autosomal recessive congenital ichthyosis, xeroderma pigmentosa, andpemphigoid.

Other aspects of the present disclosure relate to an isolated chimericpolypeptide, wherein the isolated chimeric polypeptide comprises aCollagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3polypeptide, and a linker polypeptide, wherein the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide areseparated by the linker polypeptide, to polynucleotides encoding thesame, to vectors comprising the polynucleotides, and to host cellscomprising the vectors. In some embodiments, the vector is an HSV-1amplicon or an HSV-1 hybrid amplicon. In some embodiments, the HSV-1hybrid amplicon is an HSV/AAV hybrid amplicon, an HSV/EBV hybridamplicon, and HSV/EBV/RV hybrid amplicon, or an HSV/Sleeping Beautyhybrid amplicon. In some embodiments, the vector is a recombinant herpessimplex virus genome. In some embodiments, the recombinant herpessimplex virus genome is a recombinant HSV-1 genome, a recombinant HSV-2genome, or any derivatives thereof. In some embodiments, the recombinantherpes simplex virus genome comprises an inactivating mutation in animmediate early herpes simplex virus gene. In some embodiments, theherpes simplex virus gene is ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41,or UL55. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP4, ICP27, and UL55genes. In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP4, ICP22, ICP27, ICP47, andUL55 genes. In some embodiments, the inactivating mutation in the ICP4,ICP27, and UL55 genes is a deletion of the coding sequence of the ICP4,ICP27, and UL55 genes. In some embodiments, the inactivating mutation inthe ICP22 and ICP47 genes is a deletion in the promoter region of theICP22 and ICP47 genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP4 andICP22 genes. In some embodiment, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP0 and ICP4 genes. Insome embodiments, the recombinant herpes simplex virus genome comprisesan inactivating mutation in the ICP0, ICP4, and ICP22 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, and ICP27 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes.In some embodiments, the inactivating mutation is a deletion of thecoding sequence of the genes. In some embodiments, the recombinantherpes simplex virus genome further comprises an inactivating mutationin the ICP47 gene, an inactivating mutation in the UL41 gene, or aninactivation mutation in the ICP47 and UL41 genes. In some embodiments,the recombinant herpes simplex virus genome comprises the polynucleotidewithin one or more viral gene loci. In some embodiments, the recombinantherpes simplex virus genome comprises the polynucleotide within one ormore of the ICP4 viral gene loci. In some embodiments, the recombinantherpes simplex virus genome comprises the polynucleotide within the UL41viral gene locus.

Other aspects of the present disclosure relate to a vector comprisingone or more polynucleotides encoding a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type Icytoskeletal 17 polypeptide, or any combinations thereof, wherein thevector is a recombinant herpes simplex virus genome, and to host cellscomprising the vector. In some embodiments, the recombinant herpessimplex virus genome is a recombinant HSV-1 genome, a recombinant HSV-2genome, or any derivatives thereof. In some embodiments, the recombinantherpes simplex virus genome comprises an inactivating mutation in animmediate early herpes simplex virus gene. In some embodiments, theherpes simplex virus gene is ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41,or UL55. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP4, ICP27, and UL55genes. In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP4, ICP22, ICP27, ICP47, andUL55 genes. In some embodiments, the inactivating mutation in the ICP4,ICP27, and UL55 genes is a deletion of the coding sequence of the ICP4,ICP27, and UL55 genes. In some embodiments, the inactivating mutation inthe ICP22 and ICP47 genes is a deletion in the promoter region of theICP22 and ICP47 genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP4 andICP22 genes. In some embodiment, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP0 and ICP4 genes. Insome embodiments, the recombinant herpes simplex virus genome comprisesan inactivating mutation in the ICP0, ICP4, and ICP22 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, and ICP27 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes.In some embodiments, the inactivating mutation is a deletion of thecoding sequence of the genes. In some embodiments, the recombinantherpes simplex virus genome further comprises an inactivating mutationin the ICP47 gene, an inactivating mutation in the UL41 gene, or aninactivation mutation in the ICP47 and UL41 genes. In some embodiments,the recombinant herpes simplex virus genome comprises the one or morepolynucleotides within one or more viral gene loci. In some embodiments,the recombinant herpes simplex virus genome comprises the one or morepolynucleotides within one or more of the ICP4 viral gene loci. In someembodiments, the recombinant herpes simplex virus genome comprises theone or more polynucleotides within the UL41 viral gene locus. In someembodiments, the vector comprises one polynucleotide encoding a Collagenalpha-1 (VII) chain polypeptide. In some embodiments, the vectorcomprises two polynucleotides encoding a Collagen alpha-1 (VII) chainpolypeptide.

Other aspects of the present disclosure relate to methods of collectinga herpes simplex virus, wherein a vector of interest is packaged withinsaid herpes simplex virus. In some embodiments the method comprises thesteps of contacting a host cell with a vector encoding a helper virus,contacting said host cell with a HSV-1 amplicon or HSV-1 hybrid ampliconcomprising one or more polynucleotides described herein, and collectingthe Herpes simplex virus generated by said host cell. In someembodiments, the method comprises the steps of contacting acomplementing host cell with a recombinant herpes simplex virus genomevector comprising one or more polynucleotides described herein, andcollecting the herpes simplex virus generated by said complementing hostcell. In some embodiments, the collected herpes simplex virus is aherpes simplex type 1 virus, a herpes simplex type 2 virus, or anyderivatives thereof.

Other aspects of the present disclosure relate to a kit comprising apharmaceutical composition described herein and instructions foradministering the pharmaceutical composition.

Other aspects of the present disclosure relate to relate to apharmaceutical composition comprising a virus comprising a vector,wherein the vector comprises one or more transgenes encoding a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, aKeratin type I cytoskeletal 17 polypeptide, or a chimeric polypeptidethereof, and a pharmaceutically acceptable carrier. In some embodiments,the virus is an adenovirus, adeno-associated virus, retrovirus,lentivirus, sendai virus, herpes simplex virus, vaccinia virus, or anyhybrid virus thereof. In some embodiments, the virus isreplication-defective. In some embodiments, the virus is a herpessimplex virus (HSV). In some embodiments, the herpes simplex virus is aherpes simplex type 1 virus, a herpes simplex type 2 virus, or anyderivatives thereof. In some embodiments, the vector is an HSV-1amplicon or an HSV-1 hybrid amplicon. In some embodiments, the HSV-1hybrid amplicon is an HSV/AAV hybrid amplicon, an HSV/EBV hybridamplicon, and HSV/EBV/RV hybrid amplicon, or an HSV/Sleeping Beautyhybrid amplicon. In some embodiments, the vector is a recombinant herpessimplex virus genome. In some embodiments, the recombinant herpessimplex virus genome is a recombinant HSV-1 genome, a recombinant HSV-2genome, or any derivatives thereof. In some embodiments, the recombinantherpes simplex virus genome comprises an inactivating mutation in animmediate early herpes simplex virus gene. In some embodiments, theherpes simplex virus gene is ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41,or UL55. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP4, ICP27, and UL55genes. In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP4, ICP22, ICP27, ICP47, andUL55 genes. In some embodiments, the inactivating mutation in the ICP4,ICP27, and UL55 genes is a deletion of the coding sequence of the ICP4,ICP27, and UL55 genes. In some embodiments, the inactivating mutation inthe ICP22 and ICP47 genes is a deletion in the promoter region of theICP22 and ICP47 genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP4 andICP22 genes. In some embodiment, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP0 and ICP4 genes. Insome embodiments, the recombinant herpes simplex virus genome comprisesan inactivating mutation in the ICP0, ICP4, and ICP22 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, and ICP27 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes.In some embodiments, the inactivating mutation is a deletion of thecoding sequence of the genes. In some embodiments, the recombinantherpes simplex virus genome further comprises an inactivating mutationin the ICP47 gene, an inactivating mutation in the UL41 gene, or aninactivation mutation in the ICP47 and UL41 genes. In some embodiments,the recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more viral gene loci. In some embodiments, therecombinant herpes simplex virus genome comprises the one or moretransgenes within one or more of the ICP4 viral gene loci. In someembodiments, the recombinant herpes simplex virus genome comprises theone or more transgenes within the UL41 viral gene locus. In someembodiments, the vector is capable of replicating within a target cellwhen delivered into said target cell. In some embodiments, thepharmaceutically acceptable carrier is suitable for topical ortransdermal administration. In some embodiments, the pharmaceuticallyacceptable carrier is suitable for subcutaneous or intradermaladministration. In some embodiments, the one or more transgenescomprises an miRNA binding site. In some embodiment, the vectorcomprises a transgene encoding a Collagen alpha-1 (VII) chainpolypeptide. In some embodiment, the vector comprises a transgeneencoding a Lysyl hydroxylase 3 polypeptide. In some embodiment, thevector comprises a transgene encoding a Keratin type I cytoskeletal 17polypeptide. In some embodiments, the vector comprises two transgenes,wherein each transgene encodes a Collagen alpha-1 (VII) chainpolypeptide. In some embodiments, the Collagen alpha-1 (VII) chainpolypeptide has at least 80% sequence identity to the sequence of SEQ IDNO: 2. In some embodiments, the collagen alpha-1 (VII) chain polypeptideis a fragment, wherein the fragment has at least 100 consecutive aminoacids of SEQ ID NO: 2. In some embodiments, the Collagen alpha-1 (VII)chain polypeptide enhances, increases, augments, and/or supplementsanchoring fibril formation of a subject when the polypeptide isexpressed in one or more target cells of the subject. In someembodiments, the Collagen alpha-1 (VII) chain polypeptide enhances,increases, augments, and/or supplements epithelial basement membraneorganization and/or epithelial basement adherence of a subject when thepolypeptide is expressed in one or more target cells of the subject. Insome embodiments, the Lysyl hydroxylase 3 polypeptide has at least 80%sequence identity to the sequence of SEQ ID NO: 4. In some embodiments,the Lysyl hydroxylase 3 polypeptide is a fragment, wherein the fragmenthas at least 100 consecutive amino acids of SEQ ID NO: 4. In someembodiments, the Lysyl hydroxylase 3 polypeptide enhances, increases,augments, and/or supplements the formation of hydroxylysine residues onone or more collagen polypeptides of a subject when the Lysylhydroxylase 3 polypeptide is expressed in one or more target cells ofthe subject. In some embodiments, the Lysyl hydroxylase 3 polypeptideenhances, increases, augments, and/or supplements anchoring fibrilformation, epithelial basement membrane organization, and/or epithelialbasement adherence of a subject when the polypeptide is expressed in oneor more target cells of the subject. In some embodiments, the Keratintype I cytoskeletal 17 polypeptide has at least 80% sequence identity tothe sequence of SEQ ID NO: 30. In some embodiments, the Keratin type Icytoskeletal 17 polypeptide is a fragment, wherein the fragment has atleast 100 consecutive amino acids of SEQ ID NO: 30. In some embodiments,the Keratin type I cytoskeletal 17 polypeptide enhances, increases,augments, and/or supplements wound healing in a subject. In someembodiments, the vector comprises at least a first transgene and asecond transgene. In some embodiments, the first transgene and thesecond transgene each encode a Collagen alpha-1 (VII) chain polypeptide.In some embodiments, the first transgene encodes a Collagen alpha-1(VII) chain polypeptide and the second transgene encodes a Lysylhydroxylase 3 polypeptide. In some embodiments, the first transgeneencodes a Collagen alpha-1 (VII) chain polypeptide and the secondtransgene encodes a Keratin type I cytoskeletal 17 polypeptide. In someembodiments, the first transgene encodes a Lysyl hydroxylase 3polypeptide and the second transgene encodes a Keratin type Icytoskeletal 17 polypeptide. In some embodiments, the vector comprisesat least a first transgene, a second transgene, and a third transgene.In some embodiments, the first transgene encodes a Collagen alpha-1(VII) chain polypeptide, the second transgene encodes a Lysylhydroxylase 3 polypeptide, and the third transgene encodes a Keratintype I cytoskeletal 17 polypeptide.

Other aspects of the present disclosure relate to a method of providingprophylactic, palliative, or therapeutic relief of a wound, disorder, ordisease of the skin in a subject, the method comprising administering tothe subject a pharmaceutical composition comprising a vector, whereinthe vector is a recombinant herpes simplex virus genome, and wherein thepharmaceutical composition is capable of enhancing, increasing,augmenting, and/or supplementing the levels of a Collagen alpha-1 (VII)chain polypeptide and/or a Lysyl hydroxylase 3 polypeptide and/or aKeratin type I cytoskeletal 17 polypeptide in one or more cells of thesubject. In some embodiments, the pharmaceutical composition comprises avirus comprising the vector, wherein the vector comprises one or moretransgenes encoding a Collagen alpha-1 (VII) chain polypeptide, a Lysylhydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide,or a chimeric polypeptide thereof, and a pharmaceutically acceptablecarrier. In some embodiments, the virus is an adenovirus,adeno-associated virus, retrovirus, lentivirus, sendai virus, herpessimplex virus, vaccinia virus, or any hybrid virus thereof. In someembodiments, the virus is replication-defective. In some embodiments,the virus is a herpes simplex virus (HSV). In some embodiments, theherpes simplex virus is a herpes simplex type 1 virus, a herpes simplextype 2 virus, or any derivatives thereof. In some embodiments, therecombinant herpes simplex virus genome is a recombinant HSV-1 genome, arecombinant HSV-2 genome, or any derivatives thereof. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in an immediate early herpes simplex virus gene.In some embodiments, the herpes simplex virus gene is ICP0, ICP4, ICP22,ICP27, ICP47, tk, UL41, or UL55. In some embodiments, the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP4, ICP27, and UL55 genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP4,ICP22, ICP27, ICP47, and UL55 genes. In some embodiments, theinactivating mutation in the ICP4, ICP27, and UL55 genes is a deletionof the coding sequence of the ICP4, ICP27, and UL55 genes. In someembodiments, the inactivating mutation in the ICP22 and ICP47 genes is adeletion in the promoter region of the ICP22 and ICP47 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP4 and ICP22 genes. In some embodiment,the recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0 and ICP4 genes. In some embodiments, therecombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, and ICP22 genes. In some embodiments, therecombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, ICP22, and ICP27 genes. In some embodiments,the recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes. In someembodiments, the inactivating mutation is a deletion of the codingsequence of the genes. In some embodiments, the recombinant herpessimplex virus genome further comprises an inactivating mutation in theICP47 gene, an inactivating mutation in the UL41 gene, or aninactivation mutation in the ICP47 and UL41 genes. In some embodiments,the recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more viral gene loci. In some embodiments, therecombinant herpes simplex virus genome comprises the one or moretransgenes within one or more of the ICP4 viral gene loci. In someembodiments, the recombinant herpes simplex virus genome comprises theone or more transgenes within the UL41 viral gene locus. In someembodiments, the vector is capable of replicating within a target cellwhen delivered into said target cell. In some embodiments, thepharmaceutically acceptable carrier is suitable for topical ortransdermal administration. In some embodiments, the pharmaceuticallyacceptable carrier is suitable for subcutaneous or intradermaladministration. In some embodiments, the one or more transgenescomprises an miRNA binding site. In some embodiments, the vectorcomprises a transgene encoding a Collagen alpha-1 (VII) chainpolypeptide. In some embodiments, the vector comprises a transgeneencoding a Lysyl hydroxylase 3 polypeptide. In some embodiments, thevector comprises a transgene encoding a Keratin type I cytoskeletal 17polypeptide. In some embodiments, the Collagen alpha-1 (VII) chainpolypeptide has at least 80% sequence identity to the sequence of SEQ IDNO: 2. In some embodiments, the collagen alpha-1 (VII) chain polypeptideis a fragment, wherein the fragment has at least 100 consecutive aminoacids of SEQ ID NO: 2. In some embodiments, the Collagen alpha-1 (VII)chain polypeptide enhances, increases, augments, and/or supplementsanchoring fibril formation of a subject when the polypeptide isexpressed in one or more target cells of the subject. In someembodiments, the Collagen alpha-1 (VII) chain polypeptide enhances,increases, augments, and/or supplements epithelial basement membraneorganization and/or epithelial basement adherence of a subject when thepolypeptide is expressed in one or more target cells of the subject. Insome embodiments, the Lysyl hydroxylase 3 polypeptide has at least 80%sequence identity to the sequence of SEQ ID NO: 4. In some embodiments,the Lysyl hydroxylase 3 polypeptide is a fragment, wherein the fragmenthas at least 100 consecutive amino acids of SEQ ID NO: 4. In someembodiments, the Lysyl hydroxylase 3 polypeptide enhances, increases,augments, and/or supplements the formation of hydroxylysine residues onone or more collagen polypeptides of a subject when the Lysylhydroxylase 3 polypeptide is expressed in one or more target cells ofthe subject. In some embodiments, the Lysyl hydroxylase 3 polypeptideenhances, increases, augments, and/or supplements anchoring fibrilformation, epithelial basement membrane organization, and/or epithelialbasement adherence of a subject when the polypeptide is expressed in oneor more target cells of the subject. In some embodiments, the Keratintype I cytoskeletal 17 polypeptide has at least 80% sequence identity tothe sequence of SEQ ID NO: 30. In some embodiments, the Keratin type Icytoskeletal 17 polypeptide is a fragment, wherein the fragment has atleast 100 consecutive amino acids of SEQ ID NO: 30. In some embodiments,the Keratin type I cytoskeletal 17 polypeptide enhances, increases,augments, and/or supplements wound healing in a subject. In someembodiments, the vector comprises at least a first transgene and asecond transgene. In some embodiments, the first transgene and thesecond transgene each encode a Collagen alpha-1 (VII) chain polypeptide.In some embodiments, the first transgene encodes a Collagen alpha-1(VII) chain polypeptide and the second transgene encodes a Lysylhydroxylase 3 polypeptide. In some embodiments, the first transgeneencodes a Collagen alpha-1 (VII) chain polypeptide and the secondtransgene encodes a Keratin type I cytoskeletal 17 polypeptide. In someembodiments, the first transgene encodes a Lysyl hydroxylase 3polypeptide and the second transgene encodes a Keratin type Icytoskeletal 17 polypeptide. In some embodiments, the vector comprisesat least a first transgene, a second transgene, and a third transgene.In some embodiments, the first transgene encodes a Collagen alpha-1(VII) chain polypeptide, the second transgene encodes a Lysylhydroxylase 3 polypeptide, and the third transgene encodes a Keratintype I cytoskeletal 17 polypeptide. In some embodiments, thepharmaceutical composition is administered topically or transdermally tothe subject. In some embodiments, the pharmaceutical composition isadministered subcutaneously or intradermally to the subject. In someembodiments, the pharmaceutical composition is administered one, twothree, four, five or more times per day. In some embodiments, thepharmaceutical composition is administered to one or more affectedand/or unaffected areas of the subject. In some embodiments, the diseaseor disorder of the skin is one or more of epidermolysis bullosa, skincancer, psoriasis, lichen planus, lupus, rosacea, eczema, cutaneouscandidiasis, cellulitis, impetigo, decubitus ulcers, erysipelas,ichthyosis vulgaris, dermatomyositis, acrodermatitis, stasis dermatitis,nethertons syndrome, epidermolysis bullosa simplex (LAMB3 gene),autosomal recessive congenital ichthyosis, xeroderma pigmentosa, andpemphigoid.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed incolor. Copies of this patent or patent application publication withcolor drawings will be provided by the Office upon request and paymentof the necessary fee.

FIGS. 1A-F show schematics of wild-type and modified herpes simplexvirus genomes. FIG. 1A shows a wild-type herpes simplex virus genome.FIG. 1B shows a modified herpes simplex virus genome comprising atransgene encoding a Collagen alpha-1 (VII) chain polypeptide. FIG. 1Cshows a modified herpes simplex virus genome comprising two transgenes,one encoding a Collagen alpha-1 (VII) chain polypeptide and the otherencoding a Lysyl hydroxylase 3 polypeptide, with the transgenes encodedon the same strand of DNA. FIG. 1D shows a modified herpes simplex virusgenome comprising two transgenes, one encoding a Collagen alpha-1 (VII)chain polypeptide and the other encoding a Lysyl hydroxylase 3polypeptide, with the transgenes encoded on opposite strands of DNA inan antisense orientation. FIG. 1E shows a modified herpes simplex virusgenome comprising a transgene that is polycistronic, encoding a Collagenalpha-1 (VII) chain polypeptide and a Lysyl hydroxylase 3 polypeptideseparated by an internal ribosomal entry site (IRES). FIG. 1F shows amodified herpes simplex virus genome comprising a transgene encoding achimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a linker polypeptide, and a Lysyl hydroxylase 3polypeptide.

FIGS. 2A-G show additional schematics of wild-type and modified herpessimplex virus genomes. FIG. 2A shows a wild-type herpes simplex virusgenome. FIG. 2B shows a modified herpes simplex virus genome comprisingdeletions of the coding sequences of ICP4 (both copies), ICP27, and UL55and deletions of the promoter sequences of ICP22 and ICP47, with twotransgenes encoding Collagen alpha-1 (VII) chain polypeptides integratedat the ICP4 loci. FIG. 2C shows a modified herpes simplex virus genomecomprising deletions of the coding sequences of ICP4 (both copies) andICP22, with two transgenes encoding Collagen alpha-1 (VII) chainpolypeptides integrated at the ICP4 loci. FIG. 2D shows a modifiedherpes simplex virus genome comprising deletions of the coding sequencesof ICP0 and ICP4 (both copies), with two transgenes encoding Collagenalpha-1 (VII) chain polypeptides integrated at the ICP4 loci. FIG. 2Eshows a modified herpes simplex virus genome comprising deletions of thecoding sequences of ICP0, ICP4 (both copies), and ICP22, with twotransgenes encoding Collagen alpha-1 (VII) chain polypeptides integratedat the ICP4 loci. FIG. 2F shows a modified herpes simplex virus genomecomprising deletions of the coding sequences of ICP0, ICP4 (bothcopies), ICP22, and ICP27, with two transgenes encoding Collagen alpha-1(VII) chain polypeptides integrated at the ICP4 loci. FIG. 2G shows amodified herpes simplex virus genome comprising deletions of the codingsequences of ICP0, ICP4 (both copies), ICP22, ICP27, and UL55, with twotransgenes encoding Collagen alpha-1 (VII) chain polypeptides integratedat the ICP4 loci.

FIG. 3 shows a schematic of “KB103”, a replication-defective herpessimplex type-1 virus (HSV-1) carrying a human collagen 7 (COL7A1)expression cassette.

FIGS. 4A-4B show dose-dependent increases in COLT transcript levels fromKB103-infeted RDEB human dermal keratinocytes (FIG. 4A) and RDEB humandermal fibroblasts (FIG. 4B). Transcripts were quantified relative toβ-actin levels and normalized to expression in uninfected cells.

FIGS. 5A-5B show human Col7 protein expression detected inKB103-infected cells. FIG. 5A shows human Col7 protein expression inuninfected normal and RDEB fibroblasts, as well as fibroblasts infectedwith KB103 at the indicated multiplicity of infection (MOI). FIG. 5Bshows human Col7 protein expression in uninfected normal and RDEBkeratinocytes, as well as keratinocytes infected with KB103 at theindicated multiplicity of infection (MOI). Human GAPDH proteinexpression is shown as a loading control.

FIG. 6 shows human COL7A1 protein expression in uninfected (control) orKB103 infected (C7, MOI 3) RDEB human dermal fibroblasts (EB HDF),normal human dermal keratinocytes (Normal HDK), and RDEB human dermalkeratinocytes (RDEB HDK), as assessed by immunofluorescence.

FIG. 7 shows human Col7 and LH3 protein expression in uninfected normaland RDEB human dermal keratinocytes, as well as keratinocytes infectedwith KB103 at the indicated MOI. Human GAPDH protein expression is shownas a loading control.

FIG. 8 shows human TSP-1 protein expression in uninfected normal andRDEB human dermal fibroblasts, as well as fibroblasts infected withKB103 at the indicated MOI. Human GAPDH protein expression is shown as aloading control.

FIGS. 9A-9B show cellular adhesion of uninfected (control) RDEB humandermal keratinocytes, and keratinocytes infected with KB103 at theindicated MOIs, to wells treated with increasing concentration of rattail Collagen 1 (FIG. 9A) and human Fibronectin (FIG. 9B)

FIG. 10 shows Col7 deposition at the basement membrane zone (BMZ) inKB103 infected skin-equivalent organotypic cultures byimmunofluorescence.

FIG. 11 shows the quantification of viral genome copy number and humanCol7 transcript levels in tissue isolated from KB103-infected mice.

FIG. 12 shows human Col7 protein expression in dermal tissue fromKB103-infected mice by immunofluorescence, including the initiation ofhuman Col7 deposition at the basement membrane zone (BMZ).

DETAILED DESCRIPTION

The present disclosure relates, in part, to pharmaceutical compositionscomprising one or more polynucleotides encoding a Collagen alpha-1 (VII)chain polypeptide, a Lysyl hydroxylase 3 polypeptide, a Keratin type Icytoskeletal 17 polypeptide, and/or a chimeric polypeptide thereof. Insome embodiments, the pharmaceutical composition comprises a vector,wherein the vector comprises one or more transgenes encoding a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, aKeratin type I cytoskeletal 17 polypeptide, and/or a chimericpolypeptide thereof. In some embodiments, the vector comprises one ormore transgenes suitable for enhancing, increasing, augmenting, and/orsupplementing the levels of Collagen alpha-1 (VII) chain polypeptideand/or Lysyl hydroxylase 3 polypeptide and/or Keratin type Icytoskeletal 17 polypeptide in one or more cells of a subject. Thepresent disclosure also relates, in part, to methods of providingprophylactic, palliative, or therapeutic relief of a wound, disorder, ordisease of the skin (e.g. dystrophic epidermolysis bullosa) in a subjectby administering (e.g., topically or transdermally administering) apharmaceutical composition described herein.

The following description sets forth exemplary methods, parameters, andthe like. It should be recognized, however, that such description is notintended as a limitation on the scope of the present disclosure but isinstead provided as a description of exemplary embodiments.

General Techniques

The techniques and procedures described or referenced herein aregenerally well understood and commonly employed using conventionalmethodology by those skilled in the art, such as, for example, thewidely utilized methodologies described in Sambrook et al., MolecularCloning: A Laboratory Manual 3d edition (2001) Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y.; Current Protocols inMolecular Biology (F. M. Ausubel, et al. eds., (2003)); the seriesMethods in Enzymology (Academic Press, Inc.): PCR 2: A PracticalApproach (M. J. MacPherson, B. D. Hames and G. R. Taylor eds. (1995)),Harlow and Lane, eds. (1988); Oligonucleotide Synthesis (M. J. Gait,ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: ALaboratory Notebook (J. E. Cellis, ed., 1998) Academic Press; AnimalCell Culture (R. I. Freshney), ed., 1987); Introduction to Cell andTissue Culture (J. P. Mather and P. E. Roberts, 1998) Plenum Press; Celland Tissue Culture: Laboratory Procedures (A. Doyle, J. B. Griffiths,and D. G. Newell, eds., 1993-8) J. Wiley and Sons; Gene Transfer Vectorsfor Mammalian Cells (J. M. Miller and M. P. Calos, eds., 1987); PCR: ThePolymerase Chain Reaction, (Mullis et al., eds., 1994); Short Protocolsin Molecular Biology (Wiley and Sons, 1999).

Definitions

Before describing the invention in detail, it is to be understood thatthis invention is not limited to particular compositions or biologicalsystems, which can, of course, vary. It is also to be understood thatthe terminology used herein is for the purpose of describing particularembodiments only, and is not intended to be limiting.

As used herein, the singular forms “a”, “an” and “the” include pluralreferents unless the content clearly dictates otherwise. Thus, forexample, reference to “a molecule” optionally includes a combination oftwo or more such molecules, and the like.

As used herein, the term “about” refers to the usual error range for therespective value readily known to the skilled person in this technicalfield. Reference to “about” a value or parameter herein includes (anddescribes) embodiments that are directed to that value or parameter perse.

As used herein, the terms “polynucleotide”, “nucleic acid sequence”,“nucleic acid”, and variations thereof shall be generic topolydeoxyribonucleotides (containing 2-deoxy-D-ribose), topolyribonucleotides (containing D-ribose), to any other type ofpolynucleotide that is an N-glycoside of a purine or pyrimidine base,and to other polymers containing non-nucleotidic backbones, providedthat the polymers contain nucleobases in a configuration that allows forbase pairing and base stacking, as found in DNA and RNA. Thus, theseterms include known types of nucleic acid sequence modifications, forexample, substitution of one or more of the naturally occurringnucleotides with an analog, and inter-nucleotide modifications.

As used herein, a nucleic acid is “operatively linked” or “operablylinked” when it is placed into a functional relationship with anothernucleic acid sequence. For example, a promoter or enhancer is operablylinked to a coding sequence if it affects the transcription of thesequence; or a ribosome binding site is operably linked to a codingsequence if it is positioned so as to facilitate translation. Generally,“operably linked” means that the DNA sequences being linked arecontiguous.

As used herein, the term “vector” refers to discrete elements that areused to introduce heterologous nucleic acids into cells for eitherexpression or replication thereof. An expression vector includes vectorscapable of expressing nucleic acids that are operatively linked withregulatory sequences, such as promoter regions, that are capable ofeffecting expression of such nucleic acids. Thus, an expression vectormay refer to a DNA or RNA construct, such as a plasmid, a phage,recombinant virus or other vector that, upon introduction into anappropriate host cell, results in expression of the nucleic acids.Appropriate expression vectors are well known to those of skill in theart and include those that are replicable in eukaryotic cells and thosethat remain episomal or those which integrate into the host cell genome.

As used herein, an “open reading frame” or “ORF” refers to a continuousstretch of nucleic acids, either DNA or RNA, that encode a protein orpolypeptide. Typically, the nucleic acids comprise a translation startsignal or initiation codon, such as ATG or AUG, and a termination codon.

As used herein, an “internal ribosome entry site” or “IRES” refers to anucleotide sequence that allows for translation initiation in themiddle, e.g. after the first start codon, of an mRNA sequence.

As used herein, an “untranslated region” or “UTR” refers tounstranslated nucleic acids at the 5′ and/or 3′ ends of an open readingframe. The inclusion of one or more UTRs in a polynucleotide may affectpost-transcriptional regulation, mRNA stability, and/or translation ofthe polynucleotide.

As used herein, the term “transgene” refers to a polynucleotide that iscapable of being transcribed into RNA and translated and/or expressedunder appropriate conditions, after being introduced into a cell. Insome aspects, it confers a desired property to a cell into which it wasintroduced, or otherwise leads to a desired therapeutic or diagnosticoutcome.

As used herein, the terms “polypeptide,” “protein,” and “peptide” areused interchangeably and may refer to a polymer of two or more aminoacids.

As used herein, a “subject”, “host”, or an “individual” refers to anyanimal classified as a mammal, including humans, domestic and farmanimals, and zoo, sports, or pet animals, such as dogs, horses, cats,cows, as well as animals used in research, such as mice and rats, etc.In some embodiments, the mammal is human.

As used herein, “topical administration” or “topically administering”refers to the delivery of a composition to a subject by contacting,directly or otherwise, a formulation comprising the composition to allor a portion of the skin of a subject. The term encompasses severalroutes of administration including, but not limited to, topical andtransdermal. Topical administration is used as a means to deliver acomposition to the epidermis or dermis of a subject, or to specificstrata thereof.

As used herein, an “effective amount” is at least the minimum amountrequired to effect a measurable improvement or prevention of one or moresymptoms of a particular disorder. An effective amount is also one inwhich any toxic or detrimental effects of the treatment are outweighedby the therapeutically beneficial effects. For prophylactic use,beneficial or desired results include results such as eliminating orreducing the risk, lessening the severity, or delaying the onset of thedisease, its complications and intermediate pathological phenotypespresenting during development of the disease. For therapeutic use,beneficial or desired results include clinical results such asdecreasing one or more symptoms resulting from the disease, increasingthe quality of life of those suffering from the disease, delaying theprogression of the disease, and/or prolonging survival. An effectiveamount can be administered in one or more administrations.

Pharmaceutical Compositions

Polynucleotides

In one aspect, provided herein is a pharmaceutical compositioncomprising one or more polynucleotides encoding a Collagen alpha-1 (VII)chain (Col7) polypeptide, a Lysyl hydroxylase 3 (LH3) polypeptide, aKeratin type I cytoskeletal 17 (KRT17) polypeptide, and/or a chimericpolypeptide thereof. In some embodiments, the pharmaceutical compositioncomprises one or more polynucleotides encoding a Collagen alpha-1 (VII)chain polypeptide. In some embodiments, the pharmaceutical compositioncomprises one or more polynucleotides encoding a Lysyl hydroxylase 3polypeptide. In some embodiments, the pharmaceutical compositioncomprises one or more polynucleotides encoding a Keratin type Icytoskeletal 17 polypeptide. In some embodiments, the pharmaceuticalcomposition comprises one or more polynucleotides encoding a chimericpolypeptide. In some embodiments, the pharmaceutical compositioncomprises one or more polynucleotides encoding a Collagen alpha-1 (VII)chain polypeptide and a Lysyl hydroxylase 3 polypeptide. In someembodiments, the pharmaceutical composition comprises one or morepolynucleotides encoding a Collagen alpha-1 (VII) chain polypeptide anda Keratin type I cytoskeletal 17 polypeptide. In some embodiments, thepharmaceutical composition comprises one or more polynucleotidesencoding a Lysyl hydroxylase 3 polypeptide and a Keratin type Icytoskeletal 17 polypeptide. In some embodiments, the pharmaceuticalcomposition comprises one or more polynucleotides encoding a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, anda Keratin type I cytoskeletal 17 polypeptide.

In some embodiments, the pharmaceutical composition comprises a vector,wherein the vector encodes one or more transgenes comprising apolynucleotide described herein. In some embodiments, the pharmaceuticalcomposition comprises a vector, wherein the vector comprises one or moretransgenes encoding a Collagen alpha-1 (VII) chain polypeptide, a Lysylhydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide,and/or a chimeric polypeptide thereof. In some embodiments, the vectorcomprises one or more transgenes encoding a Collagen alpha-1 (VII) chainpolypeptide. In some embodiments, the vector comprises one or moretransgenes encoding a Lysyl hydroxylase 3 polypeptide. In someembodiments, the vector comprises one or more transgenes encoding aKeratin type I cytoskeletal 17 polypeptide. In some embodiments, thevector comprises one or more transgenes encoding a chimeric polypeptide.In some embodiments, the vector comprises one or more transgenesencoding a Collagen alpha-1 (VII) chain polypeptide and one or moretransgenes encoding a Lysyl hydroxylase 3 polypeptide. In someembodiments, the vector comprises one or more transgenes encoding aCollagen alpha-1 (VII) chain polypeptide and one or more transgenesencoding a Keratin type I cytoskeletal 17 polypeptide. In someembodiments, the vector comprises one or more transgenes encoding aLysyl hydroxylase 3 polypeptide and one or more transgenes encoding aKeratin type I cytoskeletal 17 polypeptide. In some embodiments, thevector comprises one or more transgenes encoding a Collagen alpha-1(VII) chain polypeptide, one or more transgenes encoding a Lysylhydroxylase 3 polypeptide, and one or more transgenes encoding a Keratintype I cytoskeletal 17 polypeptide.

In some embodiments, the pharmaceutical composition comprises asynthetic RNA, wherein the synthetic RNA encodes one or more transgenescomprising a polynucleotide described herein. In some embodiments, thepharmaceutical composition comprises a synthetic RNA, wherein thesynthetic RNA comprises one or more transgenes encoding a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, aKeratin type I cytoskeletal 17 polypeptide, and/or a chimericpolypeptide thereof. In some embodiments, the synthetic RNA comprisesone or more transgenes encoding a Collagen alpha-1 (VII) chainpolypeptide. In some embodiments, the synthetic RNA comprises one ormore transgenes encoding a Lysyl hydroxylase 3 polypeptide. In someembodiments, the synthetic RNA comprises one or more transgenes encodinga Keratin type I cytoskeletal 17 polypeptide. In some embodiments, thesynthetic RNA comprises one or more transgenes encoding a chimericpolypeptide. In some embodiments, the synthetic RNA comprises one ormore transgenes encoding a Collagen alpha-1 (VII) chain polypeptide andone or more transgenes encoding a Lysyl hydroxylase 3 polypeptide. Insome embodiments, the synthetic RNA comprises one or more transgenesencoding a Collagen alpha-1 (VII) chain polypeptide and one or moretransgenes encoding a Keratin type I cytoskeletal 17 polypeptide. Insome embodiments, the synthetic RNA comprises one or more transgenesencoding a Lysyl hydroxylase 3 polypeptide and one or more transgenesencoding a Keratin type I cytoskeletal 17 polypeptide. In someembodiments, the synthetic RNA comprises one or more transgenes encodinga Collagen alpha-1 (VII) chain polypeptide, one or more transgenesencoding a Lysyl hydroxylase 3 polypeptide, and one or more transgenesencoding a Keratin type I cytoskeletal 17 polypeptide.

Collagen Alpha-1 (VII) Chain

In some aspects, a polynucleotide of the present disclosure encodes aCollagen alpha-1 (VII) chain polypeptide. An example of a polynucleotidethat encodes a Collagen alpha-1 (VII) chain polypeptide is SEQ ID NO: 1.Polynucleotides of the present disclosure also include polynucleotideshaving at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99%, or 100% identity to thesequence of SEQ ID NO: 1.

In some embodiments, a polynucleotide encoding a Collagen alpha-1 (VII)chain polypeptide is a polynucleotide that encodes an N-terminaltruncation, a C-terminal truncation, or a fragment of a Collagen alpha-1(VII) chain polypeptide. Polynucleotides encoding an N-terminaltruncation, a C-terminal truncation, or a fragment of a Collagen alpha-1(VII) chain polypeptide include polynucleotides that have at least 25,at least 50, at least 75, at least 100, at least 125, at least 150, atleast 175, at least 200, at least 250, at least 300, or at least 350, atleast 500, at least 1000, at least 2500, at least 5000, at least 7500,but fewer than 8835, consecutive nucleotides of SEQ ID NO: 1.

In some embodiments, a polynucleotide encoding a Collagen alpha-1 (VII)chain polypeptide is a polynucleotide that encodes a polypeptide havingan amino acid sequence of SEQ ID NO: 2. In some embodiments, apolynucleotide encoding a Collagen alpha-1 (VII) chain polypeptide is apolynucleotide that encodes a polypeptide having an amino acid sequencehaving at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99%, or 100% identity to thesequence of SEQ ID NO: 2. In some embodiments, the present disclosurerelates to polynucleotides that encode polypeptides that are homologs ofthe H. sapiens Collagen alpha-1 (VII) chain polypeptide. Methods ofidentifying polypeptides that are homologs of a polypeptide of interestare well known to one of skill in the art.

In some embodiments, a polynucleotide encoding a Collagen alpha-1 (VII)chain polypeptide is a polynucleotide that encodes N-terminaltruncations, C-terminal truncations, or fragments of the amino acidsequence of SEQ ID NO: 2. N-terminal truncations, C-terminaltruncations, or fragments may comprise at least 10, at least 12, atleast 14, at least 16, at least 18, at least 20, at least 30, at least40, at least 50, at least 75, at least 100, at least 250, at least 500,at least 750, at least 1000, at least 1500, at least 2000, or at least2500, but fewer than 2944, consecutive amino acids of SEQ ID NO: 2.

In some embodiments, the polynucleotide encoding a Collagen alpha-1(VII) chain polypeptide expresses the Collagen alpha-1 (VII) chainpolypeptide when the polynucleotide is delivered into one or more targetcells of a subject. In some embodiments, expression of the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements the levels of a Collagen alpha-1 chain polypeptide in one ormore target cells. In some embodiments, expression of the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements the function of a Collagen alpha-1 chain polypeptide in oneor more target cells. In some embodiments, expression of the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements the activity of a Collagen alpha-1 chain polypeptide in oneor more target cells. In some embodiments, expression of the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements anchoring fibril formation of the subject. In someembodiments, expression of the Collagen alpha-1 (VII) chain polypeptideenhances, increases, augments, and/or supplements epithelial basementmembrane organization and/or epithelial basement adherence of thesubject. In some embodiments, expression of the Collagen alpha-1 (VII)chain polypeptide enhances, increases, augments, and/or supplementsdermoepidermal junction integrity of the subject.

Lysyl Hydroxylase 3

In some aspects, a polynucleotide of the present disclosure encodes aLysyl hydroxylase 3 polypeptide. An example of a polynucleotide thatencodes a Lysyl hydroxylase 3 polypeptide is SEQ ID NO: 3.Polynucleotides of the present disclosure also include polynucleotideshaving at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99%, or 100% identity to thesequence of SEQ ID NO: 3.

In some embodiments, a polynucleotide encoding a Lysyl hydroxylase 3polypeptide is a polynucleotide that encodes an N-terminal truncation, aC-terminal truncation, or a fragment of a Lysyl hydroxylase 3polypeptide. Polynucleotides encoding an N-terminal truncation, aC-terminal truncation, or a fragment of a Lysyl hydroxylase 3polypeptide include polynucleotides that have at least 25, at least 50,at least 75, at least 100, at least 125, at least 150, at least 175, atleast 200, at least 250, at least 300, at least 350, at least 500, atleast 750, at least 1000, at least 1500, or at least 2000, but fewerthan 2217, consecutive nucleotides of SEQ ID NO: 3.

In some embodiments, a polynucleotide encoding a Lysyl hydroxylase 3polypeptide is a polynucleotide that encodes a polypeptide having anamino acid sequence of SEQ ID NO: 4. In some embodiments, apolynucleotide encoding a Lysyl hydroxylase 3 polypeptide is apolynucleotide that encodes a polypeptide having an amino acid sequencehaving at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99%, or 100% identity to thesequence of SEQ ID NO: 4. In some embodiments, the present disclosurerelates to polynucleotides encoding polypeptides that are homologs ofthe H. sapiens Lysyl hydroxylase 3 polypeptide. Methods of identifyingpolypeptides that are homologs of a polypeptide of interest are wellknown to one of skill in the art.

In some embodiments, a polynucleotide encoding a Lysyl hydroxylase 3polypeptide is a polynucleotide that encodes N-terminal truncations,C-terminal truncations, or fragments of the amino acid sequence of SEQID NO: 4. N-terminal truncations, C-terminal truncations, or fragmentsmay comprise at least 10, at least 12, at least 14, at least 16, atleast 18, at least 20, at least 30, at least 40, at least 50, at least75, at least 100, at least 200, at least 300, at least 400, at least500, at least 600, or at least 700, but fewer than 738, consecutiveamino acids of SEQ ID NO: 4.

In some embodiments, the polynucleotide encoding a Lysyl hydroxylase 3polypeptide expresses the Lysyl hydroxylase 3 polypeptide when thepolynucleotide is delivered into one or more target cells of a subject.In some embodiments, expression of the Lysyl hydroxylase 3 polypeptideenhances, increases, augments, and/or supplements the levels of a Lysylhydroxylase 3 polypeptide in one or more target cells. In someembodiments, expression of the Lysyl hydroxylase 3 polypeptide enhances,increases, augments, and/or supplements the function of a Lysylhydroxylase 3 polypeptide in one or more target cells. In someembodiments, expression of the Lysyl hydroxylase 3 polypeptide enhances,increases, augments, and/or supplements the activity of a Lysylhydroxylase 3 polypeptide in one or more target cells. In someembodiments, expression of the Lysyl hydroxylase 3 polypeptide enhances,increases, augments, and/or supplements the formation of hydroxylysineresidues on one or more collagen polypeptides of the subject. In someembodiments, expression of the Lysyl hydroxylase 3 polypeptide enhances,increases, augments, and/or supplements anchoring fibril formation ofthe subject. In some embodiments, expression of the Lysyl hydroxylase 3polypeptide enhances, increases, augments, and/or supplements epithelialbasement membrane organization and/or epithelial basement adherence ofthe subject. In some embodiments, expression of the Lysyl hydroxylase 3polypeptide enhances, increases, augments, and/or supplementsdermoepidermal junction integrity of the subject.

In some embodiments, the polynucleotide encoding a Collagen alpha-1(VII) chain polypeptide and the polynucleotide encoding a Lysylhydroxylase 3 polypeptide are delivered to the same cell of a subject.In some embodiments, the polynucleotide encoding a Collagen alpha-1chain (VII) polypeptide and the polynucleotide encoding a Lysylhydroxylase 3 polypeptide express the Collagen alpha-1 (VII) chainpolypeptide and the Lysyl hydroxylase 3 polypeptide when thepolynucleotides are delivered into the same cell of a subject. In someembodiments, the polynucleotide encoding a Collagen alpha-1 (VII) chainpolypeptide and the polynucleotide encoding a Lysyl hydroxylase 3polypeptide express the Collagen alpha-1 (VII) chain polypeptide andLysyl hydroxylase 3 polypeptide at equimolar ratios.

Keratin Type I Cytoskeletal 17

In some aspects, a polynucleotide of the present disclosure encodes aKeratin type I cytoskeletal 17 polypeptide. An example of apolynucleotide that encodes a Keratin type I cytoskeletal 17 polypeptideis SEQ ID NO: 29. Polynucleotides of the present disclosure also includepolynucleotides having at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identity to the sequence of SEQ ID NO: 29.

In some embodiments, a polynucleotide encoding a Keratin type Icytoskeletal 17 polypeptide is a polynucleotide that encodes anN-terminal truncation, a C-terminal truncation, or a fragment of aKeratin type I cytoskeletal 17 polypeptide. Polynucleotides encoding anN-terminal truncation, a C-terminal truncation, or a fragment of aCollagen alpha-1 (VII) chain polypeptide include polynucleotides thathave at least 25, at least 50, at least 75, at least 100, at least 125,at least 150, at least 175, at least 200, at least 250, at least 300, orat least 350, at least 500, at least 1000, at least 1250, but fewer than1299, consecutive nucleotides of SEQ ID NO: 29.

In some embodiments, a polynucleotide encoding a Keratin type Icytoskeletal 17 polypeptide is a polynucleotide that encodes apolypeptide having an amino acid sequence of SEQ ID NO: 30. In someembodiments, a polynucleotide encoding a Keratin type I cytoskeletal 17polypeptide is a polynucleotide that encodes a polypeptide having anamino acid sequence having at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identity to the sequence of SEQ ID NO: 30. In some embodiments, thepresent disclosure relates to polynucleotides that encode polypeptidesthat are homologs of the H. sapiens Keratin type I cytoskeletal 17polypeptide. Methods of identifying polypeptides that are homologs of apolypeptide of interest are well known to one of skill in the art.

In some embodiments, a polynucleotide encoding a Keratin type Icytoskeletal 17 polypeptide is a polynucleotide that encodes N-terminaltruncations, C-terminal truncations, or fragments of the amino acidsequence of SEQ ID NO: 30. N-terminal truncations, C-terminaltruncations, or fragments may comprise at least 10, at least 12, atleast 14, at least 16, at least 18, at least 20, at least 30, at least40, at least 50, at least 75, at least 100, at least 150, at least 200,at least 250, at least 300, at least 350, at least 400, at least 425,but fewer than 432, consecutive amino acids of SEQ ID NO: 30.

In some embodiments, the polynucleotide encoding a Keratin type Icytoskeletal 17 polypeptide expresses the Keratin type I cytoskeletal 17polypeptide when the polynucleotide is delivered into one or more targetcells of a subject. In some embodiments, expression of the Keratin typeI cytoskeletal 17 polypeptide enhances, increases, augments, and/orsupplements the levels of a Keratin type I cytoskeletal 17 polypeptidein one or more target cells. In some embodiments, expression of theKeratin type I cytoskeletal 17 polypeptide enhances, increases,augments, and/or supplements the function of a Keratin type Icytoskeletal 17 polypeptide in one or more target cells. In someembodiments, expression of the Keratin type I cytoskeletal 17polypeptide enhances, increases, augments, and/or supplements theactivity of a Keratin type I cytoskeletal 17 polypeptide in one or moretarget cells. In some embodiments, expression of the Keratin type Icytoskeletal 17 polypeptide enhances, increases, augments, and/orsupplements wound healing in the subject.

Chimeric Polypeptide Comprising Linker

In some embodiments, a polynucleotide of the present disclosure encodesa chimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide and a Lysyl hydroxylase 3 polypeptide. In some embodiments,the polynucleotide encoding a chimeric polypeptide further comprises apolynucleotide encoding a linker polypeptide. In some embodiments, thepolynucleotide encoding a linker polypeptide is a polynucleotideencoding a cleavable linker polypeptide. Examples of polynucleotidesencoding cleavable linker polypeptides may include, but are not limitedto, polynucleotides encoding a T2A, P2A, E2A, or F2A linker polypeptide.In some embodiments, the polynucleotide encoding a linker polypeptide isa polynucleotide encoding a T2A linker polypeptide. In some embodiments,the polynucleotide encoding a linker polypeptide is a polynucleotideencoding a P2A linker polypeptide. In some embodiments, thepolynucleotide encoding a linker polypeptide is a polynucleotideencoding an E2A linker polypeptide. In some embodiments, thepolynucleotide encoding a linker polypeptide is a polynucleotideencoding an F2A linker polypeptide.

In some aspects, a polynucleotide of the present disclosure encodes alinker polypeptide. Examples of polynucleotides that encode linkerpolypeptides are SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, and SEQ IDNO: 11. Polynucleotides of the present disclosure also includepolynucleotides having at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identity to the sequence of SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO:9, or SEQ ID NO: 11.

In some embodiments, a polynucleotide encoding a linker polypeptide is apolynucleotide that encodes an N-terminal truncation, a C-terminaltruncation, or a fragment of a linker polypeptide. Polynucleotidesencoding an N-terminal truncation, a C-terminal truncation, or afragment of a linker polypeptide include polynucleotides that have atleast 5, at least 10, at least 15, at least 20, at least 25, at least30, at least 35, at least 40, at least 45, at least 50, at least 55, orat least 60, but fewer than 66, consecutive nucleotides of SEQ ID NO: 5,SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11.

In some embodiments, a polynucleotide encoding a linker polypeptide is apolynucleotide that encodes a polypeptide having an amino acid sequenceof SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12. In someembodiments, a polynucleotide encoding a linker polypeptide is apolynucleotide that encodes a polypeptide having an amino acid sequencehaving at least 50%, at least 55%, at least 60%, at least 65%, at least70%, at least 75%, at least 80%, at least 85%, at least 90%, at least91%, at least 92%, at least 93%, at least 94%, at least 95%, at least96%, at least 97%, at least 98%, at least 99%, or 100% identity to thesequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12.

In some embodiments, a polynucleotide encoding a linker polypeptide is apolynucleotide that encodes N-terminal truncations, C-terminaltruncations, or fragments of the amino acid sequence of SEQ ID NO: 6,SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12. N-terminal truncations,C-terminal truncations, or fragments may comprise at least 4, at least6, at least 8, at least 10, at least 12, at least 14, at least 16, atleast 18, or at least 20, but fewer than 22, consecutive amino acids ofSEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10, or SEQ ID NO: 12.

In some embodiments, the polynucleotide encoding a linker polypeptidefurther comprises a polynucleotide encoding one or more furin cleavagesites. In some embodiments, the polynucleotide encoding one or morefurin cleavage sites encode an amino acid sequence that is the same orsubstantially similar to the sequence of the canonical furin cleavagesite (Arg-X-(Arg/Lys)-Arg). In some embodiments, the one or more furincleavage sites are encoded upstream of the linker polypeptide. In someembodiments, the one or more furin cleavage sites are encoded downstreamof the linker polypeptide. In some embodiments, the one or more furincleavage sites are encoded upstream of a T2A linker polypeptide. In someembodiments, the one or more furin cleavage sites are encoded downstreamof a T2A linker polypeptide. In some embodiments, the one or more furincleavage sites are encoded upstream of a P2A linker polypeptide. In someembodiments, the one or more furin cleavage sites are encoded downstreamof a P2A linker polypeptide. In some embodiments, the one or more furincleavage sites are encoded upstream of an E2A linker polypeptide. Insome embodiments, the one or more furin cleavage sites are encodeddownstream of an E2A linker polypeptide. In some embodiments, the one ormore furin cleavage sites are encoded upstream of an F2A linkerpolypeptide. In some embodiments, the one or more furin cleavage sitesare encoded downstream of an F2A linker polypeptide.

In some embodiments, the polynucleotide encoding a chimeric polypeptideencodes a chimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a linker polypeptide, and a Lysyl hydroxylase 3polypeptide. In some embodiments, the polynucleotide encoding a chimericpolypeptide comprises, from 5′ to 3′, a polynucleotide encoding aCollagen alpha-1 (VII) chain polypeptide, a polynucleotide encoding alinker polypeptide, and a polynucleotide encoding a Lysyl hydroxylase 3polypeptide. In some embodiments, the polynucleotide encoding a chimericpolypeptide comprises, from 5′ to 3′, a polynucleotide encoding a Lysylhydroxylase 3 polypeptide, a polynucleotide encoding a linkerpolypeptide, and a polynucleotide encoding a Collagen alpha-1 (VII)chain polypeptide.

Examples of polynucleotides encoding chimeric polypeptides comprising aCollagen alpha-1 (VII) chain polypeptide, a linker polypeptide, and aLysyl hydroxylase 3 polypeptide are SEQ ID NO: 13, SEQ ID NO: 15, SEQ IDNO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, andSEQ ID NO: 27. Polynucleotides of the present disclosure also includepolynucleotides having at least 50%, at least 55%, at least 60%, atleast 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identity to the sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ IDNO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, orSEQ ID NO: 27.

In some embodiments, a polynucleotide encoding a chimeric polypeptide isa polynucleotide that encodes an N-terminal truncation, a C-terminaltruncation, or a fragment of a chimeric polypeptide. Polynucleotidesencoding an N-terminal truncation, a C-terminal truncation, or afragment of a chimeric polypeptide include polynucleotides that have atleast 25, at least 50, at least 75, at least 100, at least 125, at least150, at least 175, at least 200, at least 250, at least 300, at least350, at least 400, at least 450, at least 500, at least 550, at least600, at least 650, at least 700, at least 750, at least 800, at least850, at least 900, at least 950, at least 1000, at least 2000, at least3000, at least 4000, at least 5000, at least 6000, at least 7000, atleast 8000, at least 9000, or at least 10000, but fewer than 11121,consecutive nucleotides of SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17,SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, or SEQ IDNO: 27.

In some embodiments, a polynucleotide encoding a chimeric polypeptidecomprising a Collagen alpha-1 (VII) chain polypeptide, a linkerpolypeptide, and a Lysyl hydroxylase 3 polypeptide is a polynucleotidethat encodes a polypeptide having an amino acid sequence of SEQ ID NO:14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ IDNO: 24, SEQ ID NO: 26 or SEQ ID NO: 28. In some embodiments, apolynucleotide encoding a chimeric polypeptide comprising a Collagenalpha-1 (VII) chain polypeptide, a linker polypeptide, and a Lysylhydroxylase 3 polypeptide is a polynucleotide that encodes a polypeptidehaving an amino acid sequence having at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99%, or 100% identity to the sequence of SEQ ID NO: 14, SEQ ID NO:16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ IDNO: 26 or SEQ ID NO: 28.

In some embodiments, a polynucleotide encoding a chimeric polypeptidecomprising a Collagen alpha-1 (VII) chain polypeptide, a linkerpolypeptide, and a Lysyl hydroxylase 3 polypeptide is a polynucleotidethat encodes N-terminal truncations, C-terminal truncations, orfragments of the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 16,SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO:26 or SEQ ID NO: 28. N-terminal truncations, C-terminal truncations, orfragments may comprise at least 25, at least 50, at least 75, at least100, at least 125, at least 150, at least 175, at least 200, at least250, at least 300, at least 350, at least 400, at least 450, at least500, at least 550, at least 600, at least 650, at least 700, at least750, at least 800, at least 850, at least 900, at least 950, at least1000, at least 1250, at least 1500, at least 1750, at least 2000, atleast 2250, at least 2500, at least 2750, at least 3000, at least 3250,or at least 3500, but fewer than 3706, consecutive amino acids of SEQ IDNO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQID NO: 24, SEQ ID NO: 26 or SEQ ID NO: 28.

In some embodiments, the polynucleotide encoding a chimeric polypeptideexpresses the chimeric polypeptide when the polynucleotide is deliveredinto one or more target cells of a subject. In some embodiments, thechimeric polypeptide is cleaved after being expressed in one or moretarget cells. In some embodiments, the chimeric polypeptide is cleavedwithin the linker polypeptide when expressed in one or more targetcells. In some embodiments, the chimeric polypeptide is cleaved into twopolypeptides, one comprising the Collagen alpha-1 (VII) chainpolypeptide and the other comprising the Lysyl hydroxylase 3polypeptide. In some embodiments, expression of the chimeric polypeptideenhances, increases, augments, and/or supplements the levels of aCollagen alpha-1 chain polypeptide and/or a Lysyl hydroxylase 3polypeptide in one or more target cells. In some embodiments, expressionof the chimeric polypeptide enhances, increases, augments, and/orsupplements the function of a Collagen alpha-1 chain polypeptide and/ora Lysyl hydroxylase 3 polypeptide in one or more target cells. In someembodiments, expression of the chimeric polypeptide enhances, increases,augments, and/or supplements the activity of a Collagen alpha-1 chainpolypeptide and/or a Lysyl hydroxylase 3 polypeptide in one or moretarget cells. In some embodiments, expression of the chimericpolypeptide enhances, increases, augments, and/or supplements theformation of hydroxylysine residues on one or more collagen polypeptidesof the subject. In some embodiments, expression of the chimericpolypeptide enhances, increases, augments, and/or supplements anchoringfibril formation of the subject. In some embodiments, expression of thechimeric polypeptide enhances, increases, augments, and/or supplementsepithelial basement membrane organization and/or epithelial basementadherence of the subject. In some embodiments, expression of thechimeric polypeptide enhances, increases, augments, and/or supplementsdermoepidermal junction integrity of the subject.

Polynucleotides of the present disclosure may be codon-optimized. Insome embodiments, polynucleotides of the present disclosure arecodon-optimized for human cells. In some embodiments, polynucleotides ofthe present disclosure are codon-optimized for mouse cells. In someembodiments, polynucleotides of the present disclosure arecodon-optimized for rat cells. In some embodiments, polynucleotides ofthe present disclosure are codon-optimized for hamster cells. In someembodiments, polynucleotides of the present disclosure arecodon-optimized for canine cells. In some embodiments, polynucleotidesof the present disclosure are codon-optimized for yeast cells. In someembodiments, polynucleotides of the present disclosure arecodon-optimized for bacterial cells. Polynucleotides of the presentdisclosure may be DNA polynucleotides, RNA polynucleotides, or acombination of one or more DNA polynucleotides and one or more RNApolynucleotides.

Vectors

In some aspects, the present disclosure relates to vectors, preferablyexpression vectors, containing one or more polynucleotides describedherein. In some embodiments, the vectors are DNA vectors. Generally,vectors suitable to maintain, propagate, or express polynucleotides toproduce one or more polypeptides in a subject may be used. Examples ofsuitable vectors include, but are not limited to, plasmids, cosmids,episomes, transposons, and viral vectors (e.g., adenoviral, vacciniaviral, Sindbis-viral, measles, herpes viral, lentiviral, retroviral,adeno-associated viral vectors, etc.). In some embodiments, the vectoris capable of autonomous replication in a host cell. In someembodiments, the vector is incapable of autonomous replication in a hostcell. In some embodiments, the vector is capable of integrating into ahost DNA. Methods for making vectors containing one or morepolynucleotides of interest are well known to one of skill in the art.

In some embodiments, the vector is a herpes simplex virus vector. Insome embodiments, the herpes simplex virus vector is a herpes virusamplicon vector. Herpes virus amplicon vectors, including structuralfeatures and methods of making the vectors, are generally known in theart (de Silva S. and Bowers W. “Herpes Virus Amplicon Vectors”. Viruses2009, 1, 594-629). In some embodiments, the vector is an HSV-1 amplicon.In some embodiments, the vector is an HSV-1 hybrid amplicon. Examples ofHSV-1 hybrid amplicons may include, but are not limited to, HSV/AAVhybrid amplicons, HSV/EBV hybrid amplicons, HSV/EBV/RV hybrid amplicons,and HSV/Sleeping Beauty hybrid amplicons. In some embodiments, thevector is an HSV/AAV hybrid amplicon. In some embodiments, the vector isan HSV/EBV hybrid amplicon. In some embodiments, the vector is anHSV/EBV/RV hybrid amplicon. In some embodiments, the vector is anHSV/Sleeping Beauty hybrid amplicons.

In some embodiments, the herpes simplex virus vector is a recombinantherpes simplex virus genome. In some embodiments, the recombinant herpessimplex virus genome has been engineered to decrease or eliminateexpression of one or more toxic herpes simplex virus genes. Methods ofengineering recombinant herpes simplex virus genomes are generallydescribed in WO2015/009952. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation. Examples ofinactivating mutations may include, but are not limited to, deletions,insertions, point mutations, and rearrangements. In some embodiments,the recombinant herpes simplex virus genome comprises an inactivatingmutation in at least one, at least two, at least three, at least four,at least five, at least six, at least seven, or all eight of the ICP0,ICP4, ICP22, ICP27, ICP47, tk, UL4 land UL55 herpes simplex virus genes.In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP0 gene. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP4 (one or both copies) gene. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP22 gene. In some embodiments, therecombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP27 gene. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP47gene. In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the UL41 gene. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the UL55 gene. In some embodiments, therecombinant herpes simplex virus genome is a recombinant HSV-1 genome, arecombinant HSV-2 genome, or any derivatives thereof. In someembodiments, the recombinant herpes simplex virus genome is arecombinant HSV-1 genome. In some embodiments, the recombinant herpessimplex virus genome is a recombinant HSV-2 genome.

In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP4 (one or both copies),ICP27, and UL55 genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP4 (oneor both copies), ICP22, ICP27, ICP47, and UL55 genes. In someembodiments, the inactivating mutation in the ICP4 (one or both copies),ICP27, and/or UL55 genes is a deletion of the coding sequence of theICP4 (one or both copies), ICP27, and/or UL55 genes. In someembodiments, the inactivating mutation in the ICP22 and ICP47 genes is adeletion in the promoter region of the ICP22 and ICP47 genes (e.g., theICP22 and ICP47 coding sequences are intact but are nottranscriptionally active). In some embodiments, the recombinant herpessimplex virus genome comprises a deletion in the coding sequence of theICP4 (one or both copies), ICP27, and UL55 genes and a deletion in thepromoter region of the ICP22 and ICP47 genes. In some embodiments, therecombinant herpes simplex virus genome further comprises aninactivating mutation in the UL41 gene. In some embodiments, therecombinant herpes simplex virus genome is a recombinant HSV-1 genome, arecombinant HSV-2 genome, or any derivatives thereof. In someembodiments, the recombinant herpes simplex virus genome is arecombinant HSV-1 genome. In some embodiments, the recombinant herpessimplex virus genome is a recombinant HSV-2 genome.

In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP4 (one or both copies) andICP22 genes. In some embodiments, the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP0 and ICP4 (one orboth copies) genes. In some embodiments, the recombinant herpes simplexvirus genome comprises an inactivating mutation in the ICP0, ICP4 (oneor both copies), and ICP22 genes. In some embodiments, the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4 (one or both copies), ICP22, and ICP27 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4 (one or both copies), ICP22,ICP27 and UL55 genes. In some embodiments, the inactivating mutation inthe ICP0, ICP4 (one or both copies), ICP22, ICP27 and/or UL55 genescomprises a deletion of the coding sequence of the ICP0, ICP4 (one orboth copies), ICP22, ICP27 and/or UL55 genes. In some embodiments, therecombinant herpes simplex virus genome comprises a deletion in thecoding sequence of the ICP0, ICP4 (one or both copies), ICP22, ICP27,and UL55 genes. In some embodiments, the recombinant herpes simplexvirus genome further comprises an inactivating mutation in the ICP47gene. In some embodiments, the recombinant herpes simplex virus genomefurther comprises an inactivating mutation in the UL41 gene. In someembodiments, the recombinant herpes simplex virus genome furthercomprises an inactivating mutation in the ICP47 gene and the UL41 gene.In some embodiments, the recombinant herpes simplex virus genome is arecombinant HSV-1 genome, a recombinant HSV-2 genome, or any derivativesthereof. In some embodiments, the recombinant herpes simplex virusgenome is a recombinant HSV-1 genome. In some embodiments, therecombinant herpes simplex virus genome is a recombinant HSV-2 genome.

In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in the ICP4 (one or both copies),ICP22, and ICP27 genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP4 (oneor both copies), ICP22, ICP27, ICP47, and UL55 genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4 (one or both copies), ICP22, andICP27 genes. In some embodiments, the recombinant herpes simplex virusgenome is a recombinant HSV-1 genome, a recombinant HSV-2 genome, or anyderivatives thereof. In some embodiments, the recombinant herpes simplexvirus genome is a recombinant HSV-1 genome. In some embodiments, therecombinant herpes simplex virus genome is a recombinant HSV-2 genome.

In some embodiments, a recombinant herpes simplex virus genome comprisesone or more polynucleotides of the present disclosure within one, two,three, four, five, six, seven or more viral gene loci. Examples ofsuitable viral loci may include, without limitation, the ICP0, ICP4,ICP22, ICP27, ICP47, tk, UL41 and UL55 herpes simplex viral gene loci.In some embodiments, a recombinant herpes simplex virus genome comprisesone or more polynucleotide of the present disclosure within one or moreof the viral ICP4 gene loci (e.g., a recombinant virus carrying apolynucleotide encoding Col7 in one or both of the ICP4 loci, arecombinant virus carrying a polynucleotide encoding LH3 in one or bothof the ICP4 loci, a recombinant virus carrying a polynucleotide encodingKRT17 in one or both of the ICP4 loci, a recombinant virus carrying apolynucleotide encoding Col7 in one of the ICP4 loci and apolynucleotide encoding KRT17 in the other ICP4 loci, a recombinantvirus carrying a polynucleotide encoding Col7 in one of the ICP4 lociand a polynucleotide encoding LH3 in the other ICP4 loci, a recombinantvirus carrying a polynucleotide encoding LH3 in one of the ICP4 loci anda polynucleotide encoding KRT17 in the other ICP4 loci, etc.). In someembodiments, a recombinant herpes simplex virus genome comprises one ormore polynucleotide of the present disclosure within the viral UL41 genelocus. In some embodiments, a recombinant herpes simplex virus genomecomprises one or more polynucleotide of the present disclosure withinthe viral ICP47 gene locus. In some embodiments, a recombinant herpessimplex virus genome comprises one or more polynucleotides of thepresent disclosure within one or more of the viral ICP4 gene loci, andone or more polynucleotide of the present disclosure within the viralUL41 gene locus (e.g., a recombinant virus carrying a polynucleotideencoding Col7 in one or both of the ICP4 loci and a polynucleotideencoding LH3 in the UL41 locus, a recombinant virus carrying apolynucleotide encoding Col7 in one or both of the ICP4 loci and apolynucleotide encoding Col7 in the UL41 locus, a recombinant viruscarrying a polynucleotide encoding Col7 in one or both of the ICP4 lociand a polynucleotide encoding KRT17 in the UL41 locus, a recombinantvirus carrying a polynucleotide encoding LH3 in one or both of the ICP4loci and a polynucleotide encoding LH3 in the UL41 locus, a recombinantvirus carrying a polynucleotide encoding LH3 in one or both of the ICP4loci and a polynucleotide encoding Col7 in the UL41 locus, a recombinantvirus carrying a polynucleotide encoding LH3 in one or both of the ICP4loci and a polynucleotide encoding KRT17 in the UL41 locus, arecombinant virus carrying a polynucleotide encoding KRT17 in one orboth of the ICP4 loci and a polynucleotide encoding LH3 in the UL41locus, a recombinant virus carrying a polynucleotide encoding KRT17 inone or both of the ICP4 loci and a polynucleotide encoding Col7 in theUL41 locus, a recombinant virus carrying a polynucleotide encoding KRT17in one or both of the ICP4 loci and a polynucleotide encoding KRT17 inthe UL41 locus, etc.).

A vector may include a polynucleotide of the present disclosure in aform suitable for expression of the polynucleotide in a host cell.Expression vectors may include one or more regulatory sequencesoperatively linked to the polynucleotide to be expressed. The term“regulatory sequence” includes promoters, enhancers and other expressioncontrol elements (e.g., polyadenylation signals). Examples of suitableenhancers may include, but are not limited to, enhancer sequences frommammalian genes (such as globin, elastase, albumin, α-fetoprotein,insulin and the like), and enhancer sequences from a eukaryotic cellvirus (such as SV40 enhancer on the late side of the replication origin(bp 100-270), the cytomegalovirus early promoter enhancer, the polyomaenhancer on the late side of the replication origin, adenovirusenhancers, and the like). Examples of promoters suitable fortranscription in mammalian host cells may include, but are not limitedto, promoters obtained from the genomes of viruses (such as polyomavirus, fowlpox virus, adenovirus (such as Adenovirus 2), bovinepapilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus,hepatitis-B virus, Simian Virus 40 (SV40), and the like), or fromheterologous mammalian promoters (such as the actin promoter, animmunoglobulin promoter, from heat-shock promoters, and the like),provided such promoters are compatible with the host cells. In someembodiments, polynucleotides of the present disclosure are operablylinked to one or more heterologous promoters. In some embodiments, theone or more heterologous promoters are one or more of the humancytomegalovirus (HCMV) immediate early promoter, the elongation factor-1(EF1) promoter, and/or any combinations thereof. In some embodiments,the one or more heterologous promoters are one or more of constitutivepromoters, tissue-specific promoters, temporal promoters, spatialpromoters, inducible promoters and repressible promoters. Regulatorysequences may include those which direct constitutive expression of anucleotide sequence, as well as tissue-specific regulatory and/orinducible sequences. The design of the expression vector can depend onsuch factors as the host cell to be contacted with a polynucleotide ofthe present disclosure, the level of expression of protein desired, andthe like. The expression vectors of the present disclosure can beintroduced into host cells to thereby produce proteins or polypeptides(e.g., Collagen alpha-1 (VII) chain polypeptides, Lysyl hydroxylase 3polypeptides, Keratin type I cytoskeletal 17 polypeptides, chimericpolypeptides, and the like) encoded by polynucleotides as describedherein.

In some embodiments, a vector of the present disclosure comprises one ormore transgenes comprising one or more polynucleotide described herein.The one or more transgenes may be inserted in any orientation in thevector. If the vector comprises two or more transgenes (e.g., two ormore, three or more, etc.), the transgenes may be inserted in the sameorientation or opposite orientations to one another. Without wishing tobe bound be theory, incorporating two transgenes into a vector in anantisense orientation may help to avoid read-through and ensure properexpression of each transgene. In some embodiments, the vector comprisesone or more transgenes encoding a polypeptide selected from the groupconsisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysylhydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide,and/or chimeric polypeptides thereof. In some embodiments, the vectorcomprises a single transgene encoding a Collagen alpa-1 (VII) chainpolypeptide. In some embodiments, the vector comprises two transgeneseach encoding a Collagen alpa-1 (VII) chain polypeptide. In someembodiments, the vector comprises three transgenes each encoding aCollagen alpa-1 (VII) chain polypeptide. In some embodiments, the vectorcomprises a single transgene encoding a Lysyl hydroxylase 3 polypeptide.In some embodiments, the vector comprises two transgenes each encoding aLysyl hydroxylase 3 polypeptide. In some embodiments, the vectorcomprises three transgenes each encoding a Lysyl hydroxylase 3polypeptide. In some embodiments, the vector comprises a singletransgene encoding a Keratin type I cytoskeletal 17 polypeptide. In someembodiments, the vector comprises two transgenes each encoding a Keratintype I cytoskeletal 17 polypeptide. In some embodiments, the vectorcomprises three transgenes each encoding a Keratin type I cytoskeletal17 polypeptide. In some embodiments, the vector comprises a singletransgene encoding a chimeric polypeptide comprising a Collagen alpha-1(VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, and/or aKeratin type I cytoskeletal 17 polypeptide.

In some embodiments, the vector comprises at least two transgenes (e.g.two, three, four, five, six, seven or more transgenes). In someembodiments, the at least first transgene encodes a Collagen alpha-1(VII) chain polypeptide and the at least second transgene encodes aLysyl hydroxylase 3 polypeptide. In some embodiments, the at least firsttransgene encodes a Lysyl hydroxylase 3 polypeptide and the at leastsecond transgene encodes a Collagen alpha-1 (VII) chain polypeptide. Insome embodiments, the at least first transgene encodes a Collagenalpha-1 (VII) chain polypeptide and the at least second transgeneencodes a Keratin type I cytoskeletal 17 polypeptide. In someembodiments, the at least first transgene encodes a Keratin type Icytoskeletal 17 polypeptide and the at least second transgene encodes aCollagen alpha-1 (VII) chain polypeptide. In some embodiments, the atleast first transgene encodes a Lysyl hydroxylase 3 polypeptide and theat least second transgene encodes a Keratin type I cytoskeletal 17polypeptide. In some embodiments, the at least first transgene encodes aKeratin type I cytoskeletal 17 polypeptide and the at least secondtransgene encodes a Lysyl hydroxylase 3 polypeptide. In someembodiments, the at least first transgene encodes a Collagen alpha-1(VII) chain polypeptide and the at least second transgene encodes achimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, and/or a Keratin type Icytoskeletal 17 polypeptide. In some embodiments, the at least firsttransgene encodes a Lysyl hydroxylase 3 polypeptide and the at leastsecond transgene encodes a chimeric polypeptide comprising a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide,and/or a Keratin type I cytoskeletal 17 polypeptide. In someembodiments, the at least first transgene encodes a Keratin type Icytoskeletal 17 polypeptide and the at least second transgene encodes achimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, and/or a Keratin type Icytoskeletal 17 polypeptide.

In some embodiments, the vector comprises at least three transgenes(e.g. three, four, five, six, seven or more transgenes). In someembodiments, the at least first transgene encodes a Collagen alpha-1(VII) chain polypeptide, the at least second transgene encodes a Lysylhydroxylase 3 polypeptide, and the at least third transgene encodes aKeratin type I cytoskeletal 17 polypeptide.

In some embodiments, the vector comprises a transgene that ispolycistronic. In some embodiments, the polycistronic transgene encodesa Collagen alpha-1 (VII) chain polypeptide on a first open reading frame(ORF) and a Lysyl hydroxylase 3 polypeptide on a second open readingframe (ORF). In some embodiments, the polycistronic transgene encodes aLysyl hydroxylase 3 polypeptide on a first open reading frame (ORF) anda Collagen alpha-1 (VII) chain polypeptide on a second open readingframe (ORF). In some embodiments, the polycistronic transgene encodes aCollagen alpha-1 (VII) chain polypeptide on a first open reading frame(ORF) and a keratin type I cytoskeletal 17 polypeptide on a second openreading frame (ORF). In some embodiments, the polycistronic transgeneencodes a Keratin type I cytoskeletal polypeptide on a first openreading frame (ORF) and a Collagen alpha-1 (VII) chain polypeptide on asecond open reading frame (ORF). In some embodiments, the polycistronictransgene encodes a Lysyl hydroxylase 3 polypeptide on a first openreading frame (ORF) and a keratin type I cytoskeletal 17 polypeptide ona second open reading frame (ORF). In some embodiments, thepolycistronic transgene encodes a Keratin type I cytoskeletalpolypeptide on a first open reading frame (ORF) and a Lysyl hydroxylase3 polypeptide on a second open reading frame (ORF).

In some embodiments, the polycistronic transgene encodes a Collagenalpha-1 (VII) chain polypeptide on a first open reading frame (ORF) anda chimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, and/or a Keratin type Icytoskeletal 17 polypeptide on a second open reading frame (ORF). Insome embodiments, the polycistronic transgene encodes a Lysylhydroxylase 3 polypeptide on a first open reading frame (ORF) and achimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, and/or a Keratin type Icytoskeletal 17 polypeptide on a second open reading frame (ORF). Insome embodiments, the polycistronic transgene encodes a Keratin type Icytoskeletal 17 polypeptide on a first open reading frame (ORF) and achimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, and/or a Keratin type Icytoskeletal 17 polypeptide on a second open reading frame (ORF). Insome embodiments, the first and second ORFs are separated by an internalribosomal entry site (IRES).

In some embodiments, the polycistronic transgene encodes a Collagenalpha-1 (VII) chain polypeptide on a first open reading frame (ORF), aKeratin type I cytoskeletal 17 polypeptide on a second open readingframe (ORF), and a Lysyl hydroxylase 3 polypeptide on a third openreading frame (ORF). In some embodiments, the polycistronic transgeneencodes a Collagen alpha-1 (VII) chain polypeptide on a first openreading frame (ORF), a Lysyl hydroxylase 3 polypeptide on a second openreading frame (ORF), and a Keratin type I cytoskeletal 17 polypeptide ona third open reading frame (ORF). In some embodiments, the polycistronictransgene encodes a Lysyl hydroxylase 3 polypeptide on a first openreading frame (ORF), a Collagen alpha-1 (VII) chain polypeptide on asecond open reading frame (ORF), and a Keratin type I cytoskeletal 17polypeptide on a third open reading frame (ORF). In some embodiments,the polycistronic transgene encodes a Lysyl hydroxylase 3 polypeptide ona first open reading frame (ORF), a Keratin type I cytoskeletal 17polypeptide on a second open reading frame (ORF), and a Collagen alpha-1(VII) chain polypeptide on a third open reading frame (ORF). In someembodiments, the polycistronic transgene encodes a Keratin type Icytoskeletal 17 polypeptide on a first open reading frame (ORF), a Lysylhydroxylase 3 polypeptide on a second open reading frame (ORF), and aCollagen alpha-1 (VII) chain polypeptide on a third open reading frame(ORF). In some embodiments, the polycistronic transgene encodes aKeratin type I cytoskeletal 17 polypeptide on a first open reading frame(ORF), a Collagen alpha-1 (VII) chain polypeptide on a second openreading frame (ORF), and a Lysyl hydroxylase 3 polypeptide on a thirdopen reading frame (ORF). In some embodiments, the first, second, andthird ORFs are separated by an internal ribosomal entry site (IRES).

Examples of suitable IRES's may include, but are not limited to, avirally-derived IRES (e.g. an IRES derived from a poliovirus,rhinovirus, encephalomyocarditis virus, foot-and-mouth disease virus,hepatitis C virus, classic swine fever virus, rous sarcoma virus, humanimmunodeficiency virus, cricket paralysis virus, Kaposi'ssarcoma-associated herpesvirus, etc.) and a cellular mRNA-derived IRES(e.g. an IRES derived from growth factor mRNAs, such as fibroblastgrowth factor 2, platelet-derived growth factor B, and vascularendothelial growth factor, an IRES derived from transcription factormRNAs, such as antennapedia, ultrapithoraxm, and NF-κB repressingfactor, an IRES derived from oncogene mRNAs, such as c-myc, pim-1, andprotein kinase p58^(PITSLRE), etc.)_(.)

Vectors of the present disclosure may further encode additional codingand non-coding sequences. Examples of additional coding and non-codingsequences may include, but are not limited to, sequences encodingadditional polypeptide tags, introns, 5′ and 3′ UTRs, and the like.Examples of suitable polypeptide tags may include, but are not limited,to any combination of purification tags, such as his-tags, flag-tags,maltose binding protein and glutathione-S-transferase tags, detectiontags, such as tags that may be detected photometrically (e.g., redfluorescent protein, etc.) and tags that have a detectable enzymaticactivity (e.g., alkaline phosphatase, etc.), tags containing secretorysequences, leader sequences, and/or stabilizing sequences, proteasecleavage sites (e.g., furin cleavage sites, TEV cleavage sites, Thrombincleavage sites), and the like. In some embodiments, the 5′ and/or 3′UTRsincrease the stability, localization, and/or translational efficiency ofthe polynucleotides. In some embodiments, the 5′ and/or 3′UTRs aremodified to increase the stability, localization, and/or translationalefficiency of the one or more polynucleotides. In some embodiments, the5′ and/or 3′UTRs improve the level and/or duration of proteinexpression. In some embodiments, the 5′ and/or 3′UTRs include elements(e.g., one or more miRNA binding sites, etc.) that may block or reduceoff-target transgene expression (e.g., inhibiting expression in specificcell types (e.g., neuronal cells), at specific times in the cell cycle,at specific developmental stages, etc.). In some embodiments, the 5′and/or 3′UTRs include elements (e.g., one or more miRNA binding sites,etc.) that may enhance transgene expression in specific cell types.

Synthetic RNA Polynucleotides

In some aspects, the present disclosure relates to synthetic RNAs, inparticular synthetic mRNAs, containing one or more polynucleotidesdescribed herein. In some embodiments, the synthetic mRNApolynucleotides comprise a 5′-cap structure. Examples of 5′-capstructures may include, but are not limited to, cap-0, cap-1, cap-2, andcap-3 structures, and derivatives thereof. In some embodiments, thesynthetic mRNA polynucleotides comprise a 3′-poly(A) tail. In someembodiments, the synthetic mRNA polynucleotides comprise one or more 5′and/or 3′ UTRs flanking the one or more coding sequences containedwithin the synthetic mRNA polynucleotides. In some embodiments, the 5′and/or 3′ UTRs increase the stability, localization, and/ortranslational efficiency of the synthetic mRNA polynucleotides. In someembodiments, the 5′ and/or 3′ UTRs are modified to increase thestability, localization, and/or translational efficiency of thesynthetic mRNA polynucleotides. In some embodiments, the 5′ and/or 3′UTRs improve the level and/or duration of protein expression. In someembodiments, the 5′ and/or 3′ UTRs are modified to improve the leveland/or duration of protein expression. In some embodiments, the 5′and/or 3′UTRs include elements (e.g., miRNA binding sites, etc.) thatmay limit off-target expression (e.g., inhibiting expression in specificcell types (e.g., neuronal cells), at specific times in the cell cycle,at specific developmental stages, etc.). In some embodiments, the 5′UTRs comprise a Kozak sequence. In some embodiments, the Kozak sequenceis the same or substantially similar to the Kozak consensus sequence.Methods for making synthetic mRNA polynucleotides containing one or morepolynucleotides of interest are well known to one of skill in the art.

In some aspects, the synthetic mRNA polynucleotides of the presentdisclosure comprise one or more modified ribonucleotides. Examples ofmodified ribonucleotides may include, but are not limited to,2-thiouridine, 5-azauridine, pseudouridine, 4-thiouridine,5-methyluridine, 5-aminouridine, 5-hydroxyuridine,5-methyl-5-azauridine, 5-amino-5-azauridine, 5-hydroxy-5-azauridine,5-methylpseudouridine, 5-aminopseudouridine, 5-hydroxypseudouridine,4-thio-5-azauridine, 4-thiopseudouridine, 4-thio-5-methyluridine,4-thio-5-aminouridine, 4-thio-5-hydroxyuridine,4-thio-5-methyl-5-azauridine, 4-thio-5-amino-5-azauridine,4-thio-5-hydroxy-5-azauridine, 4-thio-5-methylpseudouridine,4-thio-5-aminopseudouridine, 4-thio-5-hydroxypseudouridine,2-thiocytidine, 5-azacytidine, pseudoisocytidine, N4-methylcytidine,N4-aminocytidine, N4-hydroxycytidine, 5-methylcytidine, 5-aminocytidine,5-hydroxycytidine, 5-methyl-5-azacytidine, 5-amino-5-azacytidine,5-hydroxy-5-azacytidine, 5-methylpseudoisocytidine,5-aminopseudoisocytidine, 5-hydroxypseudoisocytidine,N4-methyl-5-azacytidine, N4-methylpseudoisocytidine,2-thio-5-azacytidine, 2-thiopseudoisocytidine, 2-thio-N4-methylcytidine,2-thio-N4-aminocytidine, 2-thio-N4-hydroxycytidine,2-thio-5-methylcytidine, 2-thio-5-aminocytidine,2-thio-5-hydroxycytidine, 2-thio-5-methyl-5-azacytidine,2-thio-5-amino-5-azacytidine, 2-thio-5-hydroxy-5-azacytidine,2-thio-5-methylpseudoisocytidine, 2-thio-5-aminopseudoisocytidine,2-thio-5-hydroxypseudoisocytidine, 2-thio-N4-methyl-5-azacytidine,2-thio-N4-methylpseudoisocytidine, N4-methyl-5-methylcytidine,N4-methyl-5-aminocytidine, N4-methyl-5-hydroxycytidine,N4-methyl-5-methyl-5-azacytidine, N4-methyl-5-amino-5-azacytidine,N4-methyl-5-hydroxy-5-azacytidine, N4-methyl-5-methylpseudoisocytidine,N4-methyl-5-aminopseudoisocytidine,N4-methyl-5-hydroxypseudoisocytidine, N4-amino-5-azacytidine,N4-aminopseudoisocytidine, N4-amino-5-methylcytidine,N4-amino-5-aminocytidine, N4-amino-5-hydroxycytidine,N4-amino-5-methyl-5-azacytidine, N4-amino-5-amino-5-azacytidine,N4-amino-5-hydroxy-5-azacytidine, N4-amino-5-methylpseudoisocytidine,N4-amino-5-aminopseudoisocytidine, N4-amino-5-hydroxypseudoisocytidine,N4-hydroxy-5-azacytidine, N4-hydroxypseudoisocytidine,N4-hydroxy-5-methylcytidine, N4-hydroxy-5-aminocytidine,N4-hydroxy-5-hydroxycytidine, N4-hydroxy-5-methyl-5-azacytidine,N4-hydroxy-5-amino-5-azacytidine, N4-hydroxy-5-hydroxy-5-azacytidine,N4-hydroxy-5-methylpseudoisocytidine,N4-hydroxy-5-aminopseudoisocytidine,N4-hydroxy-5-hydroxypseudoisocytidine,2-thio-N4-methyl-5-methylcytidine, 2-thio-N4-methyl-5-aminocytidine,2-thio-N4-methyl-5-hydroxycytidine,2-thio-N4-methyl-5-methyl-5-azacytidine,2-thio-N4-methyl-5-amino-5-azacytidine,2-thio-N4-methyl-5-hydroxy-5-azacytidine,2-thio-N4-methyl-5-methylpseudoisocytidine,2-thio-N4-methyl-5-aminopseudoisocytidine,2-thio-N4-methyl-5-hydroxypseudoisocytidine,2-thio-N4-amino-5-azacytidine, 2-thio-N4-aminopseudoisocytidine,2-thio-N4-amino-5-methylcytidine, 2-thio-N4-amino-5-aminocytidine,2-thio-N4-amino-5-hydroxycytidine,2-thio-N4-amino-5-methyl-5-azacytidine,2-thio-N4-amino-5-amino-5-azacytidine,2-thio-N4-amino-5-hydroxy-5-azacytidine,2-thio-N4-amino-5-methylpseudoisocytidine,2-thio-N4-amino-5-aminopseudoisocytidine,2-thio-N4-amino-5-hydroxypseudoisocytidine,2-thio-N4-hydroxy-5-azacytidine, 2-thio-N4-hydroxypseudoisocytidine,2-thio-N4-hydroxy-5-methylcytidine, N4-hydroxy-5-aminocytidine,2-thio-N4-hydroxy-5-hydroxycytidine,2-thio-N4-hydroxy-5-methyl-5-azacytidine,2-thio-N4-hydroxy-5-amino-5-azacytidine,2-thio-N4-hydroxy-5-hydroxy-5-azacytidine,2-thio-N4-hydroxy-5-methylpseudoisocytidine,2-thio-N4-hydroxy-5-aminopseudoisocytidine,2-thio-N4-hydroxy-5-hydroxypseudoisocytidine, N6-methyladenosine,N6-aminoadenosine, N6-hydroxyadenosine, 7-deazaadenosine,8-azaadenosine, N6-methyl-7-deazaadenosine, N6-methyl-8-azaadenosine,7-deaza-8-azaadenosine, N6-methyl-7-deaza-8-azaadenosine,N6-amino-7-deazaadenosine, N6-amino-8-azaadenosine,N6-amino-7-deaza-8-azaadenosine, N6-hydroxyadenosine,N6-hydroxy-7-deazaadenosine,N6-hydroxy-8-azaadenosine,N6-hydroxy-7-deaza-8-azaadenosine, 6-thioguanosine, 7-deazaguanosine,8-azaguanosine, 6-thio-7-deazaguanosine, 6-thio-8-azaguanosine,7-deaza-8-azaguanosine, and 6-thio-7-deaza-8-azaguanosine.

In some embodiments, a polynucleotide encoding a Collagen alpha-1 (VII)chain polypeptide and a polynucleotide encoding a Lysyl hydroxylase 3polypeptide are contained within two separate synthetic mRNApolynucleotides. In some embodiments, a polynucleotide encoding aCollagen alpha-1 (VII) chain polypeptide and a polynucleotide encoding aKeratin type I cytoskeletal 17 polypeptide are contained within twoseparate synthetic mRNA polynucleotides. In some embodiments, apolynucleotide encoding a Lysyl hydroxylase 3 polypeptide and apolynucleotide encoding a Keratin type I cytoskeletal 17 polypeptide arecontained within two separate synthetic mRNA polynucleotides. In someembodiments, a polynucleotide encoding a Collagen alpha-1 (VII) chainpolypeptide, a polynucleotide encoding a Lysyl hydroxylase 3polypeptide, and a polynucleotide encoding a Keratin type I cytoskeletal17 polypeptide are contained within three separate synthetic mRNApolynucleotides.

In some embodiments, a polynucleotide encoding a Collagen alpha-1 (VII)chain polypeptide, a polynucleotide encoding a Lysyl hydroxylase 3polypeptide, and/or a polynucleotide encoding a Keratin type Icytoskeletal 17 polypeptide is a single contiguous polynucleotidecontained within a single synthetic mRNA polynucleotide. In someembodiments, the single contiguous polynucleotide encodes a Collagenalpha-1 (VII) chain polypeptide on a first open reading frame (ORF) anda Lysyl hydroxylase 3 polypeptide on a second open reading frame (ORF)in a single synthetic mRNA. In some embodiments, the single contiguouspolynucleotide encodes a Lysyl hydroxylase 3 polypeptide on a first openreading frame (ORF) and a Collagen alpha-1 (VII) chain polypeptide on asecond open reading frame (ORF) in a single synthetic mRNA. In someembodiments, the single contiguous polynucleotide encodes a Collagenalpha-1 (VII) chain polypeptide on a first open reading frame (ORF) anda keratin type I cytoskeletal 17 polypeptide on a second open readingframe (ORF) in a single synthetic mRNA. In some embodiments, the singlecontiguous polynucleotide encodes a Keratin type I cytoskeletalpolypeptide on a first open reading frame (ORF) and a Collagen alpha-1(VII) chain polypeptide on a second open reading frame (ORF) in a singlesynthetic mRNA. In some embodiments, the single contiguouspolynucleotide encodes a Lysyl hydroxylase 3 polypeptide on a first openreading frame (ORF) and a keratin type I cytoskeletal 17 polypeptide ona second open reading frame (ORF) in a single synthetic mRNA. In someembodiments, the single contiguous polynucleotide encodes a Keratin typeI cytoskeletal polypeptide on a first open reading frame (ORF) and aLysyl hydroxylase 3 polypeptide on a second open reading frame (ORF) ina single synthetic mRNA. In some embodiments, the single contiguouspolynucleotide encodes a Collagen alpha-1 (VII) chain polypeptide on afirst open reading frame (ORF) and a chimeric polypeptide comprising aCollagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3polypeptide, and/or a Keratin type I cytoskeletal 17 polypeptide on asecond open reading frame (ORF) in a single synthetic mRNA. In someembodiments, the single contiguous polynucleotide encodes a Lysylhydroxylase 3 polypeptide on a first open reading frame (ORF) and achimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a Lysyl hydroxylase 3 polypeptide, and/or a Keratin type Icytoskeletal 17 polypeptide on a second open reading frame (ORF) in asingle synthetic mRNA. In some embodiments, the single contiguouspolynucleotide encodes a Keratin type I cytoskeletal 17 polypeptide on afirst open reading frame (ORF) and a chimeric polypeptide comprising aCollagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3polypeptide, and/or a Keratin type I cytoskeletal 17 polypeptide on asecond open reading frame (ORF) in a single synthetic mRNA. In someembodiments, the two ORFs are separated by an IRES.

In some embodiments, the single contiguous polynucleotide encodes aCollagen alpha-1 (VII) chain polypeptide on a first open reading frame(ORF), a Keratin type I cytoskeletal 17 polypeptide on a second openreading frame (ORF), and a Lysyl hydroxylase 3 polypeptide on a thirdopen reading frame (ORF) in a single synthetic mRNA. In someembodiments, the single contiguous polynucleotide encodes a Collagenalpha-1 (VII) chain polypeptide on a first open reading frame (ORF), aLysyl hydroxylase 3 polypeptide on a second open reading frame (ORF),and a Keratin type I cytoskeletal 17 polypeptide on a third open readingframe (ORF) in a single synthetic mRNA. In some embodiments, the singlecontiguous polynucleotide encodes a Lysyl hydroxylase 3 polypeptide on afirst open reading frame (ORF), a Collagen alpha-1 (VII) chainpolypeptide on a second open reading frame (ORF), and a Keratin type Icytoskeletal 17 polypeptide on a third open reading frame (ORF) in asingle synthetic mRNA. In some embodiments, the single contiguouspolynucleotide encodes a Lysyl hydroxylase 3 polypeptide on a first openreading frame (ORF), a Keratin type I cytoskeletal 17 polypeptide on asecond open reading frame (ORF), and a Collagen alpha-1 (VII) chainpolypeptide on a third open reading frame (ORF) in a single syntheticmRNA. In some embodiments, the single contiguous polynucleotide encodesa Keratin type I cytoskeletal 17 polypeptide on a first open readingframe (ORF), a Lysyl hydroxylase 3 polypeptide on a second open readingframe (ORF), and a Collagen alpha-1 (VII) chain polypeptide on a thirdopen reading frame (ORF) in a single synthetic mRNA. In someembodiments, the single contiguous polynucleotide encodes a Keratin typeI cytoskeletal 17 polypeptide on a first open reading frame (ORF), aCollagen alpha-1 (VII) chain polypeptide on a second open reading frame(ORF), and a Lysyl hydroxylase 3 polypeptide on a third open readingframe (ORF) in a single synthetic mRNA. In some embodiments, the first,second, and third ORFs are separated by an internal ribosomal entry site(IRES).

Examples of suitable IRES's may include, but are not limited to, avirally-derived IRES (e.g. an IRES derived from a poliovirus,rhinovirus, encephalomyocarditis virus, foot-and-mouth disease virus,hepatitis C virus, classic swine fever virus, rous sarcoma virus, humanimmunodeficiency virus, cricket paralysis virus, Kaposi'ssarcoma-associated herpesvirus, etc.) and a cellular mRNA-derived IRES(e.g. an IRES derived from growth factor mRNAs, such as fibroblastgrowth factor 2, platelet-derived growth factor B, and vascularendothelial growth factor, an IRES derived from transcription factormRNAs, such as antennapedia, ultrapithoraxm, and NF-κB repressingfactor, an IRES derived from oncogene mRNAs, such as c-myc, pim-1, andprotein kinase p58^(PITSLRE), etc.).

In some embodiments, a polynucleotide encoding any of the chimericpolypeptides comprising a Collagen alpha-1 (VII) chain polypeptide, aLysyl hydroxylase 3 polypeptide, and/or a Keratin type I cytoskeletal 17polypeptide described herein is encoded on a single ORF within asynthetic mRNA polynucleotide.

Synthetic mRNA polynucleotides of the present disclosure may furtherencode additional coding sequences. Examples of additional codingsequences may include, but are not limited to, sequences encodingadditional polypeptide tags. Examples of suitable polypeptide tags mayinclude, but are not limited to, any combination of purification tags,such as his-tags, flag-tags, maltose binding protein andglutathione-S-transferase tags, detection tags, such as tags that may bedetected photometrically (e.g., red fluorescent protein, etc.) and tagsthat have a detectable enzymatic activity (e.g., alkaline phosphatase,etc.), tags containing secretory sequences, leader sequences, and/orstabilizing sequences, protease cleavage sites (such as furin cleavagesites), and the like.

Delivery Vehicle

Certain aspects of the present disclosure relate to a pharmaceuticalcomposition comprising a delivery vehicle comprising one or morepolynucleotides described herein. In some embodiments, the deliveryvehicle is suitable for delivering one or more polynucleotides into oneor more target cells.

In some embodiments, the delivery vehicle is a virus. Examples of viraldelivery vehicles may include, but are not limited to, adenovirus,adeno-associated virus, retrovirus, lentivirus, sendai virus, herpessimplex virus, vaccinia virus, or any hybrid virus thereof. In someembodiments, the virus is replication-defective. In some embodiments,the virus is replication-competent. In some embodiments, the virus hasbeen modified to alter its tissue tropism relative to the tissue tropismof an unmodified, wild-type virus. Methods for producing a viruscomprising one or more polynucleotides are well known to one of skill inthe art.

In some embodiments, the viral delivery vehicle is a herpes simplexvirus. Herpes simplex virus delivery vehicles may be produced by aprocess disclosed, for example, in WO2015/009952. In some embodiments,the herpes simplex virus comprises a modified envelope. In someembodiments, the modified envelope comprises one or more (e.g., one,two, three, four or more) mutant herpes simplex virus glycoproteins.Examples of herpes simplex virus glycoproteins may include, but are notlimited to, the glycoproteins gB, gD, gH, and gL. In some embodiments,the modified envelope alters the herpes simplex virus tissue tropismrelative to a wild-type herpes simplex virus. In some embodiments, theherpes simplex virus is a herpes simplex type 1 virus, a herpes simplextype 2 virus, of any derivatives thereof. In some embodiments, the virusis a herpes simplex type 1 virus. In some embodiments, the virus is aherpes simplex type 2 virus.

In some embodiments, the delivery vehicle is a non-viral deliveryvehicle. In some embodiments, the non-viral delivery vehicle is achemical-based delivery vehicle (a chemical-based delivery reagent).Examples of chemical-based delivery vehicles may include, but are notlimited to, calcium phosphate, dendrimers, liposomes (cationicliposomes, non-cationic liposome, and mixtures), exosomes, chargedlipids, and cationic polymers (such as DEAE-dextran, polyethylenimine,and the like). In some embodiments, the non-viral delivery vehicle is anon-chemical delivery vehicle. Examples of non-chemical deliveryvehicles may include, but are not limited to, electroporation,nucleofection, sonoporation, optical transfection, and particle-basedvehicles (such as a gene gun, magnet-assisted transfection,impalefection, particle bombardment, and the like). In some embodiments,the non-viral delivery vehicle is a dendrimer, liposome, exosome,charged lipid or cationic polymer. In some embodiments, the non-viraldelivery vehicle is a dendrimer. In some embodiments, the non-viraldelivery vehicle is a liposome. In some embodiments, the non-viraldelivery vehicle is an exosome. In some embodiments, the non-viraldelivery vehicle is a charged lipid. In some embodiments, the non-viraldelivery vehicle is a cationic polymer. Methods for producing one ormore polynucleotides of interest in a complex with a non-viral deliveryvehicle are well known to one of skill in the art.

Pharmaceutically Acceptable Carrier

Certain aspects of the present disclosure relates to a pharmaceuticalcomposition comprising a pharmaceutically acceptable carrier. In someembodiments, the pharmaceutically acceptable carrier is a carriersufficient for topical and/or transdermal administration/application. Insome embodiments, the pharmaceutically acceptable carrier is a carriersufficient for subcutaneous and/or intradermaladministration/application. In some embodiments, the pharmaceuticallyacceptable carrier is minimally invasive or non-invasive.Pharmaceutically acceptable carriers are generally nontoxic torecipients at the dosages and concentrations employed, and may include,but are not limited to: buffers such as phosphate, citrate, and otherorganic acids; antioxidants including ascorbic acid and methionine;preservatives (such as octadecyldimethylbenzyl ammonium chloride;hexamethonium chloride; benzalkonium chloride; benzethonium chloride;phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol);low molecular weight (less than about 10 residues) polypeptides;proteins, such as serum albumin, gelatin, or immunoglobulins;hydrophilic polymers such as polyvinylpyrrolidone; amino acids such asglycine, glutamine, asparagine, histidine, arginine, or lysine;monosaccharides, disaccharides, and other carbohydrates includingglucose, mannose, or dextrins; chelating agents such as EDTA; sugarssuch as sucrose, mannitol, trehalose or sorbitol; polyols such asglycerol (e.g., formulations including 10% glycerol); salt-formingcounter-ions such as sodium; metal complexes (e.g. Zn-proteincomplexes); and/or non-ionic surfactants such as polyethylene glycol(PEG). A thorough discussion of pharmaceutically acceptable carriers isavailable in REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Pub. Co., N.J.1991).

In some embodiments, the pharmaceutically acceptable carrier is suitablefor topical or transdermal applications/administrations. Examples ofcarriers suitable for use in a topical or transdermalapplication/administration may include, but are not limited to,ointments, pastes, creams, suspensions, emulsions, fatty ointments,gels, powders, lotions, solutions, sprays, patches, microneedle arrays,and inhalants. In some embodiments, the pharmaceutically acceptablecarrier comprises one or more of an ointment, paste, cream, suspension,emulsion, fatty ointment, gel, powder, lotion, solution, spray, and aninhalant. In some embodiments, the pharmaceutically acceptable carriercomprises an ointment. In some embodiments, the pharmaceuticallyacceptable carrier comprises a paste. In some embodiments, thepharmaceutically acceptable carrier comprises a cream. In someembodiments, the pharmaceutically acceptable carrier comprises asuspension. In some embodiments, the pharmaceutically acceptable carriercomprises an emulsion. In some embodiments, the pharmaceuticallyacceptable carrier comprises a gel. In some embodiments, thepharmaceutically acceptable carrier comprises a powder. In someembodiments, the pharmaceutically acceptable carrier comprises a lotion.In some embodiments, the pharmaceutically acceptable carrier comprises asolution. In some embodiments, the pharmaceutically acceptable carriercomprises a spray. In some embodiments, the pharmaceutically acceptablecarrier comprises an inhalant. In some embodiments, the pharmaceuticalcarrier comprises a patch (e.g. a patch that adheres to the skin). Insome embodiments, the pharmaceutically acceptable carrier comprises amicroneedle array. Methods for making and using microneedle arrayssuitable for pharmaceutical composition delivery are generally known inthe art (Kim Y. et al. “Microneedles for drug and vaccine delivery”.Advanced Drug Delivery Reviews 2012, 64 (14): 1547-68).

In some embodiments, the pharmaceutically acceptable carrier comprises acombination of two, three, four, five or more different pharmaceuticallyacceptable carriers suitable for topical or transdermalapplications/administrations.

In some embodiments, the pharmaceutically acceptable carrier furthercomprises one or more additional components. Examples of additionalcomponents may include, but are not limited to, binding agents (e.g.,pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropylmethylcellulose, etc.); fillers (e.g., lactose and other sugars,microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethylcellulose, polyacrylates or calcium hydrogen phosphate, etc.);lubricants (e.g., magnesium stearate, talc, silica, colloidal silicondioxide, stearic acid, metallic stearates, hydrogenated vegetable oils,corn starch, polyethylene glycols, sodium benzoate, sodium acetate,etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.);wetting agents (e.g., sodium lauryl sulphate, etc.); salt solutions;alcohols; polyethylene glycols; gelatin; lactose; amylase; magnesiumstearate; talc; silicic acid; viscous paraffin; hydroxymethylcellulose;polyvinylpyrrolidone; sweetenings; flavorings; perfuming agents;colorants; moisturizers; sunscreens; antibacterial agents; agents ableto stabilize polynucleotides or prevent their degradation, and the like.

Pharmaceutical compositions and formulations as described herein may beprepared by mixing the delivery vehicle comprising one or morepolynucleotides described herein with one or more pharmaceuticallyacceptable carriers. The formulations to be used for in vivoadministration are generally sterile. Sterility may be readilyaccomplished, e.g., by filtration through sterile filtration membranes.

Methods of Treatment

The present disclosure relates, in part, to pharmaceutical compositionsand methods of use for providing prophylactic, palliative, ortherapeutic relief of a wound, disorder, or disease of the skin in asubject. Examples of diseases or disorders of the skin may include, butare not limited to, epidermolysis bullosa, skin cancer, psoriasis,lichen planus, lupus, rosacea, eczema, cutaneous candidiasis,cellulitis, impetigo, decubitus ulcers, erysipelas, ichthyosis vulgaris,dermatomyositis, acrodermatitis, stasis dermatitis, nethertons syndrome,epidermolysis bullosa simplex (LAMBS gene), autosomal recessivecongenital ichthyosis, xeroderma pigmentosa, and pemphigoid. In someembodiments, the disease or disorder of the skin is epidermolysisbullosa. In some embodiments, a subject has, or at risk of developing,one or more symptoms of epidermolysis bullosa.

The polynucleotides and pharmaceutical compositions described herein areuseful for providing prophylactic, palliative, or therapeutic relief ofa wound, disorder, or disease of the skin in a subject, including thetreatment of one or more symptoms of epidermolysis bullosa (e.g.,recessive dystrophic epidermolysis bullosa, dominant dystrophicepidermolysis bullosa, etc.). Pharmaceutical compositions of the presentdisclosure may be administered by any suitable method known in the art,including, without limitation, by oral administration, sublingualladministration, buccal administration, topical administration, rectaladministration, via inhalation, transdermal administration, subcutaneousinjection, intradermal injection, intravenous (IV) injection,intra-arterial injection, intramuscular injection, intracardiacinjection, intraosseous injection, intraperitoneal injection,transmucosal administration, vaginal administration, intravitrealadministration, intra-articular administration, peri-articularadministration, local administration, epicutaneous administration, orany combinations thereof. The pharmaceutical compositions may bedelivered to an individual via a variety of routes, including, but notlimited to, subcutaneous, intradermal, topical, transdermal, andtransmucosal administrations. The present disclosure thus alsoencompasses methods of delivering any of the polynucleotides orpharmaceutical compositions described herein to an individual (such asan individual having, or at risk of developing, epidermolysis bullosa).

In some embodiments, there is provided prophylactic, palliative, ortherapeutic relief of a wound, disorder, or disease of the skin in asubject comprising administering an effective amount of a pharmaceuticalcomposition capable of enhancing, increasing, augmenting, and/orsupplementing the levels of a Collagen alpha-1 chain polypeptide and/ora Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17polypeptide in one or more cells of the subject. In some embodiments,the pharmaceutical composition is administered intradermally and/orsubcutaneously. In some embodiments, the pharmaceutical composition isadministered topically and/or trandermally. In some embodiments, thereis provided prophylactic, palliative, or therapeutic relief of a wound,disorder, or disease of the skin in a subject comprising topicallyadministering an effective amount of a pharmaceutical compositioncapable of enhancing, increasing, augmenting, and/or supplementing thelevels of a Collagen alpha-1 chain polypeptide and/or a Lysylhydroxylase 3 polypeptide and/or a Keratin type I cytoskeletal 17polypeptide in one or more cells of the subject. The pharmaceuticalcomposition may be any pharmaceutical composition described herein. Insome embodiments, the individual is suffering from epidermolysisbullosa. In some embodiments, the individual is suffering fromdystrophic epidermolysis bullosa. In some embodiments, the individual issuffering from dominant dystrophic epidermolysis bullosa. In someembodiments, the individual is suffering from recessive dystrophicepidermolysis bullosa. In some embodiments, the pharmaceuticalcomposition is administered one, two, three, four, five or more timesper day. In some embodiments, the pharmaceutical composition isadministered to one or more affected areas of an individual. In someembodiments, the pharmaceutical composition is administered to one ormore unaffected areas of the individual.

In some embodiments, a pharmaceutical composition described herein maybe used to treat or alleviate one or more symptoms of epidermolysisbullosa. Symptoms of epidermolysis bullosa (e.g., recessive dystrophicepidermolysis bullosa, dominant dystrophic epidermolysis bullosa, etc.)may include, but are not limited to blisters on the skin (especiallyblisters on the hands, feet, knees, and elbows), blisters on the mucosa,scarring of the skin, scarring of the mucosa, skin erosion, deformity offingernails and/or toenails, loss of fingernails and/or toenails,internal blistering (including on the vocal chords, esophagus, and upperairway), thickening of the skin (especially thickening of the skin onthe palms and the soles of the feet), blistering of the scalp, scarringof the scalp, hair loss (scarring alopecia), thin-appearing skin,atrophic scarring, milia, dental conditions (such as tooth decay andpoorly formed enamel), joint deformities, fusion of the fingers andtoes, and dysphagia.

In some embodiments, there is provided a method of therapeuticallytreating an individual suffering from epidermolysis bullosa comprisingadministering an effective amount of a pharmaceutical compositioncapable of enhancing, increasing, augmenting, and/or supplementing thelevels of a Collagen alpha-1 chain polypeptide and/or a Lysylhydroxylase 3 polypeptide and/or a Keratin type I cytoskeletal 17polypeptide in one or more cells of the individual. In some embodiments,the pharmaceutical composition is administered intradermally and/orsubcutaneously. In some embodiments, the pharmaceutical composition isadministered topically and/or trandermally. In some embodiments, thereis provided a method of therapeutically treating an individual sufferingfrom epidermolysis bullosa comprising topically administering aneffective amount of a pharmaceutical composition capable of enhancing,increasing, augmenting, and/or supplementing the levels of a Collagenalpha-1 chain polypeptide and/or a Lysyl hydroxylase 3 polypeptideand/or Keratin type I cytoskeletal 17 polypeptide in one or more cellsof the individual. The pharmaceutical composition may be anypharmaceutical composition described herein. In some embodiments, theindividual is suffering from dystrophic epidermolysis bullosa. In someembodiments, the individual is suffering from dominant dystrophicepidermolysis bullosa. In some embodiments, the individual is sufferingfrom recessive dystrophic epidermolysis bullosa. In some embodiments,the pharmaceutical composition is administered one, two, three, four,five or more times per day. In some embodiments, the pharmaceuticalcomposition is administered to one or more affected areas of anindividual. In some embodiments, the pharmaceutical composition isadministered to one or more unaffected areas of the individual.

In some embodiments, there is provided a method of prophylacticallytreating an individual suffering from epidermolysis bullosa comprisingadministering an effective amount of a pharmaceutical compositioncapable of enhancing, increasing, augmenting, and/or supplementing thelevels of a Collagen alpha-1 chain polypeptide and/or a Lysylhydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17polypeptide in one or more cells of the individual. In some embodiments,the pharmaceutical composition is administered intradermally and/orsubcutaneously. In some embodiments, the pharmaceutical composition isadministered topically and/or trandermally. In some embodiments, thereis provided a method of prophylactically treating an individualsuffering from epidermolysis bullosa comprising topically administeringan effective amount of a pharmaceutical composition capable ofenhancing, increasing, augmenting, and/or supplementing the levels of aCollagen alpha-1 chain polypeptide and/or a Lysyl hydroxylase 3polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in one ormore cells of the individual. The pharmaceutical composition may be anypharmaceutical composition described herein. In some embodiments, theindividual is suffering from dystrophic epidermolysis bullosa. In someembodiments, the individual is suffering from dominant dystrophicepidermolysis bullosa. In some embodiments, the individual is sufferingfrom recessive dystrophic epidermolysis bullosa. In some embodiments,the pharmaceutical composition is administered one, two, three, four,five or more times per day. In some embodiments, the pharmaceuticalcomposition is administered to one or more affected areas of anindividual. In some embodiments, the pharmaceutical composition isadministered to one or more unaffected areas of the individual.

In some embodiments, there is provided a method of prophylacticallytreating an individual at risk of developing epidermolysis bullosacomprising administering an effective amount of a pharmaceuticalcomposition capable of enhancing, increasing, augmenting, and/orsupplementing the levels of a Collagen alpha-1 chain polypeptide and/ora Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17polypeptide in one or more cells of the individual. In some embodiments,the pharmaceutical composition is administered intradermally and/orsubcutaneously. In some embodiments, the pharmaceutical composition isadministered topically and/or trandermally. In some embodiments, thereis provided a method of prophylactically treating an individual at riskof developing epidermolysis bullosa comprising topically administeringan effective amount of a pharmaceutical composition capable ofenhancing, increasing, augmenting, and/or supplementing the levels of aCollagen alpha-1 chain polypeptide and/or a Lysyl hydroxylase 3polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in one ormore cells of the individual. The pharmaceutical composition may be anypharmaceutical composition described herein. In some embodiments, theindividual is at risk of developing dystrophic epidermolysis bullosa. Insome embodiments, the individual is at risk of developing dominantdystrophic epidermolysis bullosa. In some embodiments, the individual isat risk of developing recessive dystrophic epidermolysis bullosa. Insome embodiments, the pharmaceutical composition is administered one,two, three, four, five or more times per day. In some embodiments, thepharmaceutical composition is administered to one or more affected areasof an individual. In some embodiments, the pharmaceutical composition isadministered to one or more unaffected areas of the individual.

In some embodiments, administering to an individual an effective amountof any of the pharmaceutical compositions described herein enhances,increases, augments, and/or supplements the levels of a Collagen alpha-1chain polypeptide and/or a Lysyl hydroxylase 3 polypeptide and/orKeratin type I cytoskeletal 17 polypeptide in one or more cells of theindividual. In some embodiments, administering to an individual aneffective amount of any of the pharmaceutical compositions describedherein enhances, increases, augments, and/or supplements the function ofa Collagen alpha-1 chain polypeptide and/or a Lysyl hydroxylase 3polypeptide and/or a Keratin type I cytoskeletal 17 polypeptide in oneor more cells of the individual. In some embodiments, administering toan individual an effective amount of any of the pharmaceuticalcompositions described herein enhances, increases, augments, and/orsupplements the activity of a Collagen alpha-1 chain polypeptide and/ora Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17polypeptide in one or more cells of the individual.

In some embodiments, administering to an individual an effective amountof any of the pharmaceutical compositions described herein enhances,increases, augments, and/or supplements anchoring fibril formation ofthe individual. In some embodiments, administering to an individual aneffective amount of any of the pharmaceutical compositions describedherein enhances, increases, augments, and/or supplements epithelialbasement membrane organization of the individual. In some embodiments,administering to an individual an effective amount of any of thepharmaceutical compositions described herein enhances, increases,augments, and/or supplements epithelial basement adherence of theindividual. In some embodiments, administering to an individual aneffective amount of any of the pharmaceutical compositions describedherein enhances, increases, augments, and/or supplements dermoepidermaljunction integrity of the individual. In some embodiments, administeringto an individual an effective amount of any of the pharmaceuticalcompositions described herein enhances, increases, augments, and/orsupplements wound healing in the individual. Without wishing to be boundby theory, it is believed that increasing, augmenting, and/orsupplementing the levels of a Collagen alpha-1 (VII) chain polypeptidein one or more cells of an individual, by administering one or more ofthe pharmaceutical compositions described herein, will allow forincreased production and secretion of functional Collagen alpha-1 (VII)chain protein in the individual. Without wishing to be bound by theory,it is believed that increasing, augmenting, and/or supplementing thelevels of a Lysyl hydroxylase 3 polypeptide in one or more cells of anindividual, by administering one or more of the pharmaceuticalcompositions described herein, will increase the post-translationmodification of Collagen alpha-1 (VII) chain polypeptides, enhancingproduction and/or secretion of functional Collagen alpha-1 (VII) chainprotein in the individual. Without wishing to be bound by theory, it isfurther believed that increasing, augmenting, and/or supplementing thelevels of a Collagen alpha-1 (VII) chain polypeptide and a Lysylhydroxylase 3 polypeptide in the same cell of an individual, byadministering one or more of the pharmaceutical compositions describedherein (be it by contacting a cell with two separate polynucleotidesexpressing the polypeptides, by contacting a cell with a singlecontiguous polynucleotide separately expressing the two polypeptides, orby contacting a cell with a single contiguous polynucleotide expressinga chimeric polypeptide), will have an additive effect on enhancing theproduction and secretion of functional Collagen alpha-1 (VII) chainprotein. Without wishing to be bound by theory, it is believed thatincreased production and secretion of functional Collagen alpha-1 (VII)chain protein will allow for improved anchoring fibril formation,helping organize, stabilize, and aid in the adherence of the epithelialbasement membrane in the individual. Without wishing to be bound bytheory, it is believed that ultimately, this will lead to increaseddermal-epidermal stability for those suffering from epidermolysisbullosa, treating existing wounds, and preventing or delayingreformation of wounds in the treated areas.

Isolated Polynucleotides and Polypeptides

Certain aspects of the present disclosure relate to isolatedpolynucleotides comprising a polynucleotide encoding a Collagen alpha-1(VII) chain polypeptide. Other aspects of the present disclosure relateto isolated polynucleotides comprising a polynucleotide encoding a Lysylhydroxylase 3 polypeptide. Other aspects of the present disclosurerelate to isolated polynucleotides comprising a polynucleotide encodinga Keratin type I cytoskeletal 17 polypeptide.

Other aspects of the present disclosure relate to isolatedpolynucleotides comprising a polynucleotide encoding a Collagen alpha-1(VII) chain polypeptide and a polynucleotide encoding a Lysylhydroxylase 3 polypeptide separated by a polynucleotide encoding alinker polypeptide. In some embodiments, the isolated polynucleotideencodes a chimeric polypeptide comprising a Collagen alpha-1 (VII) chainpolypeptide, a linker polypeptide, and a Lysyl hydroxylase 3polypeptide.

In some embodiments, the polynucleotide encoding a linker polypeptidefurther comprises a polynucleotide encoding one or more furin cleavagesites. In some embodiments, the one or more furin cleavage sites areencoded upstream of the linker polypeptide. In some embodiments, the oneor more furin cleavage sites are encoded downstream of the linkerpolypeptide. In some embodiments, the one or more furin cleavage sitesare encoded upstream of a T2A linker polypeptide. In some embodiments,the one or more furin cleavage sites are encoded downstream of a T2Alinker polypeptide. In some embodiments, the one or more furin cleavagesites are encoded upstream of a P2A linker polypeptide. In someembodiments, the one or more furin cleavage sites are encoded downstreamof a P2A linker polypeptide. In some embodiments, the one or more furincleavage sites are encoded upstream of an E2A linker polypeptide. Insome embodiments, the one or more furin cleavage sites are encodeddownstream of an E2A linker polypeptide. In some embodiments, the one ormore furin cleavage sites are encoded upstream of an F2A linkerpolypeptide. In some embodiments, the one or more furin cleavage sitesare encoded downstream of an F2A linker polypeptide.

An example of a polynucleotide encoding a Collagen alpha-1 (VII) chainpolypeptide is SEQ ID NO: 1. Polynucleotides encoding a Collagen alpha-1(VII) chain polypeptide also include polynucleotides having at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQID NO: 1.

An example of a polynucleotide encoding a Lysyl hydroxylase 3polypeptide is SEQ ID NO: 3. Polynucleotides encoding a Lysylhydroxylase 3 polypeptide also include polynucleotides having at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQNO: 3.

An example of a polynucleotide encoding a Keratin type I cytoskeletal 17polypeptide is SEQ ID NO: 29. Polynucleotides encoding a Keratin type Icytoskeletal 17 polypeptide also include polynucleotides having at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQID NO: 29.

Examples of polynucleotides encoding linker polypeptides are SEQ ID NO:5, SEQ ID NO: 7, SEQ ID NO: 9, and SEQ ID NO: 11. Polynucleotidesencoding linker polypeptides also include polynucleotides having atleast 50%, at least 55%, at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100% identity to the sequenceof SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, or SEQ ID NO: 11.

Examples of polynucleotides that encode chimeric polypeptides comprisinga Collagen alpha-1 (VII) chain polypeptide, a linker polypeptide, and aLysyl hydroxylase 3 polypeptide are SEQ ID NO: 13, SEQ ID NO: 15, SEQ IDNO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, andSEQ ID NO: 27. Polynucleotides that encode chimeric polypeptides alsoinclude polynucleotides having at least 50%, at least 55%, at least 60%,at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, atleast 90%, at least 91%, at least 92%, at least 93%, at least 94%, atleast 95%, at least 96%, at least 97%, at least 98%, at least 99%, or100% identity to the sequence of SEQ ID NO: 13, SEQ ID NO: 15, SEQ IDNO: 17, SEQ ID NO: 19, SEQ ID NO: 21, SEQ ID NO: 23, SEQ ID NO: 25, orSEQ ID NO: 27.

Further aspects of the present disclosure relate to one or more (e.g.,one or more, two or more, three or more, etc.) isolated polynucleotidesdescribed herein contained within a vector. In some embodiments, thevector is an adenoviral vector, an adeno-associated viral vector, aretroviral vector, a lentiviral vector, a herpes simplex viral vector, avaccinia viral vector, or any hybrid viral vector thereof. In someembodiments, the vector is a herpes simplex viral vector. In someembodiments, the vector comprises one or more (e.g., one or more, two ormore, three or more, four or more, five or more, etc.) transgenes.

In some embodiments, the herpes simplex virus vector is a herpes virusamplicon vector. In some embodiments, the vector is an HSV-1 amplicon.In some embodiments, the vector is an HSV-1 hybrid amplicon. Examples ofHSV-1 hybrid amplicons may include, but are not limited to, HSV/AAVhybrid amplicons, HSV/EBV hybrid amplicons, HSV/EBV/RV hybrid amplicons,and HSV/Sleeping Beauty hybrid amplicons. In some embodiments, thevector is an HSV/AAV hybrid amplicon. In some embodiments, the vector isan HSV/EBV hybrid amplicon. In some embodiments, the vector is anHSV/EBV/RV hybrid amplicon. In some embodiments, the vector is anHSV/Sleeping Beauty hybrid amplicons. Further aspects of the presentdisclosure relate to a method of producing a viral delivery vehiclecontaining one or more polynucleotides described herein. In someembodiments, the method comprises contacting a host cell with one ormore viral vectors containing one or more isolated polynucleotidesdescribed herein, and collecting the viral delivery vehicle generated bythe host cell. Methods of culturing cells and contacting cells with oneor more viral vectors of interest (e.g. by transduction or transfection)are well known to one of skill in the art.

In some embodiments, the herpes simplex virus vector is a recombinantherpes simplex virus genome. In some embodiments, the recombinant herpessimplex virus genome has been engineered to decrease or eliminateexpression of one or more toxic herpes simplex virus genes. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation. Examples of inactivating mutations may include,but are not limited to, deletions (e.g., deletion of the coding sequenceof a gene or deletion of one or more of the gene's transcriptionalregulatory elements), insertions, point mutations, and rearrangements.In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in one or more immediate early genes.In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation in at least one, at least two, atleast three, at least four, at least five, at least six, at least seven,or all eight of the ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL4 land UL55herpes simplex virus genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation is in the ICP0gene. In some embodiments, the recombinant herpes simplex virus genomecomprises an inactivating mutation is in the ICP4 gene. In someembodiments, the recombinant herpes simplex virus genome comprises aninactivating mutation is in the ICP22 gene. In some embodiments, therecombinant herpes simplex virus genome comprises an inactivatingmutation is in the ICP27 gene. In some embodiments, the recombinantherpes simplex virus genome comprises an inactivating mutation is in theICP4, ICP22, and ICP27 genes. In some embodiments, the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP4, ICP27, and UL55 genes. In some embodiments, the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP4,ICP22, ICP27, ICP47, and UL55 genes. In some embodiments, therecombinant herpes simplex virus genome comprises an inactivatingmutation is in the ICP0, ICP4, ICP22, and ICP27 genes. In someembodiments, the recombinant herpes simplex virus genome is arecombinant HSV-1 genome, a recombinant HSV-2 genome, or any derivativesthereof. In some embodiments, the recombinant herpes simplex virusgenome is a recombinant HSV-1 genome. In some embodiments, therecombinant herpes simplex virus genome is a recombinant HSV-2 genome.

In some embodiments, an isolated recombinant herpes simplex virus genomecomprises one or more (e.g., one or more, two or more, three or more,four or more, five or more, etc.) polynucleotides (e.g., transgenes) ofthe present disclosure within one, two, three, four, five, six, seven ormore viral gene loci. Examples of suitable viral loci may include,without limitation, the ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41 andUL55 herpes simplex viral gene loci. In some embodiments, an isolatedrecombinant herpes simplex virus genome comprises one or morepolynucleotide of the present disclosure within one or more of the viralICP4 gene loci (e.g., a recombinant virus carrying a polynucleotideencoding Col7 in one or both of the ICP4 loci, a recombinant viruscarrying a polynucleotide encoding LH3 in one or both of the ICP4 loci,a recombinant virus carrying a polynucleotide encoding KRT17 in one orboth of the ICP4 loci, a recombinant virus carrying a polynucleotideencoding Col7 in one of the ICP4 loci and a polynucleotide encodingKRT17 in the other ICP4 loci, a recombinant virus carrying apolynucleotide encoding Col7 in one of the ICP4 loci and apolynucleotide encoding LH3 in the other ICP4 loci, a recombinant viruscarrying a polynucleotide encoding LH3 in one of the ICP4 loci and apolynucleotide encoding KRT17 in the other ICP4 loci, etc.). In someembodiments, an isolated recombinant herpes simplex virus genomecomprises one or more polynucleotide of the present disclosure withinthe viral UL41 gene locus. In some embodiments, an isolated recombinantherpes simplex virus genome comprises one or more polynucleotide of thepresent disclosure within the viral ICP47 gene locus. In someembodiments, an isolated recombinant herpes simplex virus genomecomprises one or more polynucleotides of the present disclosure withinone or more of the viral ICP4 gene loci, and one or more polynucleotideof the present disclosure within the viral UL41 gene locus (e.g., arecombinant virus carrying a polynucleotide encoding Col7 in one or bothof the ICP4 loci and a polynucleotide encoding LH3 in the UL41 locus, arecombinant virus carrying a polynucleotide encoding Col7 in one or bothof the ICP4 loci and a polynucleotide encoding Col7 in the UL41 locus, arecombinant virus carrying a polynucleotide encoding Col7 in one or bothof the ICP4 loci and a polynucleotide encoding KRT17 in the UL41 locus,a recombinant virus carrying a polynucleotide encoding LH3 in one orboth of the ICP4 loci and a polynucleotide encoding LH3 in the UL41locus, a recombinant virus carrying a polynucleotide encoding LH3 in oneor both of the ICP4 loci and a polynucleotide encoding Col7 in the UL41locus, a recombinant virus carrying a polynucleotide encoding LH3 in oneor both of the ICP4 loci and a polynucleotide encoding KRT17 in the UL41locus, a recombinant virus carrying a polynucleotide encoding KRT17 inone or both of the ICP4 loci and a polynucleotide encoding LH3 in theUL41 locus, a recombinant virus carrying a polynucleotide encoding KRT17in one or both of the ICP4 loci and a polynucleotide encoding Col7 inthe UL41 locus, a recombinant virus carrying a polynucleotide encodingKRT17 in one or both of the ICP4 loci and a polynucleotide encodingKRT17 in the UL41 locus, etc.).

In some aspects, the isolated polynucleotides described herein arecontained within a synthetic mRNA. In some embodiments, the syntheticmRNA comprises one or more modified ribonucleotides.

Certain aspects of the present disclosure relate to isolatedpolypeptides comprising a Collagen alpha-1 (VII) chain polypeptide.Other aspects of the present disclosure relate to isolated polypeptidescomprising a Lysyl hydroxylase 3 polypeptide. Other aspects of thepresent disclosure relate to isolated polypeptides comprising a Keratintype I cytoskeletal 17 polypeptide.

Other aspects of the present disclosure relate to isolated chimericpolypeptides comprising a Collagen alpha-1 (VII) chain polypeptide and aLysyl hydroxylase 3 polypeptide separated by a linker polypeptide.

In some embodiments, the linker polypeptide further comprises one ormore furin cleavage sites. In some embodiments, the amino acid sequenceof the furin cleavage site is the same or substantially similar to thesequence of the canonical furin cleavage site (Arg-X-(Arg/Lys)-Arg). Insome embodiments, the one or more furin cleavage sites are at theN-terminus of the linker polypeptide. In some embodiments, the one ormore furin cleavage sites are at the C-terminus of the linkerpolypeptide. In some embodiments, the linker polypeptide comprises, fromN-terminus to C-terminus, one or more furin cleavage sites and a T2Alinker polypeptide. In some embodiments, the linker polypeptidecomprises, from N-terminus to C-terminus, a T2A linker polypeptide andone or more furin cleavage sites. In some embodiments, the linkerpolypeptide comprises, from N-terminus to C-terminus, one or more furincleavage sites and a P2A linker polypeptide. In some embodiments, thelinker polypeptide comprises, from N-terminus to C-terminus, a P2Alinker polypeptide and one or more furin cleavage sites. In someembodiments, the linker polypeptide comprises, from N-terminus toC-terminus, one or more furin cleavage sites and an E2A linkerpolypeptide. In some embodiments, the linker polypeptide comprises, fromN-terminus to C-terminus, an E2A linker polypeptide and one or morefurin cleavage sites. In some embodiments, the linker polypeptidecomprises, from N-terminus to C-terminus, one or more furin cleavagesites and an F2A linker polypeptide. In some embodiments, the linkerpolypeptide comprises, from N-terminus to C-terminus, an F2A linkerpolypeptide and one or more furin cleavage sites.

In some aspects, the isolated polypeptide comprising a Collagen alpha-1(VII) chain polypeptide comprises the amino acid sequence of SEQ ID NO:2. Isolated polypeptides may also comprise a Collagen alpha-1 (VII)chain polypeptide containing an amino acid sequence having at least 50%,at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO:2.

In some aspects, the isolated polypeptide comprising a Lysyl hydroxylase3 polypeptide comprises the amino acid sequence of SEQ ID NO: 4.Isolated polypeptides may also comprise a Lysyl hydroxylase 3polypeptide containing an amino acid sequence having at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO:4.

In some aspects, the isolated polypeptide comprising a Keratin type Icytoskeletal 17 polypeptide comprises the amino acid sequence of SEQ IDNO: 30. Isolated polypeptides may also comprise a Keratin type Icytoskeletal 17 polypeptide containing an amino acid sequence having atleast 50%, at least 55%, at least 60%, at least 65%, at least 70%, atleast 75%, at least 80%, at least 85%, at least 90%, at least 91%, atleast 92%, at least 93%, at least 94%, at least 95%, at least 96%, atleast 97%, at least 98%, at least 99%, or 100% identity to the sequenceof SEQ ID NO: 30.

In some aspects, the chimeric polypeptide comprises a Collagen alpha-1(VII) chain polypeptide containing the amino acid sequence of SEQ ID NO:2. Chimeric polypeptides may also comprise a Collagen alpha-1 (VII)chain polypeptide containing an amino acid sequence having at least 50%,at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100% identity to the sequence of SEQ NO: 2.

In some aspects, the chimeric polypeptide comprises a Lysyl hydroxylase3 polypeptide containing the amino acid sequence of SEQ ID NO: 4.Chimeric polypeptides may also comprise a Lysyl hydroxylase 3polypeptide containing an amino acid sequence having at least 50%, atleast 55%, at least 60%, at least 65%, at least 70%, at least 75%, atleast 80%, at least 85%, at least 90%, at least 91%, at least 92%, atleast 93%, at least 94%, at least 95%, at least 96%, at least 97%, atleast 98%, at least 99%, or 100% identity to the sequence of SEQ ID NO:4.

In some aspects, the chimeric polypeptide comprises a linker polypeptidecontaining the amino acid sequence of SEQ ID NO: 6, SEQ ID NO: 8, SEQ IDNO: 10 or SEQ ID NO: 12. Chimeric polypeptides may also comprise alinker polypeptide containing an amino acid sequence having at least50%, at least 55%, at least 60%, at least 65%, at least 70%, at least75%, at least 80%, at least 85%, at least 90%, at least 91%, at least92%, at least 93%, at least 94%, at least 95%, at least 96%, at least97%, at least 98%, at least 99%, or 100% identity to the sequence of SEQID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12.

In some aspects, the chimeric polypeptide is the amino acid sequence ofSEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO:22, SEQ ID NO: 24, SEQ ID NO: 26 or SEQ ID NO: 28. Chimeric polypeptidesmay also be an amino acid sequence having at least 50%, at least 55%, atleast 60%, at least 65%, at least 70%, at least 75%, at least 80%, atleast 85%, at least 90%, at least 91%, at least 92%, at least 93%, atleast 94%, at least 95%, at least 96%, at least 97%, at least 98%, atleast 99%, or 100% identity to the sequence of SEQ ID NO: 14, SEQ ID NO:16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ IDNO: 26 or SEQ ID NO: 28.

Host Cells

Certain aspects of the present disclosure relate to one or more hostcells comprising a vector comprising a polynucleotide described herein.In some embodiments, the vector is any of the isolated recombinantherpes simplex virus vectors described herein. In some embodiments, thehost cells are bacterial cells (e.g., E. coli cells, etc.). In someembodiments, the host cells are fungal cells (e.g., S. cerevisiae cells,etc.). In some embodiments, the host cells are insect cells (e.g., S2cells, etc.). In some embodiments, the host cells are mammalian cells.In some embodiments, the host cells are cells from a cell line. Examplesof suitable host cells or cell lines may include, but are not limitedto, 293, HeLa, SH-Sy5y, Hep G2, CACO-2, A549, L929, 3T3, K562, CHO-K1,MDCK, HUVEC, Vero, N20, COS-7, PSN1, VCaP, CHO cells, and the like. Insome embodiments, the vector is an adenoviral vector, anadeno-associated viral vector, a retroviral vector, a lentiviral vector,a herpes simplex viral vector, a vaccinia viral vector, or any hybridviral vectors thereof. In some embodiments, the vector is a herpessimplex viral vector. In some embodiments, the vector is an HSV-1amplicon or HSV-1 hybrid amplicon. In some embodiments, the host cellscomprise a helper virus. In some embodiments, the host cells comprisinga helper virus are contacted with a vector described herein. In someembodiments, contacting a host cell comprising a helper virus with anHSV-1 amplicon or HSV-1 hybrid amplicon described herein results in theproduction of a virus comprising one or more vectors described herein.In some embodiments, the virus is collected from the supernatant of thecontacted host cell. Methods of generating virus by contacting hostcells comprising a helper virus with an HSV-1 amplicon or HSV-1/hybridamplicon are known in the art. In some embodiments, the host cell is acomplementing host cell. In some embodiments, the complementing hostcell expresses one or more genes that are inactivated in any of theviral vectors described herein. In some embodiments, the complementinghost cell is contacted with a recombinant herpes simplex virus genomedescribed herein. In some embodiments, contacting a complementing hostcell with a recombinant herpes simplex virus genome described hereinresults in the production of a virus comprising one or more vectorsdescribed herein. In some embodiments, the virus is collected from thesupernatant of the contacted host cell. Methods of generating virus bycontacting complementing host cells with a recombinant herpes simplexvirus are generally described in WO2015/009952.

Articles of Manufacture or Kits

Certain aspects of the present disclosure relate to an article ofmanufacture or a kit comprising a pharmaceutical composition describedherein. In some embodiments, the article of manufacture or kit comprisesa package insert comprising instructions for administering thepharmaceutical composition to provide prophylactic, palliative, ortherapeutic relief of a wound, disorder, or disease of the skin in asubject.

In some embodiments, the delivery vehicle comprising one or morepolynucleotides described herein and pharmaceutically acceptable carrierare in the same container or separate containers. Suitable containersinclude, for example, bottles, vials, bags and syringes. The containermay be formed from a variety of materials such as glass, plastic (suchas polyvinyl chloride or polyolefin), or metal alloy (such as stainlesssteel or hastelloy). In some embodiments, the container comprises alabel on, or associated with the container, wherein the label indicatesdirections for use. The article of manufacture or kit may furtherinclude other materials desirable from a commercial and user standpoint,including other buffers, diluents, filters, and the like.

ENUMERATED EMBODIMENTS Embodiment 1

A pharmaceutical composition comprising:

a) a virus comprising a vector, wherein the vector comprises one or moretransgenes encoding a polypeptide selected from the group consisting ofa Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3polypeptide, and a chimeric polypeptide thereof; and

b) a pharmaceutically acceptable carrier.

Embodiment 2

The pharmaceutical composition of embodiment 1, wherein the virus is anadenovirus, adeno-associated virus, retrovirus, lentivirus, sendaivirus, herpes simplex virus, vaccinia virus, or any hybrid virusthereof.

Embodiment 3

The pharmaceutical composition of embodiment 1, wherein the virus is aherpes simplex virus (HSV).

Embodiment 4

The pharmaceutical composition of any of embodiments 1 to 3, wherein thevirus is replication-defective.

Embodiment 5

The pharmaceutical composition of embodiment 3, wherein the herpessimplex virus is a herpes simplex type 1 virus, a herpes simplex type 2virus, or any derivatives thereof.

Embodiment 6

The pharmaceutical composition of embodiment 3, wherein the herpessimplex virus comprises a modified envelope.

Embodiment 7

The pharmaceutical composition of embodiment 6, wherein the modifiedenvelope alters the herpes simplex virus tissue tropism relative to awild-type herpes simplex virus.

Embodiment 8

The pharmaceutical composition of embodiment 6, wherein the modifiedenvelope comprises a mutant herpes simplex virus glycoprotein.

Embodiment 9

The pharmaceutical composition of embodiment 1, wherein the vector is anHSV-1 amplicon or an HSV-1 hybrid amplicon.

Embodiment 10

The pharmaceutical composition of embodiment 9, wherein the HSV-1 hybridamplicon is an HSV/AAV hybrid amplicon, an HSV/EBV hybrid amplicon, andHSV/EBV/RV hybrid amplicon, or an HSV/Sleeping Beauty hybrid amplicon.

Embodiment 11

The pharmaceutical composition of embodiment 1, wherein the vector is arecombinant herpes simplex virus genome.

Embodiment 12

The pharmaceutical composition of embodiment 11, wherein the recombinantherpes simplex virus genome is a recombinant HSV-1 genome, a recombinantHSV-2 genome, or any derivatives thereof.

Embodiment 13

The pharmaceutical composition of embodiment 11 or 12, wherein therecombinant herpes simplex virus genome comprises an inactivatingmutation in an immediate early herpes simplex virus gene.

Embodiment 14

The pharmaceutical composition of embodiment 13, wherein the herpessimplex virus gene is selected from the group consisting of ICP0, ICP4,ICP22, ICP27, ICP47, tk, UL41, and UL55.

Embodiment 15

The pharmaceutical composition of any of embodiments 11 to 14, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP4 and ICP22 genes.

Embodiment 16

The pharmaceutical composition of any of embodiments 11 to 14, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0 and ICP4 genes.

Embodiment 17

The pharmaceutical composition of embodiment 15 or embodiment 16,wherein the recombinant herpes simplex virus genome comprises aninactivating mutation in the ICP0, ICP4, and ICP22 genes.

Embodiment 18

The pharmaceutical composition of any of embodiments 15 to 17, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, ICP22, and ICP27 genes.

Embodiment 19

The pharmaceutical composition of any of embodiments 15 to 18, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes.

Embodiment 20

The pharmaceutical composition of any of embodiments 15 to 18, whereinthe inactivating mutation is a deletion of the coding sequence of thegenes.

Embodiment 21

The pharmaceutical composition of any of embodiments 15 to 20, furthercomprising an inactivating mutation in the ICP47 gene.

Embodiment 22

The pharmaceutical composition of any of embodiments 11 to 21, furthercomprising an inactivating mutation in the UL41 gene.

Embodiment 23

The pharmaceutical composition of any of embodiments 11 to 22, whereinthe recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more viral gene loci.

Embodiment 24

The pharmaceutical composition of any of embodiments 11 to 23, whereinthe recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more of the ICP4 viral gene loci.

Embodiment 25

The pharmaceutical composition of any of embodiments 11 to 24, whereinthe recombinant herpes simplex virus genome comprises the one or moretransgenes within the UL41 viral gene locus.

Embodiment 26

The pharmaceutical composition of embodiment 1, wherein the vector iscapable of replicating within a target cell when delivered into saidtarget cell.

Embodiment 27

The pharmaceutical composition of embodiment 1, wherein thepharmaceutically acceptable carrier is suitable for topical ortransdermal administration.

Embodiment 28

The pharmaceutical composition of embodiment 1, wherein the one or moretransgenes comprises an miRNA binding site.

Embodiment 29

The pharmaceutical composition of embodiment 1, wherein the one or moretransgenes are operably linked to one or more heterologous promoters.

Embodiment 30

The pharmaceutical composition of embodiment 29, wherein the one or moreheterologous promoters are selected from the group consisting of thehuman cytomegalovirus (HCMV) immediate early promoter, the elongationfactor-1 (EF1) promoter, and any combinations thereof.

Embodiment 31

The pharmaceutical composition of embodiment 1, wherein the vectorcomprises a transgene encoding a Collagen alpha-1 (VII) chainpolypeptide.

Embodiment 32

The pharmaceutical composition of embodiment 1, wherein the vectorcomprises two transgenes, wherein each transgene encodes a Collagenalpha-1 (VII) chain polypeptide.

Embodiment 33

The pharmaceutical composition of embodiment 1, wherein the Collagenalpha-1 (VII) chain polypeptide has at least 80% sequence identity tothe sequence of SEQ NO: 2.

Embodiment 34

The pharmaceutical composition of embodiment 1, wherein the collagenalpha-1 (VII) chain polypeptide is a fragment, wherein the fragment hasat least 100 consecutive amino acids of SEQ ID NO: 2.

Embodiment 35

The pharmaceutical composition of embodiment 1, wherein the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements anchoring fibril formation of a subject when the polypeptideis expressed in one or more target cells of the subject.

Embodiment 36

The pharmaceutical composition of embodiment 1, wherein the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements epithelial basement membrane organization and/or epithelialbasement adherence of a subject when the polypeptide is expressed in oneor more target cells of the subject.

Embodiment 37

The pharmaceutical composition of embodiment 1, wherein the Lysylhydroxylase 3 polypeptide has at least 80% sequence identity to thesequence of SEQ ID NO: 4.

Embodiment 38

The pharmaceutical composition of embodiment 1, wherein the Lysylhydroxylase 3 polypeptide is a fragment, wherein the fragment has atleast 100 consecutive amino acids of SEQ ID NO: 4.

Embodiment 39

The pharmaceutical composition of embodiment 1, wherein the Lysylhydroxylase 3 polypeptide enhances, increases, augments, and/orsupplements the formation of hydroxylysine residues on one or morecollagen polypeptides of a subject when the Lysyl hydroxylase 3polypeptide is expressed in one or more target cells of the subject.

Embodiment 40

The pharmaceutical composition of embodiment 1, wherein the Lysylhydroxylase 3 polypeptide enhances, increases, augments, and/orsupplements anchoring fibril formation, epithelial basement membraneorganization, and/or epithelial basement adherence of a subject when thepolypeptide is expressed in one or more target cells of the subject.

Embodiment 41

The pharmaceutical composition of embodiment 1, wherein the vectorcomprises at least a first transgene and a second transgene.

Embodiment 42

The pharmaceutical composition of embodiment 41, wherein the firsttransgene encodes a Collagen alpha-1 (VII) chain polypeptide and thesecond transgene encodes a Lysyl hydroxylase 3 polypeptide.

Embodiment 43

The pharmaceutical composition of embodiment 1, wherein the vectorcomprises a transgene that is polycistronic.

Embodiment 44

The pharmaceutical composition of embodiment 43, wherein thepolycistronic transgene encodes a Collagen alpha-1 (VII) chainpolypeptide on a first open reading frame (ORF) and a Lysyl hydroxylase3 polypeptide on a second open reading frame (ORF).

Embodiment 45

The pharmaceutical composition of embodiment 44, wherein the first andsecond ORFs are separated by an internal ribosomal entry site (IRES).

Embodiment 46

The pharmaceutical composition of any of embodiments 42 to 45, whereinthe Collagen alpha-1 (VII) chain polypeptide and the Lysyl hydroxylase 3polypeptide are at about an equimolar ratio when the polypeptides areexpressed in one or more target cells of a subject.

Embodiment 47

The pharmaceutical composition of any of embodiments 42 to 45, whereinthe Collagen alpha-1 (VII) chain polypeptide and the Lysyl hydroxylase 3polypeptide enhance, increase, augment, and/or supplement anchoringfibril formation, epithelial basement membrane organization, and/orepithelial basement adherence of a subject when the polypeptides areexpressed in one or more target cells of the subject.

Embodiment 48

The pharmaceutical composition of embodiment 1, wherein the chimericpolypeptide comprises a linker polypeptide between the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide.

Embodiment 49

The pharmaceutical composition of embodiment 48, wherein the linkerpolypeptide is a T2A, P2A, E2A, or F2A linker polypeptide.

Embodiment 50

The pharmaceutical composition of embodiment 48 or 49, wherein thelinker polypeptide has at least 80% sequence identity to the sequence ofSEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12.

Embodiment 51

The pharmaceutical composition of any of embodiments 48 to 50, whereinthe chimeric polypeptide has at least 80% sequence identity to thesequence of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20,SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26 or SEQ ID NO: 28.

Embodiment 52

The pharmaceutical composition of any of embodiments 48 to 51, whereinthe chimeric polypeptide enhances, increases, augments, and/orsupplements anchoring fibril formation, epithelial basement membraneorganization, and/or epithelial basement adherence of a subject when thepolypeptide is expressed in one or more target cells of the subject.

Embodiment 53

A method of providing prophylactic, palliative, or therapeutic relief ofa wound, disorder, or disease of the skin in a subject, the methodcomprising topically or transdermally administering a pharmaceuticalcomposition capable of enhancing, increasing, augmenting, and/orsupplementing the levels of a Collagen alpha-1 (VII) chain polypeptideand/or a Lysyl hydroxylase 3 polypeptide in one or more cells of thesubject.

Embodiment 54

The method of embodiment 53, wherein the pharmaceutical compositioncomprises:

a) a virus comprising a vector, wherein the vector comprises one or moretransgenes encoding a polypeptide selected from the group consisting ofa Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3polypeptide, and a chimeric polypeptide thereof; and b) apharmaceutically acceptable carrier.

Embodiment 55

The method of embodiment 54, wherein the virus is an adenovirus,adeno-associated virus, retrovirus, lentivirus, sendai virus, herpessimplex virus, vaccinia virus, or any hybrid virus thereof.

Embodiment 56

The method of embodiment 54, wherein the virus is a herpes simplex virus(HSV).

Embodiment 57

The method of any of embodiments 54 to 56, wherein the virus isreplication-defective.

Embodiment 58

The method of embodiment 56, wherein the herpes simplex virus is aherpes simplex type 1 virus, a herpes simplex type 2 virus, or anyderivatives thereof.

Embodiment 59

The method of embodiment 56, wherein the herpes simplex virus comprisesa modified envelope.

Embodiment 60

The method of embodiment 59, wherein the modified envelope alters theherpes simplex virus tissue tropism relative to a wild-type herpessimplex virus.

Embodiment 61

The method of embodiment 59, wherein the modified envelope comprises amutant herpes simplex virus glycoprotein.

Embodiment 62

The method of embodiment 54, wherein the vector is an HSV-1 amplicon oran HSV-1 hybrid amplicon.

Embodiment 63

The method of embodiment 62, wherein the HSV-1 hybrid amplicon is anHSV/AAV hybrid amplicon, an HSV/EBV hybrid amplicon, and HSV/EBV/RVhybrid amplicon, or an HSV/Sleeping Beauty hybrid amplicon.

Embodiment 64

The method of embodiment 54, wherein the vector is a recombinant herpessimplex virus genome.

Embodiment 65

The method of embodiment 64, wherein the recombinant herpes simplexvirus genome is a recombinant HSV-1 genome, a recombinant HSV-2 genome,or any derivatives thereof.

Embodiment 66

The method of embodiment 64 or 65, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in an immediateearly herpes simplex virus gene.

Embodiment 67

The method of embodiment 66, wherein the herpes simplex virus gene isselected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47,tk, UL41, and UL55.

Embodiment 68

The method of any of embodiments 64 to 67, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP4 and ICP22 genes.

Embodiment 69

The method of any of embodiments 64 to 67, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0 and ICP4 genes.

Embodiment 70

The method of embodiment 68 or 69, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP0,ICP4, and ICP22 genes.

Embodiment 71

The method of any of embodiments 68 to 70, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, and ICP27 genes.

Embodiment 72

The method of any of embodiments 68 to 71, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, ICP27, and UL55 genes.

Embodiment 73

The method of any of embodiments 68 to 72, wherein the inactivatingmutation is a deletion of the coding sequence of the genes.

Embodiment 74

The method of any of embodiments 68 to 73, further comprising aninactivating mutation in the ICP47 gene.

Embodiment 75

The method of any of embodiments 64 to 74, further comprising aninactivating mutation in the UL41 gene.

Embodiment 76

The method of any of embodiments 64 to 75, wherein the recombinantherpes simplex virus genome comprises the one or more transgenes withinone or more viral gene loci.

Embodiment 77

The method of any of embodiments 64 to 76, wherein the recombinantherpes simplex virus genome comprises the one or more transgenes withinone or more of the ICP4 viral gene loci.

Embodiment 78

The method of any of embodiments 64 to 77, wherein the recombinantherpes simplex virus genome comprises the one or more transgenes withinthe UL41 viral gene locus.

Embodiment 79

The method of embodiment 54, wherein the vector is capable ofreplicating within a target cell when delivered into said target cell.

Embodiment 80

The method of embodiment 54, wherein the pharmaceutically acceptablecarrier is suitable for topical or transdermal administration.

Embodiment 81

The method of embodiment 54, wherein the one or more transgenescomprises an miRNA binding site.

Embodiment 82

The method of embodiment 54, wherein the one or more transgenes areoperably linked to one or more heterologous promoters.

Embodiment 83

The method of embodiment 82, wherein the one or more heterologouspromoters are selected from the group consisting of the humancytomegalovirus (HCMV) immediate early promoter, the elongation factor-1(EF1) promoter, and any combinations thereof.

Embodiment 84

The method of embodiment 54, wherein the vector comprises a transgeneencoding a Collagen alpha-1 (VII) chain polypeptide.

Embodiment 85

The method of embodiment 54, wherein the vector comprises twotransgenes, wherein each transgene encodes a Collagen alpha-1 (VII)chain polypeptide.

Embodiment 86

The method of embodiment 54, wherein the Collagen alpha-1 (VII) chainpolypeptide has at least 80% sequence identity to the sequence of SEQ IDNO: 2.

Embodiment 87

The method of embodiment 54, wherein the Collagen alpha-1 (VII) chainpolypeptide is a fragment, wherein the fragment has at least 100consecutive amino acids of SEQ ID NO: 2.

Embodiment 88

The method of embodiment 54, wherein the Collagen alpha-1 (VII) chainpolypeptide enhances, increases, augments, and/or supplements anchoringfibril formation of a subject when the polypeptide is expressed in oneor more target cells of the subject.

Embodiment 89

The method of embodiment 54, wherein the Collagen alpha-1 (VII) chainpolypeptide enhances, increases, augments, and/or supplements epithelialbasement membrane organization and/or epithelial basement adherence of asubject when the polypeptide is expressed in one or more target cells ofthe subject.

Embodiment 90

The method of embodiment 54, wherein the Lysyl hydroxylase 3 polypeptidehas at least 80% sequence identity to the sequence of SEQ ID NO: 4.

Embodiment 91

The method of embodiment 54, wherein the Lysyl hydroxylase 3 polypeptideis a fragment, wherein the fragment has at least 100 consecutive aminoacids of SEQ ID NO: 4.

Embodiment 92

The method of embodiment 54, wherein the Lysyl hydroxylase 3 polypeptideenhances, increases, augments, and/or supplements the formation ofhydroxylysine residues on one or more collagen polypeptides of a subjectwhen the Lysyl hydroxylase 3 polypeptide is expressed in one or moretarget cells of the subject.

Embodiment 93

The method of embodiment 54, wherein the Lysyl hydroxylase 3 polypeptideenhances, increases, augments, and/or supplements anchoring fibrilformation, epithelial basement membrane organization, and/or epithelialbasement adherence of a subject when the polypeptide is expressed in oneor more target cells of the subject.

Embodiment 94

The method of embodiment 54, wherein the vector comprises at least afirst transgene and a second transgene.

Embodiment 95

The method of embodiment 94, wherein the first transgene encodes aCollagen alpha-1 (VII) chain polypeptide and the second transgeneencodes a Lysyl hydroxylase 3 polypeptide.

Embodiment 96

The method of embodiment 54, wherein the vector comprises a transgenethat is polycistronic.

Embodiment 97

The method of embodiment 96, wherein the polycistronic transgene encodesa Collagen alpha-1 (VII) chain polypeptide on a first open reading frame(ORF) and a Lysyl hydroxylase 3 polypeptide on a second open readingframe (ORF).

Embodiment 98

The method of embodiment 97, wherein the first and second ORFs areseparated by an internal ribosomal entry site (IRES).

Embodiment 99

The method of any of embodiments 95 to 98, wherein the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide are atabout an equimolar ratio when the polypeptides are expressed in one ormore target cells of a subject.

Embodiment 100

The method of any of embodiments 95 to 98, wherein the Collagen alpha-1(VII) chain polypeptide and the Lysyl hydroxylase 3 polypeptide enhance,increase, augment, and/or supplement anchoring fibril formation,epithelial basement membrane organization, and/or epithelial basementadherence of a subject when the polypeptides are expressed in one ormore target cells of the subject.

Embodiment 101

The method of embodiment 54, wherein the chimeric polypeptide comprisesa linker polypeptide between the Collagen alpha-1 (VII) chainpolypeptide and the Lysyl hydroxylase 3 polypeptide.

Embodiment 102

The method of embodiment 101, wherein the linker polypeptide is a T2A,P2A, E2A, or F2A linker polypeptide.

Embodiment 103

The method of embodiment 101 or 102, wherein the linker polypeptide hasat least 80% sequence identity to the sequence of SEQ ID NO: 6, SEQ IDNO: 8, SEQ NO: 10 or SEQ NO: 12.

Embodiment 104

The method of any of embodiments 101 to 103, wherein the chimericpolypeptide has at least 80% sequence identity to the sequence of SEQ IDNO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, SEQID NO: 24, SEQ ID NO: 26 or SEQ ID NO: 28.

Embodiment 105

The method of any of embodiments 101 to 104, wherein the chimericpolypeptide enhances, increases, augments, and/or supplements anchoringfibril formation, epithelial basement membrane organization, and/orepithelial basement adherence of a subject when the polypeptide isexpressed in one or more target cells of the subject.

Embodiment 106

The method of embodiment 53, wherein the pharmaceutical composition isadministered one, two three, four, five or more times per day.

Embodiment 107

The method of embodiment 53, wherein the pharmaceutical composition isadministered to one or more affected and/or unaffected areas of thesubject.

Embodiment 108

The method of embodiment 53, wherein the disease or disorder of the skinis one or more of epidermolysis bullosa, skin cancer, psoriasis, lichenplanus, lupus, rosacea, eczema, cutaneous candidiasis, cellulitis,impetigo, decubitus ulcers, erysipelas, ichthyosis vulgaris,dermatomyositis, acrodermatitis, stasis dermatitis, nethertons syndrome,epidermolysis bullosa simplex (LAMBS gene), autosomal recessivecongenital ichthyosis, xeroderma pigmentosa, and pemphigoid.

Embodiment 109

An isolated chimeric polypeptide, wherein the isolated chimericpolypeptide comprises;

a) a Collagen alpha-1 (VII) chain polypeptide;

b) a Lysyl hydroxylase 3 polypeptide; and

c) a linker polypeptide;

wherein the Collagen alpha-1 (VII) chain polypeptide and the Lysylhydroxylase 3 polypeptide are separated by the linker polypeptide.

Embodiment 110

The isolated chimeric polypeptide of embodiment 109, wherein theCollagen alpha-1 (VII) chain polypeptide has at least 80% sequenceidentity to the sequence of SEQ NO: 2.

Embodiment 111

The isolated chimeric polypeptide of embodiment 109, wherein the Lysylhydroxylase 3 polypeptide has at least 80% sequence identity to thesequence of SEQ ID NO: 4.

Embodiment 112

The isolated chimeric polypeptide of embodiment 109, wherein the linkerpolypeptide has at least 80% sequence identity to the sequence of SEQ IDNO: 6, SEQ ID NO: 8, SEQ ID NO: 10 or SEQ ID NO: 12.

Embodiment 113

The isolated chimeric polypeptide of any of embodiments 109 to 112,wherein the isolated chimeric polypeptide has at least 80% sequenceidentity to the sequence of SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18,SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 24, SEQ ID NO: 26 or SEQ ID NO:28.

Embodiment 114

A polynucleotide encoding the chimeric polypeptide of any of embodiments109 to 113.

Embodiment 115

A vector comprising the polynucleotide of embodiment 114.

Embodiment 116

The vector of embodiment 115, wherein the vector is an HSV-1 amplicon oran HSV-1 hybrid amplicon.

Embodiment 117

The vector of embodiment 116 wherein the HSV-1 hybrid amplicon is anHSV/AAV hybrid amplicon, an HSV/EBV hybrid amplicon, and HSV/EBV/RVhybrid amplicon, or an HSV/Sleeping Beauty hybrid amplicon.

Embodiment 118

The vector of embodiment 115, wherein the vector is a recombinant herpessimplex virus genome.

Embodiment 119

The vector of embodiment 118, wherein the recombinant herpes simplexvirus genome is a recombinant HSV-1 genome, a recombinant HSV-2 genome,or any derivatives thereof.

Embodiment 120

The vector of embodiment 118 or 119, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in an immediateearly herpes simplex virus gene.

Embodiment 121

The vector of embodiment 120, wherein the herpes simplex virus gene isselected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47,tk, UL41, and UL55.

Embodiment 122

The vector of any of embodiments 118 to 121, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP4 and ICP22 genes.

Embodiment 123

The vector of any of embodiments 118 to 121, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0 and ICP4 genes.

Embodiment 124

The vector of embodiment 122 or 123, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP0,ICP4, and ICP22 genes.

Embodiment 125

The vector of any of embodiments 122 to 124, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, and ICP27 genes.

Embodiment 126

The vector of any of embodiments 122 to 125, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, ICP27, and UL55 genes.

Embodiment 127

The vector of any of embodiments 122 to 126, wherein the inactivatingmutation is a deletion of the coding sequence of the genes.

Embodiment 128

The vector of any of embodiments 122 to 127, further comprising aninactivating mutation in the ICP47 gene.

Embodiment 129

The vector of any of embodiments 118 to 128, further comprising aninactivating mutation in the UL41 gene.

Embodiment 130

The vector of any of embodiments 118 to 129, wherein the recombinantherpes simplex virus genome comprises the polynucleotide within one ormore viral gene loci.

Embodiment 131

The vector of any of embodiments 118 to130, wherein the recombinantherpes simplex virus genome comprises the polynucleotide within one ormore of the ICP4 viral gene loci.

Embodiment 132

The vector of any of embodiments 118 to131, wherein the recombinantherpes simplex virus genome comprises the polynucleotide within the UL41viral gene locus.

Embodiment 133

A vector comprising one or more polynucleotides encoding a Collagenalpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3 polypeptide, aKeratin type I cytoskeletal 17 polypeptide, or any combinations thereof,wherein the vector is a recombinant herpes simplex virus genome.

Embodiment 134

The vector of embodiment 133, wherein the recombinant herpes simplexvirus genome is a recombinant HSV-1 genome, a recombinant HSV-2 genome,or any derivatives thereof.

Embodiment 135

The vector of embodiment 133 or 134, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in an immediateearly herpes simplex virus gene.

Embodiment 136

The vector of embodiment 135, wherein the herpes simplex virus gene isselected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47,tk, UL41, and UL55.

Embodiment 137

The vector of any of embodiments 133 to 136, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP4 and ICP22 genes.

Embodiment 138

The vector of any of embodiments 133 to 136, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0 and ICP4 genes.

Embodiment 139

The vector of embodiment 137 or 138, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP0,ICP4, and ICP22 genes.

Embodiment 140

The vector of any of embodiments 137 to 139, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, and ICP27 genes.

Embodiment 141

The vector of any of embodiments 137 to 140, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, ICP27, and UL55 genes.

Embodiment 142

The vector of any of embodiments 137 to 141, wherein the inactivatingmutation is a deletion of the coding sequence of the genes.

Embodiment 143

The vector of any of embodiments 137 to 142, further comprising aninactivating mutation in the ICP47 gene.

Embodiment 144

The vector of any of embodiments 133 to 143, further comprising aninactivating mutation in the UL41 gene.

Embodiment 145

The vector of any of embodiments 133 to 144, wherein the recombinantherpes simplex virus genome comprises the one or more polynucleotideswithin one or more viral gene loci.

Embodiment 146

The vector of any of embodiments 133 to145, wherein the recombinantherpes simplex virus genome comprises the one or more polynucleotideswithin one or more of the ICP4 viral gene loci.

Embodiment 147

The vector of any of embodiments 133 to146, wherein the recombinantherpes simplex virus genome comprises the one or more polynucleotideswithin the UL41 viral gene locus.

Embodiment 148

The vector of any of embodiments 133 to147, wherein the vector comprisesone polynucleotide encoding a Collagen alpha-1 (VII) chain polypeptide.

Embodiment 149

The vector of any of embodiments 133 to147, wherein the vector comprisestwo polynucleotides encoding a Collagen alpha-1 (VII) chain polypeptide.

Embodiment 150

A host cell comprising the vector of any of embodiments 115 to 149.

Embodiment 151

A method of collecting a herpes simplex virus, wherein a vector ofinterest is packaged within said herpes simplex virus, the methodcomprising;

a) contacting a host cell with a vector encoding a helper virus;

b) contacting said host cell with a vector of any of embodiments 115 to117; and

c) collecting the Herpes simplex virus generated by said host cell.

Embodiment 152

A method of collecting a herpes simplex virus, wherein a vector ofinterest is packaged within said herpes simplex virus, the methodcomprising;

a) contacting a complementing host cell with a vector of any ofembodiments 118 to 149; and

b) collecting the herpes simplex virus generated by said complementinghost cell.

Embodiment 153

The method of embodiment 151 or 152, wherein the herpes simplex virus isa herpes simplex type 1 virus, a herpes simplex type 2 virus, or anyderivatives thereof.

Embodiment 154

A kit comprising:

a) the pharmaceutical composition of any of embodiments 1 to 52; and

b) instructions for administering the pharmaceutical composition.

Embodiment 155

A pharmaceutical composition comprising:

a) a virus comprising a vector, wherein the vector comprises one or moretransgenes encoding a polypeptide selected from the group consisting ofa Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3polypeptide, a Keratin type I cytoskeletal 17 polypeptide, and achimeric polypeptide thereof; and

b) a pharmaceutically acceptable carrier.

Embodiment 156

The pharmaceutical composition of embodiment 155, wherein the virus isan adenovirus, adeno-associated virus, retrovirus, lentivirus, sendaivirus, herpes simplex virus, vaccinia virus, or any hybrid virusthereof.

Embodiment 157

The pharmaceutical composition of embodiment 155, wherein the virus is aherpes simplex virus (HSV).

Embodiment 158

The pharmaceutical composition of any of embodiments 155 to 157, whereinthe virus is replication-defective.

Embodiment 159

The pharmaceutical composition of any of embodiments 155 to 158, whereinthe herpes simplex virus is a herpes simplex type 1 virus, a herpessimplex type 2 virus, or any derivatives thereof.

Embodiment 160

The pharmaceutical composition of any of embodiments 155 to 159, whereinthe vector is an HSV-1 amplicon or an HSV-1 hybrid amplicon.

Embodiment 161

The pharmaceutical composition of embodiment 160, wherein the HSV-1hybrid amplicon is an HSV/AAV hybrid amplicon, an HSV/EBV hybridamplicon, and HSV/EBV/RV hybrid amplicon, or an HSV/Sleeping Beautyhybrid amplicon.

Embodiment 162

The pharmaceutical composition of any of embodiments 155 to 159, whereinthe vector is a recombinant herpes simplex virus genome.

Embodiment 163

The pharmaceutical composition of embodiment 162, wherein therecombinant herpes simplex virus genome is a recombinant HSV-1 genome, arecombinant HSV-2 genome, or any derivatives thereof.

Embodiment 164

The pharmaceutical composition of embodiment 162 or 163, wherein therecombinant herpes simplex virus genome comprises an inactivatingmutation in an immediate early herpes simplex virus gene.

Embodiment 165

The pharmaceutical composition of embodiment 164, wherein the herpessimplex virus gene is selected from the group consisting of ICP0, ICP4,ICP22, ICP27, ICP47, tk, UL41, and UL55.

Embodiment 166

The pharmaceutical composition of any of embodiments 162 to 165, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP4 and ICP22 genes.

Embodiment 167

The pharmaceutical composition of any of embodiments 162 to 165, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0 and ICP4 genes.

Embodiment 168

The pharmaceutical composition of embodiment 166 or 167, wherein therecombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, and ICP22 genes.

Embodiment 169

The pharmaceutical composition of any of embodiments 166 to 168, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, ICP22, and ICP27 genes.

Embodiment 170

The pharmaceutical composition of any of embodiments 166 to 169, whereinthe recombinant herpes simplex virus genome comprises an inactivatingmutation in the ICP0, ICP4, ICP22, ICP27, and UL55 genes.

Embodiment 171

The pharmaceutical composition of any of embodiments 166 to 170, whereinthe inactivating mutation is a deletion of the coding sequence of thegenes.

Embodiment 172

The pharmaceutical composition of any of embodiments 166 to 171, furthercomprising an inactivating mutation in the ICP47 gene.

Embodiment 173

The pharmaceutical composition of any of embodiments 162 to 172, furthercomprising an inactivating mutation in the UL41 gene.

Embodiment 174

The pharmaceutical composition of any of embodiments 162 to 173, whereinthe recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more viral gene loci.

Embodiment 175

The pharmaceutical composition of any of embodiments 162 to 174, whereinthe recombinant herpes simplex virus genome comprises the one or moretransgenes within one or more of the ICP4 viral gene loci.

Embodiment 176

The pharmaceutical composition of any of embodiments 162 to 175, whereinthe recombinant herpes simplex virus genome comprises the one or moretransgenes within the UL41 viral gene locus.

Embodiment 177

The pharmaceutical composition of embodiment 155, wherein the vector iscapable of replicating within a target cell when delivered into saidtarget cell.

Embodiment 178

The pharmaceutical composition of embodiment 155, wherein thepharmaceutically acceptable carrier is suitable for topical ortransdermal administration.

Embodiment 179

The pharmaceutical composition of embodiment 155, wherein thepharmaceutically acceptable carrier is suitable for subcutaneous orintradermal administration.

Embodiment 180

The pharmaceutical composition of embodiment 155, wherein the one ormore transgenes comprises an miRNA binding site.

Embodiment 181

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe vector comprises a transgene encoding a Collagen alpha-1 (VII) chainpolypeptide.

Embodiment 182

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe vector comprises a transgene encoding a Lysyl hydroxylase 3polypeptide.

Embodiment 183

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe vector comprises a transgene encoding a Keratin type I cytoskeletal17 polypeptide.

Embodiment 184

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Collagen alpha-1 (VII) chain polypeptide has at least 80% sequenceidentity to the sequence of SEQ ID NO: 2.

Embodiment 185

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Collagen alpha-1 (VII) chain polypeptide is a fragment, wherein thefragment has at least 100 consecutive amino acids of SEQ ID NO: 2.

Embodiment 186

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Collagen alpha-1 (VII) chain polypeptide enhances, increases,augments, and/or supplements anchoring fibril formation of a subjectwhen the polypeptide is expressed in one or more target cells of thesubject.

Embodiment 187

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Collagen alpha-1 (VII) chain polypeptide enhances, increases,augments, and/or supplements epithelial basement membrane organizationand/or epithelial basement adherence of a subject when the polypeptideis expressed in one or more target cells of the subject.

Embodiment 188

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Lysyl hydroxylase 3 polypeptide has at least 80% sequence identityto the sequence of SEQ ID NO: 4.

Embodiment 189

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Lysyl hydroxylase 3 polypeptide is a fragment, wherein the fragmenthas at least 100 consecutive amino acids of SEQ ID NO: 4.

Embodiment 190

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Lysyl hydroxylase 3 polypeptide enhances, increases, augments,and/or supplements the formation of hydroxylysine residues on one ormore collagen polypeptides of a subject when the Lysyl hydroxylase 3polypeptide is expressed in one or more target cells of the subject.

Embodiment 191

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Lysyl hydroxylase 3 polypeptide enhances, increases, augments,and/or supplements anchoring fibril formation, epithelial basementmembrane organization, and/or epithelial basement adherence of a subjectwhen the polypeptide is expressed in one or more target cells of thesubject.

Embodiment 192

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Keratin type I cytoskeletal 17 polypeptide has at least 80% sequenceidentity to the sequence of SEQ ID NO: 30.

Embodiment 193

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Keratin type I cytoskeletal 17 polypeptide is a fragment, whereinthe fragment has at least 100 consecutive amino acids of SEQ ID NO: 30.

Embodiment 194

The pharmaceutical composition of any of embodiments 155 to 180, whereinthe Keratin type I cytoskeletal 17 polypeptide enhances, increases,augments, and/or supplements wound healing in a subject.

Embodiment 195

The pharmaceutical composition of any of embodiments 155 to 194, whereinthe vector comprises at least a first transgene and a second transgene.

Embodiment 196

The pharmaceutical composition of embodiment 195, wherein the firsttransgene and the second transgene each encode a Collagen alpha-1 (VII)chain polypeptide.

Embodiment 197

The pharmaceutical composition of embodiment 195, wherein the firsttransgene encodes a Collagen alpha-1 (VII) chain polypeptide and thesecond transgene encodes a Lysyl hydroxylase 3 polypeptide.

Embodiment 198

The pharmaceutical composition of embodiment 195, wherein the firsttransgene encodes a Collagen alpha-1 (VII) chain polypeptide and thesecond transgene encodes a Keratin type I cytoskeletal 17 polypeptide.

Embodiment 199

The pharmaceutical composition of embodiment 195, wherein the firsttransgene encodes a Lysyl hydroxylase 3 polypeptide and the secondtransgene encodes a Keratin type I cytoskeletal 17 polypeptide.

Embodiment 200

The pharmaceutical composition of embodiment 155, wherein the vectorcomprises at least a first transgene, a second transgene, and a thirdtransgene.

Embodiment 201

The pharmaceutical composition of embodiment 200, wherein the firsttransgene encodes a Collagen alpha-1 (VII) chain polypeptide, the secondtransgene encodes a Lysyl hydroxylase 3 polypeptide, and the thirdtransgene encodes a Keratin type I cytoskeletal 17 polypeptide.

Embodiment 202

A method of providing prophylactic, palliative, or therapeutic relief ofa wound, disorder, or disease of the skin in a subject, the methodcomprising administering to the subject a pharmaceutical compositioncomprising a vector, wherein the vector is a recombinant herpes simplexvirus genome, and wherein the pharmaceutical composition is capable ofenhancing, increasing, augmenting, and/or supplementing the levels of aCollagen alpha-1 (VII) chain polypeptide and/or a Lysyl hydroxylase 3polypeptide and/or a Keratin type I cytoskeletal 17 polypeptide in oneor more cells of the subject.

Embodiment 203

The method of embodiment 202, wherein the pharmaceutical compositioncomprises:

a) a virus comprising the vector, wherein the vector comprises one ormore transgenes encoding a polypeptide selected from the groupconsisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysylhydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide,and a chimeric polypeptide thereof; and

b) a pharmaceutically acceptable carrier.

Embodiment 204

The method of embodiment 203, wherein the virus is an adenovirus,adeno-associated virus, retrovirus, lentivirus, sendai virus, herpessimplex virus, vaccinia virus, or any hybrid virus thereof.

Embodiment 205

The method of embodiment 203, wherein the virus is a herpes simplexvirus (HSV).

Embodiment 206

The method of any of embodiments 203 to 205, wherein the virus isreplication-defective.

Embodiment 207

The method of any of embodiment 203 to 206, wherein the herpes simplexvirus is a herpes simplex type 1 virus, a herpes simplex type 2 virus,or any derivatives thereof.

Embodiment 208

The method of any of embodiments 202 to 207, wherein the recombinantherpes simplex virus genome is a recombinant HSV-1 genome, a recombinantHSV-2 genome, or any derivatives thereof.

Embodiment 209

The method of embodiment 202 to 208, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in an immediateearly herpes simplex virus gene.

Embodiment 210

The method of embodiment 209, wherein the herpes simplex virus gene isselected from the group consisting of ICP0, ICP4, ICP22, ICP27, ICP47,tk, UL41, and UL55.

Embodiment 211

The method of any of embodiments 202 to 210, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP4 and ICP22 genes.

Embodiment 212

The method of any of embodiments 202 to 210, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0 and ICP4 genes.

Embodiment 213

The method of embodiment 211 or 212, wherein the recombinant herpessimplex virus genome comprises an inactivating mutation in the ICP0,ICP4, and ICP22 genes.

Embodiment 214

The method of any of embodiments 211 to 213, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, and ICP27 genes.

Embodiment 215

The method of any of embodiments 211 to 214, wherein the recombinantherpes simplex virus genome comprises an inactivating mutation in theICP0, ICP4, ICP22, ICP27, and UL55 genes.

Embodiment 216

The method of any of embodiments 211 to 215, wherein the inactivatingmutation is a deletion of the coding sequence of the genes.

Embodiment 217

The method of any of embodiments 211 to 216, further comprising aninactivating mutation in the ICP47 gene.

Embodiment 218

The method of any of embodiments 202 to 217, further comprising aninactivating mutation in the UL41 gene.

Embodiment 219

The method of any of embodiments 202 to 218, wherein the recombinantherpes simplex virus genome comprises the one or more transgenes withinone or more viral gene loci.

Embodiment 220

The method of any of embodiments 202 to 219, wherein the recombinantherpes simplex virus genome comprises the one or more transgenes withinone or more of the ICP4 viral gene loci.

Embodiment 221

The method of any of embodiments 202 to 220, wherein the recombinantherpes simplex virus genome comprises the one or more transgenes withinthe UL41 viral gene locus.

Embodiment 222

The method of embodiment 202, wherein the vector is capable ofreplicating within a target cell when delivered into said target cell.

Embodiment 223

The method of embodiment 203, wherein the pharmaceutically acceptablecarrier is suitable for topical or transdermal administration.

Embodiment 224

The method of embodiment 203, wherein the pharmaceutically acceptablecarrier is suitable for subcutaneous or intradermal administration.

Embodiment 225

The method of embodiment 203, wherein the one or more transgenescomprises an miRNA binding site.

Embodiment 226

The method of any of embodiments 202 to 225, wherein the vectorcomprises a transgene encoding a Collagen alpha-1 (VII) chainpolypeptide.

Embodiment 227

The method of any of embodiments 202 to 225, wherein the vectorcomprises a transgene encoding a Lysyl hydroxylase 3 polypeptide.

Embodiment 228

The method of any of embodiments 202 to 225, wherein the vectorcomprises a transgene encoding a Keratin type I cytoskeletal 17polypeptide.

Embodiment 229

The method of any of embodiments 202 to 225, wherein the Collagenalpha-1 (VII) chain polypeptide has at least 80% sequence identity tothe sequence of SEQ NO: 2.

Embodiment 230

The method of any of embodiments 202 to 225, wherein the Collagenalpha-1 (VII) chain polypeptide is a fragment, wherein the fragment hasat least 100 consecutive amino acids of SEQ ID NO: 2.

Embodiment 231

The method of any of embodiments 202 to 225, wherein the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements anchoring fibril formation of a subject when the polypeptideis expressed in one or more target cells of the subject.

Embodiment 232

The method of any of embodiments 202 to 225, wherein the Collagenalpha-1 (VII) chain polypeptide enhances, increases, augments, and/orsupplements epithelial basement membrane organization and/or epithelialbasement adherence of a subject when the polypeptide is expressed in oneor more target cells of the subject.

Embodiment 233

The method of any of embodiments 202 to 225, wherein the Lysylhydroxylase 3 polypeptide has at least 80% sequence identity to thesequence of SEQ ID NO: 4.

Embodiment 234

The method of any of embodiments 202 to 225, wherein the Lysylhydroxylase 3 polypeptide is a fragment, wherein the fragment has atleast 100 consecutive amino acids of SEQ ID NO: 4.

Embodiment 235

The method of any of embodiments 202 to 225, wherein the Lysylhydroxylase 3 polypeptide enhances, increases, augments, and/orsupplements the formation of hydroxylysine residues on one or morecollagen polypeptides of a subject when the Lysyl hydroxylase 3polypeptide is expressed in one or more target cells of the subject.

Embodiment 236

The method of any of embodiments 202 to 225, wherein the Lysylhydroxylase 3 polypeptide enhances, increases, augments, and/orsupplements anchoring fibril formation, epithelial basement membraneorganization, and/or epithelial basement adherence of a subject when thepolypeptide is expressed in one or more target cells of the subject.

Embodiment 237

The method of any of embodiments 202 to 225, wherein the Keratin type Icytoskeletal 17 polypeptide has at least 80% sequence identity to thesequence of SEQ ID NO: 30.

Embodiment 238

The method of any of embodiments 202 to 225, wherein the Keratin type Icytoskeletal 17 polypeptide is a fragment, wherein the fragment has atleast 100 consecutive amino acids of SEQ ID NO: 30.

Embodiment 239

The method of any of embodiments 202 to 225, wherein the Keratin type Icytoskeletal 17 polypeptide enhances, increases, augments, and/orsupplements wound healing in a subject.

Embodiment 240

The method of any of embodiments 202 to 239, wherein the vectorcomprises at least a first transgene and a second transgene.

Embodiment 241

The method of embodiment 240, wherein the first transgene and the secondtransgene each encode a Collagen alpha-1 (VII) chain polypeptide.

Embodiment 242

The method of embodiment 240, wherein the first transgene encodes aCollagen alpha-1 (VII) chain polypeptide and the second transgeneencodes a Lysyl hydroxylase 3 polypeptide.

Embodiment 243

The method of embodiment 240, wherein the first transgene encodes aCollagen alpha-1 (VII) chain polypeptide and the second transgeneencodes a Keratin type I cytoskeletal 17 polypeptide.

Embodiment 244

The method of embodiment 240, wherein the first transgene encodes aLysyl hydroxylase 3 polypeptide and the second transgene encodes aKeratin type I cytoskeletal 17 polypeptide.

Embodiment 245

The method of any of embodiments 202 to 239, wherein the vectorcomprises at least a first transgene, a second transgene, and a thirdtransgene.

Embodiment 246

The method of embodiment 245, wherein the first transgene encodes aCollagen alpha-1 (VII) chain polypeptide, the second transgene encodes aLysyl hydroxylase 3 polypeptide, and the third transgene encodes aKeratin type I cytoskeletal 17 polypeptide.

Embodiment 247

The method of any of embodiments 202 to 246, wherein the pharmaceuticalcomposition is administered topically or transdermally to the subject.

Embodiment 248

The method of any of embodiments 202 to 246, wherein the pharmaceuticalcomposition is administered subcutaneously or intradermally to thesubject.

Embodiment 249

The method of any of embodiments 202 to 248, wherein the pharmaceuticalcomposition is administered one, two three, four, five or more times perday.

Embodiment 250

The method of any of embodiments 202 to 249, wherein the pharmaceuticalcomposition is administered to one or more affected and/or unaffectedareas of the subject.

Embodiment 251

The method of any of embodiments 202 to 250, wherein the disease ordisorder of the skin is one or more of epidermolysis bullosa, skincancer, psoriasis, lichen planus, lupus, rosacea, eczema, cutaneouscandidiasis, cellulitis, impetigo, decubitus ulcers, erysipelas,ichthyosis vulgaris, dermatomyositis, acrodermatitis, stasis dermatitis,nethertons syndrome, epidermolysis bullosa simplex (LAMBS gene),autosomal recessive congenital ichthyosis, xeroderma pigmentosa, andpemphigoid.

The specification is considered to be sufficient to enable one skilledin the art to practice the invention. Various modifications of theinvention in addition to those shown and described herein will becomeapparent to those skilled in the art from the foregoing description andfall within the scope of the appended claims.

EXAMPLES

The present disclosure will be more fully understood by reference to thefollowing example. It should not, however, be construed as limiting thescope of the present disclosure. It is understood that the examples andembodiments described herein are for illustrative purposes only and thatvarious modifications or changes in light thereof will be suggested topersons skilled in the art and are to be included within the spirit andpurview of this application and scope of the appended claims.

Example 1: Generating Modified Herpes Simplex Virus Vectors, andProducing/Isolating Virus Containing the Vectors

To make modified herpes simplex virus genome vectors capable ofexpressing one or more transgenes in a target mammalian cell, a herpessimplex virus genome (FIG. 1A) is modified to inactivate the immediateearly genes ICP0, ICP4, and ICP27, while the immediate early gene ICP22is modified to include a heterologous, inducible promoter. Thisdecreases the toxicity of the genome in mammalian cells. Next, acassette is inserted into the modified herpes virus genome byrestriction cloning. The cassette contains a heterologous promotercapable of expressing a transgene in a target mammalian cell. Thepromoter is operably linked to the nucleic acid sequence encoding aCollagen alpha-1 (VII) chain polypeptide, as well as downstreamregulatory elements (FIG. 1B) ensuring proper production of the mRNA.Alternatively, the cassette includes two transgenes, each of which hasits own heterologous promoter operably linked to the nucleic acidencoding either a Collagen alpha-1 (VII) chain polypeptide or a Lysylhydroxylase 3 polypeptide. The transgenes are encoded either on the samestrand of DNA (FIG. 1C), or on opposite strands of DNA in an antisenseorientation (FIG. 1D). Linking each transgene with its own promoter andregulatory elements allows for independent expression of each codingsequence on separate mRNA transcripts. Expressing the transgenes fromdistinct promoters allows for the ability to operably link the codingsequences to different promoter types, which can drive expression of thetransgenes at different levels, at different times in the cell cycle, indifferent cell types, or under the control of different inducers orrepressors.

A modified herpes virus genome is also constructed that includes acassette expressing a single mRNA encoding a Collagen alpha-1 (VII)chain polypeptide and a Lysyl hydroxylase 3 polypeptide separated by aninternal ribosomal entry site (FIG. 1E). This allows for approximatelyequimolar production of each polypeptide when expressed in a targetcell. Finally, a modified herpes virus genome is constructed thatincludes a cassette expressing a chimeric polypeptide. This chimericpolypeptide includes, from N-terminus to C-terminus, a Collagen alpha-1(VII) chain polypeptide, a cleavable peptide linker, and a Lysylhydroxylase 3 polypeptide (FIG. 1F).

Additional modified herpes virus genomes are constructed that includetwo cassettes, each expressing Collagen alpha-1 (VII) chainpolypeptides, where each cassette is inserted into a copy of the ICP4gene locus (FIGS. 2B-2G) of the wild-type herpes simplex virus genome(FIG. 2A). These additional recombinant herpes virus genomes areconstructed with various combinations of herpes virus genedeletions/modifications.

A recombinant herpes virus genome is constructed which containsdeletions of the coding sequences of both copies of the ICP4 gene, aswell as deletions of the coding sequences of the ICP27 and UL55 genes.These recombinant viruses are further modified to contain inactivatingmutations in the promoter regions of the ICP22 and ICP47 genes such thatthe ICP22 and ICP47 genes are not expressed with normal kinetics (FIG.2B).

Further recombinant herpes simplex viruses are constructed whichincorporate expression cassettes for Collagen alpha-1 (VII) chainpolypeptides into both loci of the herpes ICP4 genes. These recombinantviruses include: viruses containing deletions of the coding sequences ofthe ICP22 gene and both copies of the ICP4 gene (FIG. 2C); deletions ofthe coding sequences of the ICP0 gene and both copies of the ICP4 gene(FIG. 2D); deletions of the coding sequences of the ICP0 and ICP22genes, and both copies of the ICP4 gene (FIG. 2E); deletions of thecoding sequences of the ICP0, ICP22, and ICP27 genes, and both copies ofthe ICP4 gene (FIG. 2F); and deletions of the coding sequences of theICP0, ICP22, ICP27, and UL55 genes, and both copies of the ICP4 gene(FIG. 2G). Additional vectors are constructed based upon the vectorsshown in FIGS. 2C-2G which further comprise one or more transgenesencoding one or more additional effectors (e.g., LH3, KRT17) in the ICP0and/or UL41 loci.

These modified herpes simplex virus genome vectors are transfected intoengineered Vero cells that are modified to express herpes virus genes.These engineered Vero cells secrete replication-defective herpes simplexvirus with the modified genomes packaged within into the supernatant.The supernatant is then collected, concentrated, and sterile filteredthrough a 5 μm filter.

Example 2: Rescuing Col7 Expression with Replication Defective HSV-1

The following example describes the construction of a replicationdefective herpes simplex type-1 virus modified to express the humanCOL7A1 gene, and use of such a viral vector to rescue several defectsobserved in cells isolated from RDEB patients.

Methods

Cells and Cell Culture

Normal and RDEB human dermal fibroblasts and keratinocytes were isolatedas described previously (NG, Y. Z. et al. (2012) Cancer Res. 72:3522-3534; Rheinwald, J. G. and Green, H. (1975) Cell 6: 331-42). Cellswere cultured according to standard techniques.

Construction of KB103

The KB103 vector was generated from D3GFP, a replication-defective HSV-1vector backbone harboring GFP in place of the viral ICP4. The sequenceof the GFP in D3GFP was replaced with the coding sequence of humanCOL7A1 using a transfer plasmid by cloning COL7A1 into the EcoRI site ofthe ICP4 recombination plasmid pSASB3. A mixed transfection/infection ofthe COL7A1 containing transfer plasmid and D3GFP vector was performed onVeroD cells. Resulting plaques which did not express GFP were isolatedand tested by western blot for Col7 protein expression.

Virus Purification

KB103 virus was purified according to standard techniques (SeeDiefenbach, R. and Fraefel, C. Herpes Simplex Virus. New York: HumanaPress, 2014).

Viral Infections

Cells were seeded in duplicates or triplicates in six-well plates atapproximately 50% confluency one day prior to viral infection. Anadditional well was seeded in parallel for cell counting and MOIdetermination. 24 hours after cell seeding, cells from one well weretrypsinized and counted to calculate the MOI, and viral stocks werethawed and diluted in cell culture medium to achieve the desired MOI.Culture medium was aspirated from each well to be infected, and 500 μLof KB103-containing medium (or control medium) was added to each well.Plates were incubated at 37° C. with 5-7.5% CO₂ for 1.5-2 hours withintermittent rocking every 15-20 minutes, then 1.5-2 mL of complete cellculture medium was added to each well, and the plates were incubated for24-72 hours at 37° C. After incubation, the cells and supernatants wereharvested and processed for analysis.

mRNA Quantification

Col7 transcripts were amplified from RNA isolated from primary RDEBkeratinocytes after infection using a SYBR PCR assay (Sybr Select MasterMix, Life Technologies) according to the manufacturer's protocol. Col7transcript levels were normalized to β-actin transcript levels.

Western Blot Analysis

Cell lysates were generated from cells 48 hours post-infection, andwestern blots were carried out according to standard techniques usingthe following antibodies: rabbit anti-human Col7 polyclonal antibody(Sigma, Cat. # HPA042420), mouse anti-human GAPDH antibody (Santa CruzBiotechnology, Cat. # sc-365062), rabbit anti-LH3 antibody (ProteinTech, Cat. #11027-1-AP), and mouse anti-TSP1 antibody (Santa CruzBiotechnology, Cat. # sc-59887).

Immunofluorescence

Cells were plated on cover slips prior to infection, fixed 48 hourspost-infection, and stained with a primary rabbit anti-human Col7polyclonal antibody (Sigma, Cat. # HPA042420), washed, and furtherstained with a fluorescently labelled anti-rabbit secondary antibody(Invitrogen, Cat. 3 A11012). Cell nuclei were stained with DAPI usingstandard techniques.

Cellular Adhesion

96-well plates were coated with 10, 20, or 50 μg/mL rat tail Collagen 1(Marathon Laboratory Supply) or human fibronectin (Sigma-Aldrich) in 100μL reaction volume at 4° C. overnight, then washed with PBS, and blockedwith PBS+0.1% BSA for 1 hour at 37° C. Mock (control) infected or KB103infected RDEB keratinocytes (2.4*10⁴ cells in 100 μL of DMEM/HamF12+0.1%BSA) were added to the plates and incubated at 37° C. for 40-90 minutes.Wells were washed three times with PBS to remove any unbound cells, andadherent cells were fixed with PFE for 20 minutes. The fixed cells werethen treated with 70% ethanol, stained with crystal violet, resolved in100% ethanol, and were quantified by measuring absorbance at 630 nm.

Skin Equivalent (SE) Organotypic Cultures

A skin equivalent organotypic culture composed of RDEB fibroblasts andkeratinocytes was used to evaluate the expression of Col7 at thebasement membrane zone (BMZ). Briefly, RDEB fibroblasts (2*10⁵ cells perwell) were embedded in fibrin gel matrix in six-well plates andincubated in DMEM+10% serum containing ascorbic acid and aprotinin for24 hours at 37° C. and 5% CO₂. RDEB keratinocytes (1*10⁶ cells per well)were then seeded on the matrix, grown to confluence in DMEM/F-12keratinocyte medium containing 50 mg/mL of ascorbic acid, and raised atthe air-liquid interface. Two days post raising, KB103 virus was addedto the cultures (at an MOI of 3) and incubated for 1.5 hours. Followingincubation, cultures were washed and incubated for 5-14 days to favorstratification and differentiation into an epithelium. Skin equivalents(SEs) were manually detached from the plates and embedded in optimalcutting temperature compound, frozen in liquid nitrogen, and cut into 6mm sections for immunofluorescence staining with a monoclonal anti-Col7antibody.

Results

KB103 Pharmacology in Normal and RDEB Cells

A number of ex vivo approaches have been undertaken to deliver the humanCOL7A1 gene to primary cells isolated from RDEB patients in an attemptto correct Col7 deficiencies (Ortiz-Urda, S. et al. (2003) J. Clin.Invest. 111(2) 251-5; Woodley, D. T. et al. (2003) J. Invest. Dematol.121(5) 1021-8). Although successful in achieving durable correction ofkey disease features, an ex vivo gene delivery strategy for treatingepidermolysis bullosa has a number of key disadvantages, including highcost, poor graft takes, surgical debridement, complex bandaging andwound care, and the high potential for post-surgical infection. Anattractive alternate route for gene therapy is the use of viral ornon-viral vectors to deliver gene products. However, non-viral vectorsusing plasmid DNA suffer from very low gene transfer efficiency wheninjected or topically administered, while the most widely used viralvectors in human gene therapy trials (retroviral vectors) do not infectnon-dividing cells. This is problematic for gene delivery to the skin,as manipulation of the tissue (such as wounding) to create an adequatepopulation of dividing cells would be required for retroviral genetherapy. Large-capacity adenoviral vectors can deliver genome-sizedtranscription units and survive in transduced cells for long periods oftime, but the toxicity and immunogenicity of adenoviral particles, aswell as the requirements for helper virus during vector production,remain as significant hurdles for their use in human gene therapystrategies. While replication-defective HSV vectors have been employedas delivery vehicles in a number of pre-clinical studies, nopre-clinical evidence supporting the use of HSV-based viral vectors forepidermolysis bullosa or other dermatological applications has beenreported.

To this end, a replication defective herpes simplex type-1 virus (HSV-1)encoding the human COL7A1 gene was developed as a novel vector usefulfor gene therapy treatment of DEB patients. An HSV-1 virus was modifiedto harbor complete deletions of the viral ICP4, ICP27, and UL55 genes,with the ICP4 deletion resulting in the removal of the upstream promotersequences driving the transcription of the immediate early viral genesICP22 and ICP47. The virus was further modified to include a humancytomegalovirus (HCMV) immediate early promoter-driven human COL7A1expression cassette encoded within both copies of the deleted ICP4 loci,resulting in a replication-defective HSV-1 vector, termed KB103,suitable for delivering human COL7A1 to target cells (FIG. 3).

To test the ability of KB103 to deliver and express Col7 in human cells,and to rescue Col7 deficiencies in RDEB patients, patient-derived humandermal fibroblasts and keratinocytes were isolated from healthyindividuals, as well as individuals suffering from RDEB, and theseprimary cells were infected with KB103 at various MOIs. 24-72 hours postinfection, COL7A1 gene expression was measured by real-time PCR intransduced cells, while Col7 protein expression was analyzed in parallelby both western blot and immunofluorescence analysis.

Dose-dependent increases in COL7A1 gene expression were observed in RDEBkeratinocytes (FIG. 4A) and fibroblasts (FIG. 4B) infected with KB103.KB103 infection increased COL7A1 gene expression by approximately 7.5fold, 12.5 fold, and 25 fold in RDEB keratinocytes infected at an MOI of0.3, 1, and 3, respectively (FIG. 4A). Surprisingly, even more drasticchanges in COL7A1 gene expression was observed in infected RDEBfibroblasts. While infections at an MOI of 0.1 and 0.3 showed moderateincreases in COL7A1 gene expression, an approximate 30 fold increase inCOL7A1 gene expression was measured for RDEB fibroblasts infected at anMOI of 1, while a 60 fold increase was observed in this cell typeinfected at an MOI of 3. This data showed that COL7A1 gene expressionwas massively upregulated in RDEB primary cells after infection withKB103.

Consequently, robust Col7 protein expression was also observed in cellsinfected with KB103. Col7 protein expression was detected in both normaland RDEB keratinocytes (FIG. 5A) and fibroblasts (FIG. 5B) 48 hoursafter infection with KB103 at an MOI of 0.3, 1, and 3, with an apparentdose-dependent increase in Col7 protein expression observed at higherviral titers. Expression of Col7 was observed in both the supernatantsand cell lysates from infected cells. Surprisingly, RDEB fibroblastsinfected at an MOI of 0.3 showed higher levels of Col7 than was observedin uninfected normal fibroblasts (FIG. 5B), suggesting complete rescueof Col7 expression in RDEB fibroblasts using KB103, even at low viraltiters. No obvious effects on cell morphology using high viral doses(MOI of 3) were observed. Additionally, no negative impacts onfibroblast or keratinocyte cell proliferation using high doses of KB103were indicated in these experiments, as determined by GAPDH expression.

In agreement with the above experiments, a robust and dose-dependentincrease in Col7 protein expression was confirmed in normal and RDEBcells infected with KB103, as demonstrated by immunofluorescentdetection of Col7 protein expression (FIG. 6). As expected, no Col7protein was detected in uninfected RDEB human dermal fibroblasts orkeratinocytes; limited Col7 protein was detected in uninfected normalkeratinocytes and fibroblasts. However, infection with KB103 was capableof rescuing Col7 protein expression in RDEB fibroblasts andkeratinocytes at or above the levels observed in uninfected normalcells. Furthermore, infection efficiency of KB103 (at an MOI of 3) wascalculated to be ≧95% based on an assessment of three or moreindependent panels for each infected replicate, showing that KB103efficiently delivered and expressed the COL7A1 expression cassette.Taken together, this data suggested that KB103 was capable of deliveringand expressing COL7A1 in normal and RDEB primary cells, and that KB103was well tolerated by both human dermal fibroblasts and keratinocytes.

Functional Assessment of KB103 in RDEB Cells

The functionality of the human Col7 protein expressed from KB103 wasnext investigated in human dermal fibroblasts and keratinocytes. First,the effect of Col7 expression on the levels of lysyl hydroxylase 3 wastested in KB103-infected cells. LH3 is required for the deposition andorganization of extracellular matrix, and it has been reported that LH3levels are reduced in RDEB skin (Watt, S. A. et al. (2015) PLoS One10(9): p. e0137639). Little to no LH3 was observed in uninfected RDEBkeratinocytes relative to normal keratinocytes (FIG. 7, lanes 1 vs. 5),in agreement with previous studies. However, unexpectedly, adose-dependent increase in LH3 levels, concomitant with increased Col7protein expression, was observed in RDEB keratinocytes infected withKB103 (FIG. 7), suggesting that KB103 was capable of rescuing not onlyCol7 protein expression, but also LH3 expression in RDEB cells.

Next, the effect of Col7 expression on TSP-1 levels was tested. TSP-1 isa negative regulator of angiogenesis, and has been reported to beincreased in RDEB fibroblasts (Ng, Y. Z. et al. (2012) Cancer Res.72(14): p. 3522-34). In agreement with previous studies, higher levelsof TSP-1 were observed in uninfected RDEB vs. normal human dermalfibroblasts (FIG. 8, lanes 1 and 4). Surprisingly, TSP-1 proteinexpression was robustly inhibited upon infection of either normal orRDEB fibroblasts infected with KB103 (FIG. 8). This data suggested thatKB103 may not only increase Col7 and LH3 levels in infected cells, butmay also promote angiogenesis by inhibiting the negative regulatorTSP-1.

Finally, the ability of KB103 to increase cellular adherence of RDEBkeratinocytes to either Collagen 1 or Fibronectin was tested. Adose-dependent increase in cellular adherence to both Collagen 1 andFibronectin was observed in RDEB keratinocytes infected with KB103 atvarious MOIs (FIGS. 9A and 9B). Infection of RDEB keratinocytes at allMOIs tested showed higher adhesion to wells treated with allconcentrations of both substrates relative to uninfected (control)cells. Taken together, this data indicated that the human Col7 proteinexpressed from KB103 was functional in the transduced cells.Functionality of this protein was indicated by its ability to increaseLH3 protein levels, decrease TSP-1 protein levels, and improve cellularadherence to both Collagen 1 and Fibronectin relative to mock-infectedsamples.

KB103 Pharmacology and Toxicity in RDEB Organotypic Cultures

A skin equivalent (SE) organotypic culture composed of RDEB fibroblastsand keratinocytes was used to evaluate the expression of Col7 proteinexpressed from KB103 at the Basement Membrane Zone (BMZ). RDEBfibroblasts and keratinocytes were mock infected or infected with KB103at an MOI of 3, and incubated for 5 days to favor stratification anddifferentiation into epithelium. The resulting skin equivalents (SEs)were isolated, sectioned, and stained for immunofluorescence to detectCol7 protein expression. Col7 expression was detected in theseorganotypic cultures from cells infected with KB103, and the initiationof Col7 protein deposition at the BMZ was observed relative tomock-infected controls (FIG. 10). This data suggested that not onlycould KB103 deliver COL7A1 and express Col7 protein efficiently, but theCol7 protein began to organize in organotypic cultures similar to thepattern of organization expected for Col7 protein in vivo.

Taken as whole, these experiments revealed, for the first time, that areplication-defective HSV-1 vector may be employed as a vehicle fordelivering a COL7A1 expression cassette into primary cells isolated fromepidermolysis bullosa patients. Moreover, these data revealed that Col7protein could be expressed at high levels from this expression cassettein two different human cell types from healthy individuals, as well asindividuals suffering from a dermatological disorder. Finally, the Col7protein was shown to be functional, as it was capable of increasingexpression of LH3, decreasing expression ofTSP-1, increasing cellularadherence to Collagen 1 and Fibronectin, and could organize inorganotypic cultures in a pattern similar to the organization of Col7 invivo. Without wishing to be bound by theory, the data presented hereinsuggests that KB103 and other HSV-1 vectors may be useful as novel invivo treatment strategies for epidermolysis bullosa and/or otherdermatological applications.

Example 3: In Vivo Col7 Expression Using Replication Defective HSV-1

The following example describes the use of a replication defectiveherpes simplex type-1 virus (modified to contain a human COL7A1transgene) as a delivery vehicle for expression of human Col7 protein invivo.

Methods Construction and Purification of KB103

The KB103 virus was constructed and purified as described in Example 2above.

Viral Infections

KB103 virus was delivered to wild-type Balb/c or skhl-elite mice byintradermal injection as follows: each animal was injected once at 2-4sites within the flank region of the animal with 1×10⁸ plaque formingunits (PFU) of virus/site in a volume of 50 μL. Animals were sacrificed48 hours post KB103 administration, and the inject sites were harvestedand processed for either real time qPCR or immunofluorescence analysis.

For qPCR analysis, skin tissue was dissected down to the fascia using a6 mm punch biopsy tool. The biopsy was bisected into two pieces, andeach piece was snap frozen using liquid nitrogen. Total RNA and DNA wereisolated from one half of the biopsy using the Qiagen AllPrep DNA/RNAkit.

For immunofluorescence analysis, a circular area approximately one cm indiameter was excised from skin at the injection site, cut in half, andmounted in OCT so that the central portion of the circular area wasfacing upward. The prepared samples were freeze plunged into liquidnitrogen cooled isopentane, and stored at −80° C.

mRNA Quantification

Col7 transcripts were amplified from RNA isolated from mouse dermaltissue after KB103 injection using a 2-step protocol: 1) cDNA synthesiswas carried out using the superscript III First Strand Synthesis kit(Thermofisher, Cat. #18-080-051), and 2) qPCR amplification wasperformed using the Quantitect Probe PCR kit (Qiagen, Cat. #204345)according to the manufacturer's protocol. 100 ng of cDNA was used ineach reaction. Col7 transcript levels were normalized to GAPDHtranscript levels.

Genome Copy Quantification

The copy number of KB103 viral genomes in the KB103 injected mice wasquantified by qPCR amplification using the Quantitect Probe PCR kit(Qiagen Cat. #204345). 100 ng of mouse genomic DNA was used in eachreaction, and mouse genomic GAPDH was used as a control.

Immunofluorescence

Tissue sections from mice injected with KB103 were fixed, andsubsequently stained with a primary rabbit anti-human Col7 polyclonalantibody (Sigma, Cat. # HPA042420), washed, and further stained with afluorescently labelled anti-rabbit secondary antibody (Invitrogen, Cat.3 A11012). Cell nuclei were stained with DAPI using standard techniques.

Results

To test the ability of KB103 to successfully deliver and express humanCol7 protein in vivo, mice were intradermally administered the KB103virus. Viral genome copy number in infected mouse tissue was assessed,and delivery of high levels (>1,000,000 viral genome copies/100 ng mouseDNA) of the KB103 viral genome was observed in the mice (FIG. 11). Next,the ability of the ability of the virus to express human Col7 in vivowas examined. Quantification of human Col7 transcripts in KB103-infectedmice were measured and assessed compared to expression of a controlmouse housekeeping gene. High levels of human Col7 transcript wereobserved in the infected mouse tissue (FIG. 11), suggesting that thedelivered viral genomes were capable of successfully expressing theirhuman gene cargo. Finally, the ability of KB103 to express Col7 proteinwas tested in the infected mice. Mouse dermal tissue was excised frommice after infection, and Col7 protein expression was assessed byimmunohistochemical staining of the mouse tissue. High levels of humanCol7 protein were detected after tissue staining (FIG. 12).Surprisingly, not only was human Col7 protein expressed from the KB103virus in mouse dermis, but the initiation of deposition of human Col7 atthe Basement Membrane Zone in KB103-infected mice was observed (FIG.12). Without wishing to be bound by theory, this data suggests that: 1)the KB103 virus can successfully infect relevant tissue in vivo,delivering high genome copy numbers to these tissues tissue, 2) deliveryof the KB103 virus to relevant tissue results in significant expressionof the encoded human genes on this virus, and 3) KB103 not onlysuccessfully expresses human Col7 protein in vivo, but this protein iscapable of beginning to organize (e.g. at the Basement Membrane Zone) ina way suggesting its ability to rescue endogenous Col7 defects inaffected individuals.

1. A pharmaceutical composition useful for topical and/or intradermaltreatment of skin wounds in a subject comprising: a) a herpes simplexvirus (HSV) comprising a vector, wherein the vector comprises one ormore transgenes encoding a polypeptide selected from the groupconsisting of a Collagen alpha-1 (VII) chain polypeptide, a Lysylhydroxylase 3 polypeptide, a Keratin type I cytoskeletal 17 polypeptide,and a chimeric polypeptide thereof; and b) a pharmaceutically acceptablecarrier.
 2. (canceled)
 3. The pharmaceutical composition of claim 1,wherein the virus is replication-defective.
 4. The pharmaceuticalcomposition of claim 1, wherein the vector is a recombinant herpessimplex virus genome.
 5. The pharmaceutical composition of claim 4,wherein the recombinant herpes simplex virus genome comprises aninactivating mutation in an immediate early herpes simplex virus gene.6. The pharmaceutical composition of claim 5, wherein the herpes simplexvirus gene is selected from the group consisting of infected cellprotein (ICP)0, ICP4, ICP22, ICP27, ICP47, thymidine kinase (tk), longunique region (UL)41, and UL55.
 7. The pharmaceutical composition ofclaim 6, wherein the recombinant herpes simplex virus genome comprisesan inactivating mutation in the ICP4 and ICP22 genes.
 8. Thepharmaceutical composition of claim 1, wherein the recombinant herpessimplex virus genome comprises the one or more transgenes within one ormore viral gene loci.
 9. The pharmaceutical composition of claim 8,wherein the recombinant herpes simplex virus genome comprises the one ormore transgenes within one or more of the ICP4 viral gene loci.
 10. Thepharmaceutical composition of claim 1, wherein the pharmaceuticallyacceptable carrier is suitable for topical or transdermaladministration.
 11. The pharmaceutical composition of claim 1, whereinthe vector comprises a transgene encoding a Collagen alpha-1 (VII) chainpolypeptide.
 12. The pharmaceutical composition of claim 1, wherein theCollagen alpha-1 (VII) chain polypeptide has at least 80% sequenceidentity to the sequence of SEQ ID NO:
 2. 13. The pharmaceuticalcomposition of claim 1, wherein the Collagen alpha-1 (VII) chainpolypeptide enhances, increases, augments, and/or supplements anchoringfibril formation of a subject when the polypeptide is expressed in oneor more target cells of the subject.
 14. The pharmaceutical compositionof claim 1, wherein the Collagen alpha-1 (VII) chain polypeptideenhances, increases, augments, and/or supplements epithelial basementmembrane organization and/or epithelial basement adherence of a subjectwhen the polypeptide is expressed in one or more target cells of thesubject.
 15. A method of providing prophylactic, palliative, ortherapeutic relief of a wound, disorder, or disease of the skin in asubject, the method comprising administering to the subject apharmaceutical composition comprising a vector, wherein the vector is arecombinant herpes simplex virus genome, and wherein the pharmaceuticalcomposition is capable of enhancing, increasing, augmenting, and/orsupplementing the levels of a Collagen alpha-1 (VII) chain polypeptideand/or a Lysyl hydroxylase 3 polypeptide and/or a Keratin type Icytoskeletal 17 polypeptide in one or more cells of the subject.
 16. Themethod of claim 15, wherein the pharmaceutical composition comprises: a)a virus comprising the vector, wherein the vector comprises one or moretransgenes encoding a polypeptide selected from the group consisting ofa Collagen alpha-1 (VII) chain polypeptide, a Lysyl hydroxylase 3polypeptide, a Keratin type I cytoskeletal 17 polypeptide, and achimeric polypeptide thereof; and b) a pharmaceutically acceptablecarrier.
 17. The method of claim 16, wherein the virus is a herpessimplex virus (HSV).
 18. The method of claim 16, wherein the virus isreplication-defective.
 19. The method of claim 15, wherein therecombinant herpes simplex virus genome comprises an inactivatingmutation in an immediate early herpes simplex virus gene.
 20. The methodof claim 19, wherein the herpes simplex virus gene is selected from thegroup consisting of ICP0, ICP4, ICP22, ICP27, ICP47, tk, UL41, and UL55.21. The method of claim 20, wherein the recombinant herpes simplex virusgenome comprises an inactivating mutation in the ICP4 and ICP22 genes.22. The method of claim 16, wherein the recombinant herpes simplex virusgenome comprises the one or more transgenes within one or more viralgene loci.
 23. The method of claim 22, wherein the recombinant herpessimplex virus genome comprises the one or more transgenes within one ormore of the ICP4 viral gene loci.
 24. The method of claim 16, whereinthe pharmaceutically acceptable carrier is suitable for topical ortransdermal administration.
 25. The method of claim 16, wherein thevector comprises a transgene encoding a Collagen alpha-1 (VII) chainpolypeptide.
 26. The method of claim 16, wherein the Collagen alpha-1(VII) chain polypeptide has at least 80% sequence identity to thesequence of SEQ ID NO:
 2. 27. The method of claim 16, wherein theCollagen alpha-1 (VII) chain polypeptide enhances, increases, augments,and/or supplements anchoring fibril formation of a subject when thepolypeptide is expressed in one or more target cells of the subject. 28.The method of claim 16, wherein the Collagen alpha-1 (VII) chainpolypeptide enhances, increases, augments, and/or supplements epithelialbasement membrane organization and/or epithelial basement adherence of asubject when the polypeptide is expressed in one or more target cells ofthe subject.
 29. The method of claim 16, wherein the pharmaceuticalcomposition is administered topically or transdermally to the subject.30. The method of claim 15, wherein the disease or disorder of the skinis one or more of epidermolysis bullosa, skin cancer, psoriasis, lichenplanus, lupus, rosacea, eczema, cutaneous candidiasis, cellulitis,impetigo, decubitus ulcers, erysipelas, ichthyosis vulgaris,dermatomyositis, acrodermatitis, stasis dermatitis, nethertons syndrome,epidermolysis bullosa simplex (LAMB3 gene), autosomal recessivecongenital ichthyosis, xeroderma pigmentosa, and pemphigoid.
 31. Thecomposition of claim 1, wherein the pharmaceutically acceptable carrieris a hydroxypropyl methylcellulose gel or phosphate buffer.
 32. Thecomposition of claim 1, wherein the subject suffers from epidermolysisbullosa (EB).
 33. The composition of claim 1, wherein the subject is ahuman.